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FOREWORD 
Occasionally in medicine a single individual makes a contribution of 
such magnitude and significance that it clearly represents a new di-
rection in the field. Such is the case in this monograph devoted to 
transplantation of the liver which originally appeared in Current 
Problems in Surgery. Dr. Thomas Starzl and his colleagues, for-
merly of the University of Colorado and now of the University of 
Pittsburgh, have, by their many seminal contributions, had a great 
influence on the entire field of transplantation; but it is transplanta-
tion of the liver which has gained these scientists their widest recog-
nition. 
The operation began as an idea only 30 years ago and the seem-
ingly painful and slow steps which subsequently led from early clin-
ical trials to the current stage of development are remarkable. Today, 
the procedure is performed in a number of medical centers around 
the world, in all age groups of patients, and for a wide variety of in-
dications-a tribute to the remarkable efforts and the persistence of 
Dr. Starzl and his group. 
In this volume, Dr. Starzl and Dr. Demetris cover all aspects of he-
patic transplantation, including the technical points of the replace-
ment operation, the prevention of rejection, and the complications 
both of the operation and of the postoperative immunosuppressed 
state. In the closing parts of this treatise, the authors review the 
newly emerging technique of multiple organ transplantation, auxil-
Iary transplantation, and the practical limitations of the procedure, 
including organ donation and economic factors. 
This contribution is authoritative and excellent, and will surely be-
come a classic in the field. 
Samuel A. Wells, Jr., M.D. 
Professor and Chairman 
Department of Surgery 
Washington University School 
of Medicine 
St. Louis, Missouri 
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INTRODUCTION 
Liver transplantation has had intellectual as well as practical ram-
ifications in all aspects of hepatology. In 1955, when the concept of 
transplanting a whole liver was first mentioned in the medical liter-
ature/ the specialty of hepatology still had ambiguous boundaries 
and purposes. This account will show how such a seemingly fanci-
ful idea as transplanting a liver became a practical reality and 
thereby helped shape the specialty of hepatology during the suc-
ceeding 30 years. During the same period, transplantation fostered 
changes in practically every aspect of hepatology and liver surgery to 
the extent that it is no longer possible to have a liver disease center 
without hepatic transplant capability. 
FIG 1. 
Orthotopic liver transplantation (liver replacement). Biliary tract reconstruction usually is 
with choledochojejunostomy (to a Roux limb) or (inset) with a choledochocholedochos-
tomy, which is stented with a T tube. 
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The liver can be transplanted as an extra (auxiliary) organ at an 
ectopic site or in the normal (orthotopic) location after removal of 
the host liver (Fig 1). This review will be preoccupied with the 
orthotopic procedure. However, there has been renewed interest in 
the auxiliary operation, which will be discussed separately at the 
end of this monograph. In addition to the potential clinical value of 
auxiliaIY hepatic transplants, efforts to define the optimal way of 
revascularizing auxiliary liver grafts opened a new field of physio-
logic and biochemical research by demonstrating that splanchnic 
venous blood possesses specific liver supporting (hepatotrophic) 
qualities.2 • 3 
As we develop the subject of orthotopic transplantation, we will 
provide a running historical perspective since even the earliest ma-
jor publications on this subject are less than 30 years old, and many 
are still of current interest. However, particular attention will be paid 
to the massive literature that has developed since June 1983, when 
the conclusion was reached by a Consensus Development Confer-
ence that orthotopic liver transplantation had become a service as 
opposed to an experimental procedure.4 
2 
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DEVELOPMENT OF THE 
REPLACEMENT OPERATION 
The distinction between creative and delusional thinking usually 
becomes clear only in retrospect. The idea of liver replacement first 
surfaced in 1956 with a publication by Dr. Jack Cannon, who was 
working at the new Department of Surgery, University of California, 
Los Angeles (UCLA).5 Because it was suspected at that time that the 
liver might playa role in rejection, Cannon apparently hoped that a 
hepatic homograft would be more kindly received than other trans-
planted organs since presumably it would not contribute to its own 
destruction. There was no journal devoted to transplantation in 
1956, and abstracts or brief articles in this field were published in an 
appendix to Plastic and Reconstructive Surgery, which was called 
Transplantation Bulletin. Cannon's article in Transplantation Bulletin 
was less than one page long. It did not have a title, and descriptions 
of the procedure or even of the animal species used were omitted. 
Cannon referred to "several successful operations" but without sur-
vival of the recipients. 
Even for nonhistorians, Cannon's one-page article may have the 
special fascination of a solitary dot on a nearly empty canvas on 
which a complex mural was to quickly and unexpectedly appear. 
There was no identifiable reason in 1956 to hope that any whole or-
gan could be transplanted successfully, including the kidney, much 
less more complicated grafts such as the liver, heart, or lung. 
The most unattainable ingredient of potential success was preven-
tion of rejection of transplanted tissues and organs. The seeming in-
surmountability of this biologic barrier undoubtedly discouraged 
research efforts at liver replacement. Nevertheless, the technical 
feasibility of liver transplantation was to be tested in dogs with 
increasing conviction and determination by independent teams in 
Boston6 ,7 and Chicago/\,9 beginning in the summer of 1958, The ca-
nine model proved to be a difficult one technically, and systematic 
investigation of liver replacement was hampered seriously by the 
fact that this operation could be done successfully in only a few lab-
oratories in the world. In recent times, improvements in the clinical 
operation have been incorporated into the dog procedure.lO, 11 
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The technical requirements for liver transplantation in dogs are al-
most too complex for simple categorization. However, two cardinal 
requirements for perioperative survival emerged from this work 
more than 30 years ago. The first was adequate preseIvation of the 
homograft during its procurement and the period of devasculariza-
tion.8 The second was decompression with veno-venous bypasses of 
the obstructed recipient splanchnic and systemic venous beds dur-
ing the anhepatic period when the host liver was being removed and 
the new liver was being inserted.6 ,8 
We will consider these principles as they have been applied clini-
cally under the general headings of donor and recipient operations 
and then discuss the more conventional surgical components of 
liver transplantations including recipient hepatectomy, graft revas-
cularization, biliary tract reconstruction, and hemostasis. 
DONOR HEPATECTOMY AND INITIAL COOLING 
Hypothermia and Core Cooling 
Steps in the development of liver graft procurement and preserva-
tion have been few. However, these steps have had an importance 
beyond their application for liver replacement, since the principles 
involved are germane to the preservation of other whole organs. The 
first innovation of core cooling by infusion of chilled lactated Ring-
er's solution into the p0l1al vein may have been the most important.8 
Before core cooling was used, survival of dogs after liver transplanta-
tion was virtually never obtained, but afterward, success became al-
most routine.s 
At an even earlier time, it was appreciated by cardiac surgeons 
that hypothermia protected ischemic tissues and organs below the 
level of aortic12 and renal pedicleD crossclamping. To our knowl-
edge, Lillehei and associates were the first to use hypothermia in 
transplantation.14 They immersed dog intestinal grafts in iced saline 
before autotransplantation or homotransplantation. Later, the extent 
of hypothermic protection from ischemia was quantified by Sicular 
and Moore, who reported that enzyme degradation in hepatic slices 
was greatly slowed by refrigeration. l !> 
The cooling of organs with fluids infused via the vascular system 
was such an obvious expedient that failure to do it can only be de-
scribed as surprising. Even more inexplicable was failure to core 
cool kidney transplants. This was not done until long after the initial 
research with canine liver transplantation had been completed. 
Then, as a direct result of our experience with the dog livers, we in-
troduced core cooling of kidney grafts into clinical practice. At first, 
we had protected human renal homografts by inducing total body 
hypothermia of living volunteer donors) but before long, we replaced 
4 
this cumbersome and potentially dangerous method with infusion 
of chilled fluid into the kidney immediately after its removal.16 
Today, core cooling is the first step in the preservation of all whole 
organ grafts, and it is most often done with the organs in place by 
some variant of the in situ technique originally described by Mar-
chioro and associates.17 These investigators used a heart-lung appa-
ratus that contained a heat exchanger to cool the carcass of dogs be-
fore beginning organ removal and to maintain hypothermic perfu-
sion thereafter. This method (Fig 2) for the immediate or continuous 
in situ hypothermic perfusion of cadaveric livers and kidneys was 
used clinically long before the acceptance of brain death conditionsl8; 
the technique has had a renaissance recently for procurement of 
thoracic organs.19,3D Ackerman and Sne1l3I and Merkel and col-
l1l 
Q) 
:r 
Arterial inflow_ 
FIG 2. 
First technique of in situ cooling by extracorporeal hypothermic perfusion. The catheters 
were inserted via the femoral vessels into the aorta and vena cava as soon as possible 
after death. Temperature control was provided with a heat exchanger. Crossclamping of 
the thoracic aorta limited perfusion to the lower part of the body. This method of cadaveric 
organ procurement was used from 1962 to 1969, before the acceptance of brain death. 
The preliminary stages of this approach provided the basis for subsequent In situ infusion 
techniques. (Redrawn from Starzl TE: Experience in Renal Transplantation. WB Saunders 
Co, Philadelphia, 1964.) 
--------- ----------------
leagues22 popularized much simpler methods of in situ cooling of 
cadaveric kidneys with cold electrolyte solutions infused into the 
distal aorta. 
Core Cooling for Multiple-Organ Procurement 
An extension of these primitive in situ cold infusion techniques 
has allowed removal of all thoracic and abdominal organs, including 
the liver, without jeopardizing any of the individual organs.23 The 
techniques of organ procurement and preservation used clinically 
came from the laboratory procedures as described earlier. However, 
much further development was required for the procurement of 
multiple organs from human cadaveric donors that were expected 
to provide kidneys, hearts, pancreases, and other tissues as well as 
livers. 
In the first trials of multiple-organ procurement, in situ cooling 
was not used. The individual organs were skeletonized, and after all 
of the dissection was completed, the kidneys were removed and 
cold perfused on the back table. At a second stage, the liver and 
heart were removed simultaneously. The removal of all four organs 
was a rare event, and the first time the kidneys, liver, and heart were 
removed from a single donor was on April 17, 1978 during a visit by 
the University of Colorado team to the University of Minnesota. 
n quickly became obvious that in situ cooling of organs was going 
to be necessary if extrarenal organ transplantation were to flourish. 
During the times when the numbers of liver or heart transplants 
were small, the annoyance caused for renal transplant surgeons by 
multiple-organ procurement was relatively minor. As multiple-organ 
procurement became routine, a major educational effort was re-
quired to recruit the cooperation of kidney transplanters. The in situ 
procedures were developed in Denver, and when the Colorado team 
moved to Pittsburgh, these were demonstrated throughout the east-
ern two thirds of the United States. At the request of the Surgeon 
General of the United States, Dr. C. E. Koop, a description of the new 
operation of multiple-organ procurement was published.23 Modifica-
tions of this procedure have been made for unstable donors and 
even for donors whose hearts have ceased to beat.24 In less than 5 
years, multiple-organ procurement, using techniques that are inter-
changeable not only from city to city but from country to country, 
had become standardized in all parts of the world. 
A complete midline abdominal and thoracic incision is made (Fig 
3). The aorta at the diaphragm is encircled so that it can be cross-
clamped when the core cooling is begun. The distal aorta is used as 
an entry site for the fluid infusion (Fig 4). By coordination of the fluid 
infusion and the crossclamping of the great vessels and by dissec-
tion and ligation of appropriate arterial branches, the cold infusate 
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FIG 3. 
.----;- CuI al fusion of 
pericardium & 
diaphragm 
+---+- Pubic symphysis 
Total midline incision used for cadaveric donors. (Redrawn from Starzl TE: Surg Gynecol 
Obstet 1984; 158:223-230.) 
can be made to go selectively to those organs (including the liver) 
that are to be used (see Fig 4). The portal vein of the liver also is in-
fused after a catheter is placed into it through the splenic vein or 
other major tributary (see Fig 4). Core cooling of the thoracic organs 
is accomplished with the same principles.23 
There is little point in providing further details of the donor oper-
ation. Those interested in procurement procedures should study 
the description of the originally described technique23 or the deriva-
tive method called the rapid flush technique,24 which can be used for 
unstable donors or even for donors who develop a cardiac arrest 
(see the next section). With the rapid flush method, almost no dis-
section is performed initially. The organs are quickly chilled and 
washed free of blood in situ by aortic infusion and infusion through 
a distal portal branch such as the inferior mesenteric vein. They can 
then be removed swiftly in a bloodless field. 
Liver Procurement In Non-Hearl-Beating Donors 
When liver transplantation was first performed experimentally and 
clinically, it was thought that the liver would be exquisitely sensitive 
to warm ischemia.8 This perception has changed in the ensuing 
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FIG 4. 
Principle of in situ cooling used for multiple organ procurement. With limited preliminary 
dissection of the aorta and of the great splanchnic veins (in this case the splenic vein), 
cold infusates can be used to chill organs in situ. In this case, the kidneys and liver were 
to be removed. Note the aortic crossclamp above the celiac axis. (From Starzl TE, Hakala 
TR, Shaw BW Jr, et al: Surg Gynecol Obstet 1984; 158:223-230.) 
years, particularly with the demonstration by Huguet and associates 
that the human liver can tolerate at least 1 hour of warm ischemia 
with relative impunity.25 Studies in normal dogs have shown that 
the pOltal triad usually can be cross clamped for at least 2 hours 
without mortality, providing there is perfect decompression of the 
obstructed portal venous drainage.26 
If a cardiac arrest occurs in a patient considered to be a good do-
nor, it is possible to quickly open the abdomen, encircle the proxi-
mal aorta at the level of the diaphragm, and cannulate the terminal 
abdominal aorta or one of the iliac arteries (Fig 5). Within 5 or 10 
minutes, core cooling can be started with an infusion of cold solu-
tion. The aorta is crossclamped near the diaphragm. The inferior 
vena cava is decompressed by incising it. The liver becomes 
blanched and free of blood with surprising rapidity. Within 2 or 3 
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FIG 5. 
If there is not time to insert a splanchnic venous catheter for infusion, the rapid infusion of 
cold fluid into the aorta alone will promptly cool the liver since the superior mesenteric 
venous blood contributes to the hepatic cooling (see Fig 6). All that is necessary is to in-
sert the catheter into the distal aorta and to crossclamp the aorta at the diaphragm. (From 
Starzl TE, Iwatsuki S, Shaw BW Jr, et al: Transplant Proc 1985; 17:250-258. Used by per-
mission.) 
minutes, the liver becomes palpably cold. At the same time, the in-
testines become blanched from the superior mesenteric artery infu-
sion, and blood in the portal vein that has passed through the 
splanchnic capillary bed becomes clear and hemoglobin free (Fig 6). 
Thus, full perfusion of the liver eventually is assured even though 
the chilled fluid is instilled only into the aorta (see Figs 5 and 6). 
In adults, 2 or 3 L of cold solution rapidly infused into the distal 
aorta are required to bring the liver into a cryoprotective range of 
less than 28°C. After this has been achieved, the rest of the procure-
9 
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FIG 6. 
Core cooling of the liver with aortic infusion alone. Note that the body (and liver) tempera-
ture becomes cryoprotective within 2 or 3 minutes after beginning the aortic infusion. The 
hematocrit of the portal venous blood is qUickly diluted, meaning that the liver is being 
perfused with the increasingly asanguinous cold blood returning from the splanchnic 
venous bed. 
ment can be carried out at a more leisurely pace. This is facilitated 
by the fact that there is now a bloodless field. We have used this 
technique to recover satisfactory livers from many donors with ab-
sent or ineffective heartbeat.27 The method has been used with con-
siderable success in Sweden, which did not have "brain death" laws 
until recently.28 Our experience and that of the Swedish workers un-
der these circumstances have been almost as good as with the stan-
dard procurements in cadaveric donors with beating hearts. How-
ever, a high level of skill is required to prevent the loss of these 
organs, and discriminating judgment is necessary about which or-
gans have a good chance of being satisfactory. Only surgeons expe-
rienced in procurement of donor organs will be capable of this kind 
of work. 
Donor Anomalies 
In at least one third of the human donors, arterial anomalies will 
be encountered whereby some or all of the liver is supplied by 
branches of the left gastric aItery, superior' mesenteric artery, or di-
rect branches from the aorta instead of by ramifications of the com-
mon or proper hepatic artery (Fig 7). Special techniques that allow 
essentially all such livers to be used have been developed.29-:1 r. Most 
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FIG 7. 
Sup. mesenteric 
a. 
A common anomaly in which a right hepatic artery originates from the superior mesenteric 
artery. This right artery always is posterior to the portal vein. 
of these techniques have in common the conversion of multiple ves-
sels into a single trunk by back-table dissection and anastomoses 
(Figs 8-10). Uniting the celiac axis and superior mesenteric artery as 
shown in Figure 10 may leave an excessively long vessel and a bulge 
at the site of the fold-over anastomosis. Consequently, if this princi-
S.a. 
FIGS. 
With the anomaly in Figure 7, the splenic artery can be anastomosed to the anomalous 
right hepatic artery, thereby converting the origin of the blood supply to a single vessel 
based on the celiac axis. (Redrawn from Starzl TE: Experience in Hepatic Transplantation. 
Philadelphia, WB Saunders Co, 1969.) 
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FIG 9. 
M. hepatic a. 
Rt. hepatic 
a. 
Distal 
Lt. hepatic a. 
II 
Celiac 
axis 
"-Proximal 
8.m.a. 
Recipient 
hepatic a. 
Alternative methods to reconstruct the anomaly shown in Figure 7. The proximal (left) or 
distal (right) end of the superior mesenteric artery containing the anomalous right hepatic 
artery is anastomosed to the graft celiac axis. The open end is sewed to the recipient ce-
liac axis. 
pIe is employed, an end-to-end celiac axis to superior mesenteric ar-
tery anastomosis may be preferable (see Fig 8 or 9). 
Vascular Homografts 
An integral pm1 of the donor operation should be procurement of 
free grafts of the iliac arteries and veins, since these can be used to 
reconstruct anomalies or damaged vessels of livers (Fig 11), kidneys, 
and other organs. At the time of procurement, these grafts are 
placed in a solution developed at the University of Wisconsin (UW 
solution), where they can be used for at least 1 or 2 days or possibly 
longer. When arterial grafts are needed, they are usually based below 
the recipient renal arteries. They can be brought anterior to the pan-
creas (Fig 12) or behind the pancreas through tunnels created by 
finger dissection (Fig 13). Vein grafts will be discussed later. 
MEANS OF SUBSEQUENT PRESERVATION 
In dogs, the liver can be transplanted successfully as long as 6 to 
12 hours after cooling with lactated Ringer's solution and storage at 
4°C.36 Further extension of this period and improvement of safety 
have depended on one of two prototype strategies, derived from re-
search done mainly with kidneys and applied secondarily to livers. 
12 
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FIG 10. 
Same principle as the reconstruction of Figure 9 (left). However, the origin of the superior 
mesenteric artery and celiac axis are folded together, leaving the distal end of the superior 
mesenteric artery for anastomosis to the recipient. There is a small left hepatic artery in 
this case originating from the left gastric artery. This latter anomaly is very commonly 
found in association with a right hepatic artery of superior mesenteric arterial origin. (From 
Gordon RD, Shaw BW Jr, Iwatsuki S, et al Surg Gynecol Obstet 1985; 160:474-476. 
Used by permission.) 
EX Vivo Perfusion After Initial Cooling 
With one approach, a continuous circulation has been provided 
with a cold perfusate primed with blood and oxygenated within a 
hyperbaric oxygen chamber.37 This method, which originally was 
used for kidneys by Ackerman and Barnard,38 has permitted the suc-
cessful preservation of dog livers for as long as 2 d ays37 and was ap-
plied clinically with remarkable success in several human cases in 
the pre-brain death era.39 When Belzer and associates were able to 
eliminate the hemoglobin and hyperbaric chamber components for 
kidney preservation,40 their asanguinous perfusion technique for ca-
daveric renal grafts become a worldwide standard. However, efforts 
were unsuccessful to use continuous asanguinous perfusion for liv-
ers 41 
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FIG 11. 
Arterial graft from 
infrarenal aorta 
By 1979, all of the demonstrated grafts had been used clinically. The use of vascular 
grafts has been life saving, and liver transplantation should never be attempted without an 
emergency assortment of these grafts. (Redrawn from Starzl TE, Halgrimson CG, Koep LJ, 
et al: Surg Gyneco/ Obstet 1979; 14976-77.) 
Slush Techniques 
The alternative strategy for the subsequent preservation of kid-
neys, livers, and other organs has been the instillation of special so-
lutions (Table 1) such as those described by Collins and co-workers42 
or the plasma-like Schalm solutionK4:~ The original Collins solution or 
modifications of it have been used for almost 20 years for the so-
called slush techniques of kidney preservation in which the organ is 
packed in an ice chest at 4°C after its infusion. The experimental 
work of Benichou and colleagues36 and Wall and associates44 with 
the Collins and Schalm solutions opened up the possibility in 1976 
of clinical sharing of livers between cities but within narrow time 
limitations. The outer limit of safety for human livers was generally 
set at 8 hours in spite of the fact that dog livers could be maintained 
for much longer than this with the Collins and Schalm solutions. 
The VW Solution for Slush Preservation 
The development of the UW solution has been the first major de-
velopment in liver preservation since that time.45 The UW solution is 
a generic advance that also is applicable to the preservation of the 
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FIG 12. 
An antepancreatic route for a vascular graft placed onto the infrarenal abdominal aorta. 
The graft is brought either to the right or left of the middle colic vessels, anterior to the 
pancreas, and beneath the pyloris. (From Tzakls AG, Todo S, Starzl TE: Transplant Int 
1989; 2:121. Used by permission.) 
FIG 13. 
Posterior routes by which the arterial grafts shown in Figure 11 can be brought from their 
aortic origin to the liver hilum behind the pancreas. The tunnels are created by blunt finger 
dissection. Route A is rarely used because it is potentially dangerous. (From Todo S, Ma-
kowka L, Tzakis AG, et al: Transplant Proc 1987; 19:2406-2411. Used by permission.) 
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TABLE 1. 
Characteristics and Constituents of Test Solutions*t 
EC LR UW UMI UMZ UM3 
Anions 
Bicarbonate (mM/L) 10 
Chloride (mM/L) 15 109 20 5 
Lactate (mM/L) 28 
Phosphate (mM/L) 57.5 25 0.72 
Lactobionate (mM/L) 100 90 
Cations 
Calcium (mM/L) 1.5 0.6-1.4 
Sodium (mM/Li 10 130 30 146 146 1 
Potassium (mMiLi 115 4 120 4.3 24.3 124 
Magnesium (mM/L) 5 4 7.8 
Colloids and osmotically 
active agents 
Hydroxy ethyl starch 50 
(gm/L) 
Proteins (gm/LJ 65.2 90 65 
Mannitol IgmlLJ 3.75 
Raffinose (gm/LJ 17.8 48 
Glucose (gmILJ 194 99 
Others 
Adenosine IgmIL) 1.34 
Glutathione Igm/L) 0.922 
Insulin lunits) 100 
AllopUI'inol (gm/LJ U.136 
Antibiotics and steroids 
Ampicillin (mg) 250 50 
Sulfamethoxazole (mg) 40 
Trimethoprim (mg) 8 
Dexamethasone (mg) 8 
Methyl prednisolone 250 500 
(mg) 
Osmolality ImOsm/L) 375 273 320 308 301 
pH 7.4 6.3 7.4 7.4 7.4 7.4 
'From Todo S, Podesta I., lJeda Y, et aI: CUn Transplant 1989; 3:253-259. Used by permission. 
tEC = Euro,Coilins; LR = Lactated Ringer's; UW = University of Wisconsin; UM1 = University of Min-
nesota I; UMZ = University of Minnesota II; UM3 = University of Minnesota III. 
pancreas,46 kidney,47,48 and heart,49 possibly by mechanisms com-
mon to all organs (see later) ,50 The superiority of the U\V solution to 
any previous infusion solution for preservation of the liver has been 
established in clinical trials.5154 In our trials,52-54 the livers infused 
with U\V solution performed better even though they were preselved 
on the average for almost twice as long as livers preserved with 
Euro-Collins solutions, The livers in U\V solution permitted a higher 
rate of graft survival, and they had a lower rate of primal)' nonfunc-
tion, hepatic artel)' thrombosis and retransplantation, They ap-
peared to be safe for at least 1 day and possibly longer. 
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When the UW solution was undergoing its first clinical trials, it 
was in such short supply that only a final portal flush was possible. 
In adult donors, 1 L of the UW solution was given on the back table 
via the portal vein just before packing the liver in ice. By this time, 
the liver had been cooled in situ with lactated Ringer's or Collins' 
solution and excised. In addition to a shortage of UW solution, the 
use of lactated Ringer's or Collins' solution for preliminary cooling 
was insisted on almost invariably by the local procurement team as 
a condition for the collaborative effort with the renal transplant sur-
geon. 
The positive results clinically that have been reported with the UW 
solution were obtained with this mixed use of fluids in which only 
the final flush was with UW solution. However, the best practice 
probably is to use only UW solution for all infusions from the outset, 
a practice that became feasible (as of 1 June 1989) with the commer-
cial availability of UW solution. The high cost of the UW solution 
($400/L) is the principal disadvantage of this practice. Approximately 
5 L of solution are required for a multiple organ procurement in 
adults, exclusive of the thoracic organs. Because it has been shown 
that the UW solution is superior to previously used solutions for the 
kidney47,48 as well as the liver, there can no longer be any objection 
to this use of UW solution. 
Although the extension with the UW solution of acceptable cold 
ischemia from 6 or 8 hours out to 1 day does not seem like a large 
gain, the effect has been phenomenal. Until 18 months ago, logistic 
problems dominated the use of cadaveric livers that had to be re-
moved, transported to their destination, and revascularized with an 
overriding sense of urgency. With the longer preservation time that 
has been made practical with the UW solution, countrywide and 
worldwide networks of organ sharing have been set up. The conse-
quences in the future should be a reduction in organ wastage, a 
greater flexibility for use of grafts that can be trimmed to the appro-
priate size for pediatric recipients, and more efficient recipient travel 
and preparation. The use of slower propeller planes instead of ex-
pensive jet planes for recipient and organ transplantation already 
has become feasible. 
An explanation for the effectiveness of the UW solution has been 
provided by Belzer and Southard.55 The UW solution contains more 
than 10 ingredients (see Table 1). Important components and their 
effects are (1) lactobionate and raffinose to prevent cell swelling, (2) 
hydroxyethyl starch to support colloidal pressure, (3) allopurinol 
and glutathione to inhibit oxygen free-radical generation, and (4) ad-
enosine to enhance adenosine triphosphate (ATP) synthesis after 
reperfusion. In studies peIformed in our laboratmy, the difference in 
the performance of different solutions may provide sketchy insight 
into the relative importance of some constituents.56 These studies 
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have shown that an intracellular-like electrolyte solution (Collins) or 
a hyperosmolar colloid solution such as those developed at the 
University of Minnesota (see Table 1) do not allow long-term cold 
storage of the liver, even though these can be useful for the 
pancreas. 57! 58 Lactobionate and raffinose, two sugars that prevent 
imbibition of water by cells, have seemed to be the essential ingredi-
ents without which the effectiveness of UW solution is lost.56 Others 
have come to the same conclusion.59,60 
Much remains to be learned about liver preservation, the effects of 
ischemia on hepatic function and the hepatic microvasculature, and 
the role of these factors in the early and late postoperative course of 
recipients. We will return to these subjects further on. In the mean-
while, a discussion of slush preservation would be incomplete with-
out mentioning the potential dangers of the preservation solutions. 
For example, the bolus of potassium washed out during the reperfu-
sion of a liver containing Collins' or UW fluid has caused a number 
of cardiac arrests. It also should be noted that other ingredients 
than potassium in present-day preservation solutions may impose a 
risk. Prien and associates have shown that bradycardia or even more 
serious arrhythmias are caused in recipients of kidneys preserved 
with UW solution if these organs are not washed out first.61 They be-
lieve that the offending agent is adenosine, which is known to be ar-
rhythmiagenic. Aside from this consideration, and the elimination of 
potassium, the preservation fluid should be washed out of liver 
grafts before they are placed into the recipient circulation to elimi-
nate air bubbles entrapped in the graft.62 Moen and co-workers have 
shown that sodium can be substituted for potassium in the UW so-
lution.60 This change will make safer the reperfusion of liver grafts by 
eliminating the potential bolus of potassium at the time of reperfu-
sian. 
RECIPIENT OPERATION 
The component parts of the recipient operation are so dissimilar 
that a single surgeon operating from skin to skin may find it difficult 
to adjust to the changing pace. Removal of the diseased liver can be 
one of the most bloody and stressful experiences in a surgeon's life. 
Yet, the subsequent performance of the vascular anastomoses can be 
among the most delicate and sophisticated, especially in very small 
children. Obtaining perfect hemostasis subsequently is often a te-
dious third phase that, if not accomplished, will ruin all that has 
gone before. At the end, success depends on adequate biliary tract 
reconstruction. In some centers, various parts of the procedure are 
being done by independent and fresh teams. However, the total re-
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FIG 14. 
The usual incision used for the recipient of an orthotopic liver graft. A right subcostal inci-
sion is always made, usually with an upper midline extension, and often With a left subcos-
tal extension. Removal of the xyphoid process gives extra exposure of the suprahepatic 
vena cava. (From Starzl TE, Bell RH, Bearl RW, et al: Surg Gynecol Obstet 1975; 
141:429-437. Used by permission.) 
sponsibility still rests with a single surgeon who must understand 
each part of the operation. 
A right subcostal incision is almost always used for the recipient 
operation (Fig 14), but its exact location is dictated by previous right 
upper quadrant incisions and by the size and configuration of the 
liver. An upper midline extension has been particularly valuable. If 
the upper midline extension is made, the xiphoid process usually is 
excised since better access to the hepatic veins and suprahepatic 
vena cava can be obtained. In the majority of cases, the patients end 
up with a bilateral subcostal incision, with a superior midline T ex-
tension (see Fig 14). Thoracic extensions are almost never needed. 
Once the abdomen is entered, an effort is made to find a plane of 
dissection just outside of the liver capsule if there are major adhe-
sions. Movement away from this plane invites disruption of varices 
that may be large enough to cause unpleasant or even lethal hemor-
rhage during the preliminary dissection. 
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Veno-Venous Bypasses 
During recipient hepatectomy and performance of the vascular 
anastomoses of the homograft, the portal vein and inferior vena cava 
are crosscJamped (Fig 15). The choice of the dog in 1958 as the spe-
cies to develop the operation focused attention immediately on the 
need to decompress the acutely obstructed venous beds. The nor-
mal dog cannot tolerate venous hypertension of the splanchnic cap-
illary bed for more than 15 or 20 minutes without the development 
of hemorrhagic necrosis of the intestinal mucosa. Passive veno-
venous bypasses from the stagnant venous pools to the upper part 
of the dog's body can circumvent these lethal complications without 
the need for heparinization.G• 8 
Such passive bypasses were used for several patients in the first 
clinical tlialsG3• G4; however, either the bypasses clotted and did not 
function at all or, far worse, clots were released from the bypass tub-
ing and passed to the lung, causing lethal pulmonary emboli.G4 In 
addition, it quickly was appreciated that the human can tolerate ob-
struction of the inferior vena cava and portal vein better than the 
dog, that other species, including the pig, were more like humans in 
this respect, and that even in the dog venous crossclamping could 
be made safer by the expedient of bile duct ligation several weeks in 
advance.G5 The logical conclusion from this last observation was that 
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FIG 15. 
Pump-driven vena-venous bypass. which allows decompression of the splanchnic and 
systemic venous beds without the need for heparinization. (Redrawn from GriHith BP, 
Shaw BW Jr, Hardesty RL, et al: Surg Gynecol Obstet 1985: 160:270-272.) 
.20 
the stimulation of venous collaterals by liver disease diminished the 
magnitude of venous hypertension caused by acute venous obstruc-
tion. Efforts to decompress the obstructed venous beds were aban-
doned by 1964 and were not resumed for almost 20 years. 
So persuasive were the arguments against using vena-venous by-
passes that liver transplantation was repetitively performed in hu-
mans under conditions that limited its usefulness, increased its 
perioperative risk, and made training of the next generation of he-
patic surgeons difficult. Liver transplantation was widely viewed as 
being too dangerous and difficult to be generally applicable. The 
mistake had been made of believing that a fundamental principle of 
surgical physiology worked out in animals, namely that veno-venous 
bypass was essential for effective liver transplantation, was not truly 
relevant in humans. 
It was possible to cany out liver transplantation successfully with-
out veno-venous bypasses,66,67 but the operation could be per-
formed only by highly experienced surgeons and frequently with 
such a sense of urgency that training of new teams in any numbers 
was not possible. All too often, a virtuoso performance was required, 
and even when the anhepatic period was kept to a minimum, major 
declines in cardiac output and variable hypotension were common.68 
The fact that recovery usually occurred in the hands of skilled teams 
created a false impression about the expendability of the bypass. 
Usually there was gross swelling of the intestine during the period of 
occlusion. Subsequently, many patients suffered from third space 
sequestration and postoperative renal failure. The extent to which 
these complex physiologic events contributed to the high perioper-
ative morbidity of the 1960s and 1970s was not fully appreciated un-
tillater.67,69 
How this deficiency in technique was rectified cannot be traced 
easily from the articles describing the work. The stimulus for reas-
sessment was a persistent 5% to 10% intraoperative mortality that 
was due almost entirely to poor patient tolerance of the venous oc-
clusions during the anhepatic phase. However, nothing decisive was 
done to reetilY the situation until a tragedy occurred in Pittsburgh in 
May 1982 that utterly demoralized the transplant team. A popular 
male hemophiliac teenager with chronic active hepatitis died on the 
operating table from the combination of bleeding, third space fluid 
sequestration, and cardiovascular instability that was then common 
during hepatectomy and the sewing in of the new liver. 
The program was closed for more than 1 month until June 15, 
1982 when cardiac surgeon Dr. Henry T. Bahnson, Chairman of the 
Department of Surgery at the University of Pittsburgh, was requested 
to set up a pump-driven bypass for the next case. Bahnson grasped 
the essence of the problem instinctively, and he agreed immediately. 
That night, a liver replacement was carried out under vena-venous 
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bypass in a 6-year-old child with biliary atresia. The bypass was per-
formed under 3 mg of heparin/kg with a roller pump and other con-
ventional equipment used for open-heart surgeIy. This technique of 
a pump-driven bypass had been described in dogs 10 years earlier 
by Cutropia and associates/o but their article was unknown to us at 
the time. There was little trouble in reversing the heparin effect af-
terward. Those who were there that night were ecstatic about the 
ease and nonstressful nature of the transplantation under bypass 
conditions. 
The ways in which liver transplantation was facilitated by veno-
venous bypass were verified in a number of other cases.67 By July 
1~UOI abstracts describing the technique were submitted under the 
senior authorship of Bahnson to the Southern Surgical Association 
and to the American Association for the Study of Liver Diseases. 
Both were rejected. In the meanwhile, problems with reversal of the 
heparin effect had been encountered in several of the adult recipi-
ents. Vena-venous bypass under systemic heparinization had 
worked weB in those patients with relatively "simple" diseases such 
as primary biliary cirrhosis and in recipients who had not had pre-
vious abdominal operations. The same was not true in patients with 
difficult pathology, exceptionally advanced disease, and especially in 
those who had undergone multiple procedures previously. Here, the 
bleeding from the raw surfaces was so great and the heparin effect 
reversed with such difficulty that the value of bypass technique was 
vitiated. In fact, two patients with vena-venous bypass under hepa-
rin died of hemorrhage when clotting could not be restored. 
Two of Bahnson's young associates, Drs. Bartley Griffith and Rob-
ert Hardesty, had avoided systemic heparin in patients with pulmo-
nary insufficiency who had been treated with pump-driven extracor-
pOI'eal membrane oxygenators. Griffith and Hardesty recently had 
purchased an atraumatic centrifugal pump that they thought would 
permit the pumping of venous blood without anticoagulation. Work 
on the nonheparin bypass began in dogs in the laboratory on Sep-
tember 30, 1982. The project was assigned to Dr. Scot Denmark, a 
resident who was in his "lab year." Gr'iffith and Denmark provided 
the bypass capability. The liver transplantations were peIformed by 
members of the transplantation service, including the second-year 
transplantation fellow Dr. Byers Shaw, Jr. By the end of 1982, most of 
the work that was reported by Denmark at the Surgical Forum of the 
American College of Surgeons in October 1983 already had been 
completed.71 However, clinical trials of the nonheparin bypass were 
not started, in part because it was difficult to predict which patients 
really needed it. In addition, there still was uneasiness about the 
possibility of clot formation in bypass tubing and consequent pul-
monary emboli. 
During the Christmas season of 1982 and in January 1983, three 
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more deaths occurred on the operating table in much the same way 
as with the earlier hemophiliac patient. As a consequence, a policy 
decision was made at the end of January 1983 that veno-venous by-
passes must be used for all adult recipients of liver transplants from 
that time onward (see Fig 15). It became obvious almost immediately 
that liver transplantation had become a far more reasonable proce-
dure than in the past.69,72 Kam and associates have shown subse-
quently that these techniques are easy to use and safe in many pe-
diatric recipients, particularly those weighing more than 15 kg?O 
Not all liver transplant surgeons believe that vena-venous bypasses 
are of overriding imp0I1ance?3-77 CaIne and co-workers have de-
scribed a venoarterial bypass, sometimes with an intervening oxy-
genator, that is used only when venous cross clamping causes car-
diodynamic instability.73 They contend that strain on the heart is re-
lieved thereby. Even today, most infants and small children undergo 
liver transplantation without vena-venous bypass, and some sur-
geons routinely omit it for their adult recipients?4-77 Nevertheless, 
vena-venous bypass converted liver transplantation to a procedure 
that can be carried out by many well-trained general or vascular sur-
geons. The consequence was that effective teams could be devel-
oped quickly, blanketing the United States and Europe almost over-
night with a network of competent liver transplant services. 
Recipient Hepatectomy 
There is no single best way to remove a diseased native liver. In 
each case, an ad hoc decision is required on the best technical ap-
proach that the abnormal anatomy will permit. In some patients, ef-
forts to mobilize the liver from the hepatic fossa can cause lethal 
hemorrhage unless the hepatic arterial and portal venous blood 
supply are ligated first. In the other recipients, it may even be im-
possible because of scarring from previous operations or because of 
the massive formation of varices to dissect individually the struc-
tures of the portal triad. 
Finally, the method of hepatectomy, as well as the conduct of the 
rest of the operation, are determined largely by whether or not veno-
venous bypasses are going to be used. If the bypass is omitted, it is 
important to limit the venous occlusion period as much as possible, 
hopefully to the time required for performance of the two vena caval 
and the portal anastomoses. Otherwise, damage to the splanchnic 
and systemic capillary beds may be excessive, with grossly obvious 
petechial hemorrhages and edema in the intestines and elsewhere. 
With occlusion of both the vena cava and the portal vein, hemor-
rhage from the thin-walled varices and from all other raw surfaces of 
the operative wound is predictably amplified. The bleeding often 
cannot be controlled by any mechanical means until decompression 
is accomplished by opening of the vena caval and portal venous 
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anastomoses of the new liver. Thus, if veno-venous bypasses are to 
be omitted, as much preliminaIY dissection as possible is desirable 
so that the occlusion period can be made as short as possible. 
In contrast, the extent of preliminary dissection can be greatly de-
creased if a veno-venous bypass is to be used. The individual struc-
tures of the hilu m usually are skeletonized, but no other areas need 
be invaded. When the bypass is ready for implementation, the he-
patic artery and the common duct are ligated. The portal vein can-
nula for the veno-venous bypass is inserted, as is a femoral cannula, 
allowing both the splanchnic and systemic systems to be brought 
into the veno-venous circuit (see Fig 15). Entry into the superior vena 
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FIG 16. 
Technique for removal of the liver from below upward. This is a particularly attractive ap-
proach if a vena-venous bypass is used as shown. (Redrawn from Starzl TE, Porter KA, 
Putnam CW, et al: Surg Gynecol Obstet 1976; 142:487-505.) 
caval system usually is via the axillary vein (Fig 16). In adults, 1 to 6 L 
of blood per minute are bypassed. Simultaneous obstruction of the 
portal vein and inferior vena cava should cause little change in 
blood pressure or other measures of cardiovascular function. 
With the hemodynamic stability afforded by the veno-venous by-
pass, it is possible to systematically dissect all other structures that 
are holding the now-devascularized liver, including the infrahepatic 
vena cava. The triangular ligaments and the leaves of peritoneal re-
flection that make up the coronary ligament are cut if these have not 
been incised already (Fig 17). The bare areas are entered on both the 
right and left sides. After these maneuvers have been carried out, the 
right hepatic lobe can be retracted into the wound. If it has not been 
possible to encircle the inferior vena cava earlier, this can be done 
now just below or above the liver, and eventually at both locations. 
The liver can then be shelled out on the stalk defined by the vena 
caval connection (see Fig 17), and the vena caval cuff for eventual 
anastomosis can be developed (see Fig 17, inset). 
Once the liver has been removed, it is possible using vena-venous 
bypass time to close most of the raw surfaces that were created dur-
FIG 17. 
__ W"::< Lt. triangular 
lig. 
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Completion of removal of the liver from below upward, leaving the liver attached only by a 
stalk of vena cava at the diaphragm. (Redrawn from Starzl TE, Porter KA, Putnam, CW, et 
al Surg Gyneco/ Obstet 1976; 142:487-505.) 
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FIG 18. 
Closure and hemostasis of the bare area after peeling out the liver. Under conditions of 
veno-venous bypass, there is plenty of time to do this so that the wound is dry when the 
anastomoses to the new liver are carried out. (Redrawn from Starzl TE, Iwatsuki S, Shaw 
BW Jr, et al: Transplant Proc 1985; 17: 1 07 -119.) 
ing the hepatectomy (Fig 18). Closure is usually done with a contin-
uous polypropylene suture, beginning at the tip of the right triangu-
lar ligament and continuing centrally in rows that eventually are 
connected.78 The superior leaf of the coronary ligament can be the 
starting point, with continuation into the bare area itself and even-
tually to the inferior portion of the coronary ligament (see Fig 18). 
When these continuous suture lines are eventually incorporated into 
a single suture line, all of the right bare area may be eliminated if 
desired. The same principle is followed in dealing with the left 
triangular and falciform ligaments as well as other bare areas (see 
Fig 18). 
The foregoing well-ordered strategy of hepatectomy is not always 
possible, particularly in patients who have undergone previous op-
erations in the upper abdomen. In some cases, the only way to get 
the liver out is by placing clamps across the entire hilum. The lu-
mens of the individual hilar structures can then be seen after 
transecting between the mass clamps, and these individual struc-
tures can be dissected downward toward the clamp (Fig 19). 
Another drastic variation that may be especially helpful in chil-
dren in whom the infrahepatic vena cava is inaccessible is to encir-
cle and transect the vena cava above the liver. When this is done, 
one or two fingers are thrust downward into the retrohepatic vena 
cava to prevent massive hemorrhage (Fig 20). Then the liver can be 
peeled down from above. 
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FIG 19. 
Crossclamping of portal triad, which is sometimes necessary when preliminary dissection 
of the Individual structures is too difficult. Once the triad has been clamped, the triad 
structures are seen head on and are dissected downward. A portal venous cannula for 
vena-venous bypass can then be inserted. (Redrawn from Starzl TE: Experience in He-
patic Transplantation. Philadelphia, WB Saunders Co, 1969.) 
Preservation of the Vena Cava and the Piggyback Technique 
An integral part of the standard orthotopic liver transplantation is 
removal of the inferior vena cava from above the renal veins to the 
diaphragm. Complete excision of this retrohepatic vena cava is not 
necessary, and Stieber and co-workers have pointed out that it 
may not be desirable.79 They recommend leaving that portion of 
vena cava into which the right adrenal vein drains and then over-
sewing it. 
In another modification, the full length of the recipient inferior 
vena cava is preserved, and the new liver is placed "piggyback" onto 
its anterior sUIface. A particularly appealing feature of the piggyback 
operation in children for whom veno-venous bypass might not be 
feasible is that vena caval occlusion can be avoided during the hepa-
tectomy and sewing in of the homograft. The piggyback operation 
has been used for a number of years. In some of our first patients, 
this operation was employed,80 and one of CaIne's first five recipi-
ents had a piggyback operation.81 However, the formal description 
and widespread use of the piggyback operation has been recent.82 At 
the present time, about one fifth of our recipients are having the pig-
gyback modification. 
The essence of this operation is shown in Figure 21. By rotating 
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FIG 20. 
Removal of the liver from above downward, preventing hemorrhage with a finger or fingers 
thrust down the lumen of the transected suprahepatic vena cava. The maneuver is indi-
cated if it is difficult or impossible to safely encircle the inferior vena cava below the liver. 
This technique is almost specific for certain cases of biliary atresia with extensive subhe-
patic scarring in which the small size of these livers makes it possible to completely oc-
clude the vena cava with a single finger. (Redrawn from Starzl TE, Iwatsuki S, Shaw BW Jr, 
et al: Transplant Proc 1985; 17: 1 07 -119.) 
the liver out of the wound, either to the right or to the left, one can 
dissect the individual hepatic veins, ligate them, and divide them 
(Fig 22). The major hepatic veins are crossdamped and eventually 
used to fashion an orifice for the outflow anastomosis of the ho-
mograft (Fig 23). The right, middle, and left hepatic veins or, more 
commonly, the middle and left are joined by dividing the interven-
ing septum. 
If difficulty is encountered in dissecting the hepatic veins from an 
exterior approach, an alternative technique is to split the liver like a 
book. A tributary-free plane is identified at the upper portion of the 
liver, and with gentle blunt dissection, the finger is burrowed down 
the anterior surface of the vena cava (Fig 24). The liver is then di-
vided with a knife from its anterior surface down to the finger using 
a knife (Fig 25). 
The exact technique of the outflow anastomosis depends on 
which hepatic veins have been selected for this purpose. The lower 
end of the vena cava of the homograft is ligated or sutured (see Fig 21). 
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FIG 21. 
Transplantation of a liver piggyback onto an inferior vena cava, which is preserved 
through its length. Note that the suprahepatic vena cava of the homograft is anastomosed 
to the anterior wall of the recipient vena cava. The retrohepatic vena cava of the homograft 
is sutured or ligated, leaving a blind sac into which empty numerous hepatic veins. (From 
Tzakis A, Todo S, Starzl TE Ann Surg 1989; 210649-652. Used by permission.) 
FIG 22. 
Steps in preparation of the recipient vena cava for the piggyback operation. All of the 
small hepatic veins entering the retrohepatic vena cava are ligated and divided, and the 
large principal tributaries (right, middle, and left hepatic veins) are dissected free. (From 
Tzakis A, Todo S, Starzl TE Ann Surg 1989; 210:649-652. Used by permission.) 
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FIG 23. 
Formation of the site for anastomosis, The three main hepatic veins can be connected as 
shown, or other combinations can be used, of which the most common is a left and middle 
hepatic cloaca, (From Tzakis A, Todo S, Starzl TE: Ann Surg 1989; 210:649-652, Used by 
permission. ) 
The applicability of the piggyback operation depends on finding 
favorable anatomic conditions as the recipient hepatectomy pro-
ceeds. If the liver is VeIY cirrhotic, small, and firmly adherent to its 
retrohepatic vena cava, it is foolish to persist in efforts to save the 
vena cava. When it is easy to peIform, there is little that can be said 
in criticism of this variant technique, which is being used in about 
75 cases per year in our Pittsburgh program.82 
Graft Revascularization 
In most cases, anastomoses of the vena cava above and below the 
liver are performed first. While the lower vena cava anastomosis is 
being constructed, the liver is flushed with lactated Ringer's solution 
to remove entrapped air from its major veins and to rid the graft of 
the highly concentrated potassium that is contained in the preserva-
tion fluid (Fig 26). Failure to observe these precautions can result in 
air embolus or in cardiac arrest from hyperkalemia.62 The portal 
venous anastomosis usually is done next, and the liver is revascular-
ized with a portal blood supply. A very aggressive effort then is made 
to find major bleeders and to control these before proceeding with 
rearterialization. As already mentioned under donor hepatectomy, 
many options have been described for dealing with anomalies or 
other unusual anatomic features of the donor or recipient arteries. 
The objective in all is to ohtain as large a caliber recipient vessel as 
possihle, consistent with the size of the donor artery. This usually 
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FIG 24. 
Maneuver that facilitates cleaning the 
dissection of the retrohepatic vena 
cava and removing the liver. A vascular 
plane exists on the anterior surface of 
the retrohepatic vena cava, which is 
developed with a gently inserted finger. 
(From Tzakis A, Todo S, Starzl TE Ann 
Surg 1989; 210:649-652. Used by 
permission.) 
FIG 25. 
After the plane is developed as 
shown in Figure 24, the liver is 
boldly transected, bringing into view 
the vena cava, and the right and left 
fragments are removed as quickly 
as possible. (From Tzakis A, Todo 
S, Starzl TE Ann Surg 1989; 
210:649-652. Used by permission.) 
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Technique of washing out the homograft, which is performed with both the piggyback and 
standard operations. The organ is washed with a solution of low potassium concentration 
(A) to avoid the infusion of a bolus of potassium from the preservation fluid during revas-
cularizatlon. In addition, it is important to wash out air that may be trapped in the large 
hepatic veins (8 and C). Failure to eliminate these bubbles could lead to air embolism. 
(Redrawn from Starzl TE, Schneck SA, Mazzoni G, et al Ann Surg 1978; 187:236-240.) 
requires making the anastomosis proximal to the gastroduodenal ar-
tel)' in recipients with normal arterial anatomy and often proximal 
to the splenic and left gastric arteries in those recipients with anom-
alies. 
Vein grafts of the portal vein can be inserted above the pancreas, 
usually at the confluence of the splenic and superior mesenteric 
vein (see Fig 11). If a portal vein thrombosis extends too far distally 
to allow insertion of a vein graft superior to the pancreas, a jump 
graft can be placed on the anterior surface of the superior mesen-
teric vein below the transverse mesocolon. The graft is brought ante-
rior to the pancreas and beneath the pylorous (Fig 27). 
In restoration of the portal venous and hepatic arterial circula-
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FIG 27. 
The use of an antepancreatic portal vein graft from the superior mesenteric vein through 
the same pathway as shown for an arterial graft In Figure 12. The use of these grafts has 
eliminated portal vein thrombosis as a contraindication to transplantation, providing a 
good superior mesenteric vein is still open. (From Tzakis A, Todo S, Stieber A: Transplan-
tation 1989; 48:530-531. Used by permission.) 
tions, perlonnance of a poor anastomosis with subsequent thrombo-
sis usually will cause death or necessitate retransplanlation. We 
have described special techniques to prevent flawed anastomoses, 
particularly in children who have small vessels.83 These special tech-
niques were designed to prevent anastomotic strictures.83 The anas-
tomoses are done in the usual way with a continuous polypropylene 
suture (Figs 28,A and B), but a so-called growth factor is left by tieing 
the sutures at a considerable distance from the vessel wall (Fig 28,C). 
After flow is restored through the hepatic arteIY or portal vein, the 
excessive suture recedes back into the vessels and distributes itself 
throughout the circumference of the suture line (Fig 28,D). If an ad-
ditional suture is placed at the point where the two ends of the con-
tinuous suture line meet, thus pI'eventing distraction of the lips at 
this point, the amount of hemorrhage at the time of flow restoration 
is surprisingly small. Suture materials other than polypropylene are 
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FIG 28. 
Method of avoiding strictures of small vascular anastomoses. See text for explanation. 
(Redrawn from Starzl TE, Iwatsuki S, Shaw BW Jr: Surg Gynecol Obstet 1984; 
159: 164- 165. Used by permission.) 
not satisfactory for this technique. The polypropylene is so slippery 
that it is not caught by the adventitia and can easily work itself back 
through the entire circumference of the suture line. 
Biliary Reconstruction 
An acceptable technique of biliary tract reconstruction if the ana-
tomic conditions permit is end-to-end anastomosis of the donor and 
recipient common ducts over aT-tube stent (see Fig 1).67 Variants of 
this principle include a side-to-side choledochocholedochostomy 
after closure or ligation of the donor and recipient duct ends.84 Al-
ternatively, the homograft common duct can be anastomosed to a 
defunctionalized (Roux) limb of jejunum (see Fig 1) with equally 
good resuits.67,85,86 Whichever method is used, there has been a 
10% to 15% incidence of late bile duct obstruction that required cor-
rection by interventional radiologic techniques, secondary duct re-
construction, or in occasional cases with retransplantation.85 - 89 
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FIG 29. 
Typical extrinsic mass effect on homograft common hepatic duct, which is caused by ob-
structing a cystic duct at both ends. This surgical complication results in obstructive jaun-
dice and requires secondary excision of the resulting mucocele. (From Koneru B, Zajko 
AB, Sher L, et al Surg Gynecol Obstet 1989; 168:394-396 Used by permission.) 
One kind of biliary obstruction that is highly avoidable is caused 
by leaving an obstructed segment of the cystic duct with the graft. 
Usually, this occurs when the cystic duct enters the common duct 
at an anomalously low level, creating a double lumen at the site of 
duct transection. If the distal and proximal ends are occluded, a 
mucocele can form in the obstructed segment and lead to extrinsic 
compression (Fig O9FD~Fl The best way to avoid this is to completely 
resect the cystic duct at the time of transplantation. Alternative tech-
niques are shown in Figure 30. 
Rarely, there may be an indication to use a technique that incor-
pm'ates a donor gallbladder conduit between the donor common 
duct and the recipient anastomotic site.91. D2 This method (Fig 31), 
which was described by Waddell and Grover91 and by Calne,9z has 
had a high incidence of late sludge and stone formation. In our ex-
perience, almost one half of the biliary tracts reconstructed with the 
Waddell-CaIne technique eventually developed the characteristic ob-
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FIG 30. 
The best way to prevent mucocele formation is to completely excise the cystic duct, but 
alternative techniques to prevent a blind cystic duct remnant are shown. (From Koneru B, 
Zajko AB, Sher L, et al: Surg Gynecol Obstet 1989; 168:394-396. Used by permission.) 
struction shown in Figure 32.93 It has been possible to rectiJY the sit-
uation by conversion to a choledochojejunostomy. 
Need for Hemostasis 
Complete hemostasis is mandatory before closing. The assump-
tion that nature will take care of bleeding if effective liver function is 
provided by a homograft has proved to be a vain hope on many oc-
casions. Often a coagulopathy will be present intraoperatively that 
can persist into the postoperative period. 
The presence of the coagulation expert Dr. Kurt von KauUa at the 
University of Colorado in the 1960s was a key element in the devel-
opment of the transplantation programs there. Von Kaulla and asso-
ciates studied the renal94 and hepatic95 recipients and characterized 
the clotting defects in both classes of patients. In the first three liver 
recipients, they demonstrated clotting factor defects, showed the se-
riousness of fibrinolysis as well as how to treat this problem.63 They 
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FIG 31. 
The Waddell-Caine technique of gallbladder conduit biliary reconstruction. Note that the 
homograft common duct has alternative pathways of emptying, both through the gallblad-
der conduit. The choledochocholecystostomy is stented with a T tube brought out through 
the gallbladder. (Frorn Halff G, Todo S, Hall R, et al: Transplantation 1989; 48:537-539. 
Used by permission.) 
recommended the thromboelastogram to follow the minute-to-
minute clotting changes in the operating room in much the same 
way as is recommended and practiced currently. Other studies 
showing consumption of clotting factors, including platelets within 
the graft itself6,97 and the development in some patients of a hyper-
coagulable state postoperatively, completed the picture. Flute of 
Cambridge provided confirmatOIY data.98 Ultimately, this kind of in-
formation was acted on systematically for therapeutic correction by 
the anesthesiologists at the University of Pittsburgh in the early 
1980s under the direction of Drs. Jessica Lewis, Frank Bontempo, 
and Yoo Goo Kang.99-103 Now cautious correction of coagulation de-
fects is an integral part of liver transplantation, greatly diminishing 
the hemorrhages of nightmare proportions that were common. As 
already emphasized, the other factor that has ameliorated the intra-
operative bleeding problems has been the systematic use of veno-
venous bypasses. 
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FIG 32. 
Typical complication with the Waddell-Caine reconstruction. (From Half! G, Todo S, Hall R, 
et al Transplantation 1989; 48537-539. Used by permission.) 
Many hours of tedious and exhausting effort may be necessary 
to obtain perfect hemostasis, but these efforts are eventually re-
warded with a dry wound. After hemostasis has been accomplished, 
closed sump drains are placed in two or three locations above and 
below the liver, and the wound is closed with nonabsorbable su-
tUI"CS. 
Modifications of This Standard Procedure 
The piggyback operation, in which the graft is placed onto the an-
terior surface of the retained recipient inferior vena cava, was men-
tioned previously. The other structures are anastomosed in the 
usual way. The piggyback reconstruction gives an unusual degree of 
mobility to the liver and a greater freedom in tailoring vessel lengths. 
These may be impOItant advantages if the donor liver is substantially 
smaller than the diseased native organ that was removed. The piggy-
back operation has also been espeCially helpful for four of our pa-
tients with situs inversus, of whom one has been reported (Fig 33). A 
patient with situs inversus also has had an orthotopic liver trans-
plantation performed by Raynor and colleagues, with removal of the 
vena cava in the usual way.l04 
Size reduction techniques that permit the transplantation of part 
of a liver have been perfected in recent years in Paris/O!i.,06 Han-
nover,107, 101' Brussels/09 and Chicago,110,111 allowing greater flexibil-
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FIG 33. 
Reconstruction after transplantation to a child with situs inversus. Note suprahepatic infe-
rior vena cava of the graft was anastomosed to the anterolateral surface of the recipient 
inferior vena cava. The graft infrahepatic vena cava was ligated. (From Todo S, Hall R, 
Tzakis A, et al: Clin Transplantation, in press. Used by permission.) 
ity in matching donor availability to recipient needs. Pediatric recip-
ients have benefitted most from this development. The first known 
example of partial liver transplantation occurred on March 26, 1975 
at the University of Colorado. The left lateral segment of an adult 
liver was transplanted into the orthotopic position in an infant with 
biliary atresia. Because of its historic interest, the case is described 
here. 
The recipient, a 23-month-old boy weighing 8.2 kg, had a failed Kasai POI'-
toenterostomy and subsequent cholangitis. Absence of the retrohepatic in-
ferior vena cava shadow was noted on a chest x-ray film. At the time of 
transplantation, the absence of the retrohepatic inferior vena cava was con-
finned. The portal vein was in a pl'Cduodenal location. Multiple splenic 
nodules were situated in the uppel' left quadrant (splenosis), and intestinal 
malrotation was present. This constellation of anomalies is not rare in bil-
iaIY atresiaU2 Removal of the 40S-gm liver was difficult because of multiple 
dense vascular adhesions and portal hypertension. The liver graft was taken 
fmm a large adult male donor whose exact weight is not known. A right tri-
segmentectomy was done with an intact circulation, leaving the left lateral 
segment (weighing 700 gm) vascularized in the donor until the last possible 
moment. The graft was revascularized by connecting the donor left hepatic 
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FIG 34. 
The first-known effort at use of a cut-down liver. The lateral segment of a large donor was 
transplanted to a 7V2-year-old child who was dying of biliary atresia. The head of the child 
is to the left, and the legs are to the right. The lateral segment was too large, and the 
wound could not be closed. This operation was first used successfully by Bismuth of Paris 
and has been used extensively in France, Germany, Belgium, and the United States (see 
text). 
vein end to end to the venous cloaca into which the diseased liver had 
drained. The donor left hepatic artery and left portal branch were anasto-
mosed end to end to the recipient's common hepatic artery and portal vein, 
respectively. The donor left hepatic duct was anastomosed to a previously 
created Roux-en-Y jejunostomy. 
After revascularization, the liver segment had immediate return of normal 
color and consistency. However, the fragment was too large to permit clo-
sure of the abdomen (Fig 34). Consequently, Dr. John Lilly covered the 
wound by suturing a sheet of Silastic-Marlex mesh to the peritoneum and 
fascia of the abdominal wound. A persistent bleeding diathesis occUlTed in-
traoperatively and subsequently. The child died 36 hours later, and at au-
topsy, the liver was relatively normal except for scattered focal infarcts. 
There was a 4S0-mL hemoperitoneum. PulmonaIY i-isomerism and patent 
ductus arteriosus were also noted. 
In this 1975 case, the fragment of liver that was retained still 
weighed almost twice as much as the excised native liver, dooming 
the effort to failure. In addition to the senior author of this mono-
graph, members of the surgical team included many young surgeons 
whose continued academic activities are reflected in their current 
University appointments: John H.. Lilly (Professor, University of Colo-
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rado), C. W. Putnam, (Professor, University of Arizona), R. H. Bell (As-
sociate Professor, University of Cincinnati), R. W. Beart (Professor, 
Mayo Clinic), M. Ishikawa (Professor, Tohoku University, Japan), and 
M. A. Haberal (Professor, Turkish Transplantation and Burn Founda-
tion, Ankara). 
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EARLY GRAFT FUNCTION 
The correction of preexisting liver function abnormalities begins 
intraoperatively if good graft function is obtained. When the graft 
fails completely to provide function, the only recourse is prompt re-
transplantation before cerebral edema and br'ain stem herniation oc-
cur.113 Lesser degrees of graft injury can lead to renal failure, altered 
consciousness, a need for prolonged ventilatOlY support, ileus, and a 
host of other complications, which, even if they are not lethal, re-
quire protracted intensive care unit stays and generate astronomical 
hospital bills.114 The penalties of primary dysfunction or nonfunc-
tion are so severe that much effort has been made to delineate the 
causes, to prevent these, to quickly quantitate the prospects of re-
covery, and to facilitate decisions about urgent retransplantation. 
Since late 1987, the incidence of early graft failure necessitating re-
transplantation in the first 3 months or leading to death has been 
about 10% .52 This incidence was down from 18% in the immediately 
preceding period.52 113 However, primary graft failure still occurs in 
10% to 15% of cases.52. 115, 116 There are four general reasons for graft 
failure, which are not necessarily mutually exclusive: (1) unrecog-
nized liver disease in the donor, (2) a technically imperfect recipient 
operation, (3) ischemic injury of the graft, or (4) an immune event peri-
operatively. In Part II (CPS, March 1990) we will discuss the fourth 
factor, and will add a fifth factor, namely, endotoxemia, which is still 
speculative but too important to ignore as a possibility. 
PREEXISTING DISEASE 
When a liver has primary nonfunction in spite of a seemingly per-
fect operation, it may have been diseased in the donor even though 
the tests used to screen donors were acceptable. Undetected 
chronic disease has been distinctly uncommon in livers that have 
passed through the donor screening process.117-. 119 However, a few 
indisputable examples in which the donor livers had diffuse fatty 
infiltration (Fig 35) or other serious abnormalities have been re-
ported.117• uo Rarely, an unrecognized malignancy can be trans-
ferred with the donor liver?21 
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FIG 35. 
Transplantation of a liver with severe macrovesicular steatosis involving more than 80% of 
hepatocytes, as is shown in (A), from a back-table biopsy predictably results in graft fail-
ure. After reperfusion (8) lysed hepatocytes release the fat (F, clear spaces), which con-
tributes to microvasculature disruption with fibrin deposition and leukocyte sludging. 
(From Todo S, Demetris A, Makowka L, et aJ: Transplantation 1989; 47:903-905. Used by 
permission.) 
The pathologist frequently is requested to evaluate a donor liver 
by frozen section before implantation because of gross physical al-
terations or suspicious agonal events in the donor. Gross inspection 
of the potential allograft by the pathologist is mandatory. Donor dis-
eases recognized on frozen section in Pittsburgh have included met-
astatic carcinoma, diffuse regenerative hyperplasia, focal nodular hy-
perplasia, small noncaseating granulomas, severe steatosis, probable 
alcohol-induced injury, changes consistent with chronic active, per-
sistent or nonspecific reactive hepatitis, and multiple small subcap-
sular infarcts. The livers with carcinomas, diffuse regeneration hy-
perplasia, and chronic active hepatitis have not been used. Those 
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with severe steatosis (see Fig 35) have also been routinely disre-
garded after several organs with similar changes were transplanted 
and failed.120 Donor organs with nonspecific reactive hepatitis, small 
noncaseating granulomas, and other mild nonspecific changes are 
routinely used and have not caused problems. Usually, small focal 
nodular hyperplasia lesions are removed before implantation. In the 
absence of any of the obvious contraindications or severe ischemic 
injury, the pathologist is unable to predict the adequacy of organ 
function after transplantation based on frozen section light micros-
copy prior to the operation. 
TECHNICAL FAILURE 
Early retransplantation has been successful in less than one half 
of the cases when carried out in patients whose primary graft failure 
was caused by technical deficiencies.113 This reflects in part the in-
fections that quickly develop in or around a graft that is imperfectly 
transplanted as well as the rapidity of hepatic decompensation in 
many of the recipients. 
Florid technical complications account for less than 10% of pri-
mary graft failures in adults compared with 30% in pediatric recipi-
ents.113 With very small pediatric recipients, defined by a weight of 
less than 10 kg or by an age less than 1 year, technical complications 
have been a significant factor in a 35% i-year mortality.122 Vascular 
thrombosis has been a particularly troubling problem in these tiny 
recipients.122-124 
Thrombosis of the hepatic artery or portal vein is usually classified 
as a technical error. Most technical errors are obvious, but subtle 
flaws in revascularization can be hard to diagnose. Suboptimal por-
tal venous flow or reduced hepatic arterial flow has been found with 
electromagnetic flow meter studies .125 - 127 In some of these cases, an 
unsatisfactory and ultimately correctable situation was not sus-
pected before the flow determinations were obtained. A few patients 
have undergone emergency reconstruction of the thrombosed arter-
ies.126,128 
When a graft fails because of arterial thrombosis, the pathologist 
may be able to find an underlying defect in the artery such as in-
traluminal mural flaps, devitalization of part of the wall, or intramu-
ral dissection. In a multivariate factor analysis in pediatric recipi-
ents,129 the risk of arterial thrombosis was increased if the vessels 
were smaller than 3 mm, if the anastomoses had to be revised, or 
if aortic or iliac grafts were needed as "conduits" to the hepatic ar-
tery. 
Portal vein thrombosis has been rare and usually occurs when the 
splanchnic venous bed of the recipient was altered by a previous op-
eration, such as a portal-systemic shunt or splenectomy.13o Unless 
they are looked for, venous thrombi can be carried to the recipient 
in the portal vein of the liver graft, particularly if there has been a 
splenic injury in the donor?31 Spontaneous resolution of a portal 
vein thrombosis has been reported?32 However, early portal vein 
thrombosis usually requires retransplantation.130 A few patients 
have been saved by immediate or delayed operation and secondary 
portal vein reconstruction.67,133 Two patients whose reconstructed 
portal vein thrombosed have had distal splenorenal shunts.134-136 
The first of these patients is still well 7 years after transplantation 
and 6 years after the shunt ,134, laS 
It is also true that hepatic artery thrombosis does not necessarily 
lead to graft loss. The event may be completely asymptomatic in 20% 
to 30% of cases?23. 137, 1311 Until Doppler ultrasound examinations 
were used routinelyI1P~ the diagnosis would not have been sus-
pected in these recipients. In contrast, all of the syndromes that 
develop in symptomatic patients are serious and include primary 
non function, regional septic hepatic infarction of a liver of which 
the viable portions may retain good function, bacteremia, abscess 
formation, rupture of the dearterialized ducts with bile peritonitis or 
with bile leakage, and biloma formation within the graft paren-
chyma (Fig 36) ?4.123, 137, 138, 140-143 Later, multiple intrahepatic biliary 
FIG 36. 
Formation of a biloma wit~lin a dearterialized liver. Typically, patients with this complication 
have good liver function. It is possible to drain the biloma with a radiologically directed 
catheter, but retransplantation usually IS necessary. (From Zajko AB, Campbell WL, Logs-
don GA, et al: Transplant Proc 1988; 20[suppl 1]607-609. Used by permission.) 
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strictures resembling the lesions of sclerosing cholangitis may form 
(Fig 37).138,141,142 
The diagnosis of hepatic artery thrombosis has been made much 
more frequently since the availability of Doppler ultrasound. Before 
then, arteriography was needed as a definitive step, but this was not 
commonly done. Needle biopsy is a rather insensitive method for es-
tablishing the diagnosis of hepatic artery thrombosis?44, 145 The his-
tologic changes can be quite variable and core needle biopsies are 
subject to more sampling error than usual. The findings may range 
from completely normal to frank coagulative necrosis. Marked peri-
venular hepatocellular swelling, cholangiolar proliferation, often 
with bile plugs, and acute cholangiolitis similar to that seen with 
"preservation injury" may also be observed. The pathologist should 
routinely search for microorganisms when necrotic tissue in en-
countered, since these foci frequently become seeded with bacteria 
and fungi (Fig 38). 
FIG 37. 
Multiple strictures in a patient whose hepatic artery clotted early. The recipient survived 
but ultimately developed cholangitis from multiple strictu red and obstructive sites. The 
resulting appearance of the duct system has some resemblance to sclerosing chol-
angitis. (From Zajko AB, Campbell WL, Logsdon GA, et al: Transplant Proc 1988; 
20[suppl 1]:607-609. Used by permission.) 
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FIG 38. 
A, gross examination of a failed allograft with hepatic artery thrombosis often reveals ne-
crosis of the hilar structures, including the connective tissue (arrowhead). B, microscopi-
cally, the large bile ducts are often necrotic, and the dead tissue becomes seeded with 
microorganisms, which was Candida in this case. (From Demetris AJ, Kakizoe S, Oguma 
S, Pathology of liver transplantation, in William JW led]: Hepatic Transplantation. Philadel-
phia, WB Saunders Co, 1990, pp 60-113. Used by permission.) 
Since the hepatic artery is the sole direct supply of blood to the 
major bile ducts, intrahepatic ducts, hilar connective tissue, lymph 
nodes, and walls of the portal vein/46 compromise to arterial flow 
frequently leads to selective necrosis of these structures (see Fig 
38). In addition, an allograft may be more susceptible than non-
grafted livers to this form of injury since it is devoid of the natural 
cascade type of arterial collaterals, at least in the early postoperative 
period. The areas prone to necrosis are not easily accessible to 
routine needle biopsy sampling. Therefore, biopsy monitoring of an 
allograft with a thrombosed artery may lead to a false sense of 
security. 
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"Medical" Factors Contributing to Vascular Thrombosis 
Preoccupation about mechanical and technical causes of graft 
thrombosis is justified. However, so-called medical factors can con-
tribute to or even make inevitable the thrombosis of a hepatic artery 
or portal vein. Overzealous correction of dotting defects during op-
eration was shown long ago to predispose to vascular thrombosis in 
small children,147 a lesson recently relearned with the use of fresh 
frozen plasma.129 Polycythemia caused by transfusion is another iat-
rogenic risk factor.148 The tendency of children to clot their vessels 
may be greater than in adults because of deficiencies in protein C 
and antithrombin and by defective flbrinolysis?49 
An additional factor of unknown significance is the institution of 
cyclosporine therapy. This drug alters the prostanoid metabolism 
and other hemostatic processes of vascular endothelial cells.150-153 
Finally, a drastic reduction in hepatic blood flow is a well-known 
feature of rejection.154 In a French clinical study, hepatic artery or 
portal vein thrombosis was associated with rejection more strongly 
than with any other definable factor. 155 
Microvascular Injury 
Another factor making the new liver vulnerable to thrombosis dur-
ing the perioperative and early postoperative periods is injury to the 
hepatic microvasculature from ischemia and cold preservation.150-159 
The denudation of the sinusoidal lining in preserved livers as as-
sessed by light and electron microscopic studies is now known to be 
so extensive159 that it is surprising that vascular thrombosis is not 
even more common than it is. 
ISCHEMIC INJURY 
It is not practical at present to measure in advance or even to es-
timate very accurately the ischemic injury during the events causing 
donor death, the procurement operation itself, and the period of for-
mal cold preservation. The interval from cessation of donor circula-
tion to cooling of the liver with preservation fluid is called warm 
ischemia time. The storage time after this plus the time to sew in the 
liver and restore its portal flow after removing it from an ice chest 
are termed cold ischemia. Under conditions of brain death pro-
nouncement, and with modern techniques of multiple-organ pro-
curement,23,24 there is virtually no warm ischemia. 
Thus, almost all clinical reports equate cold ischemia with global 
ischemia. If this simplistic view were correct, the degree of organ 
damage would be a direct reflection of preservation time. The ex-
pected association can be demonstrated easily in controlled animal 
experiments30,44,SO, 157-160 but far less clearly in a clinical setting, 
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Part of the unpredictability could be caused by the variability of the 
time required to establish portal reperfusion and after this to restore 
the arterial supply. Rearterialization may be accomplished in some 
cases within 20 or 30 minutes after portal revascularization, but in 
others in which bleeding disrupts the desired routine, the inteIval 
can be many hours. 
As described earlier, with the preservation techniques that were in 
clinical use through 1987, the safe preservation limits for human liv-
ers were set at 6 to 8 hours. These limits were conservative since dog 
livers could be stored for two or three times this interval after infu-
sion with oncoticallv controlled electrolyte (Collins') solutions with a 
high potassium cl~lcentrationPd or with a plasma-like solution.44 
When the potassium-rich Euro-Collins solution was used to store 
human livers for 3 to 8 hours, there was no correlation at all be-
tween liver injury and preservation time as judged by a battery of 
liver function tests.52,S;{ Makowka and associates161 and Miller and 
colleagues162 made the additional perplexing observation that the 
condition of the donor was not important in influencing the out-
come. Seemingly "unsatisfactory" cadaveric donors with poor blood 
gases, an unstable cardiodynamic state, or even moderately abnor-
mal hepatic function tests provided livers that performed as well as 
organs removed from ideal donors. The same thing has been re-
ported from the European liver registry?6:l 
The fact that liver injury as judged by hepatic function tests, as 
well as graft and patient survival, has not had a significant associa-
tion with preservation time does not mean that long storage times 
should be accepted lightly. Even ~vith the UW solution,161 very signif-
icant deterioration of graft quality has been demonstrated in con-
trolled canine experiments between 1 and 24 hours of preservation. 56 
Apparently, undefined factors in the heterogeneous human donor 
and recipient popUlation are important enough to obscure the ex-
pected time/tissue damage I'elationship. 
At present, the transplantation itself serves as the test by which 
the assessment of ischemic injury is made after the fact instead of 
prospectively. lntracellular pH, energy charge, mitochondrial func-
tion, and surrogate or direct measures of oxygen free-radical species 
in preserved liver tissue do not accurately predict graft quality in ex-
perimental animals. l!i4, IG5 Instead, the ATP content of the preserved 
graft falls sharply even during the initial chilling infusion. Because it 
is the rapidity of ATP restoration after revascularization rather than 
its level before reperfusion that is discriminating as a prognostic 
sign, ATP measurements during preservation have not been thought 
to be helpful prospectively, with the exception of a single clinical re-
port.1G6 
It may be that none of these metabolic tests are appropriate since 
they all reflect hepatocyte metabolism. This would seem logical 
50 
since in the past, it has been assumed that the parenchymal cells of 
whole organ grafts were the most vulnerable targets of ischemia. As 
was described in an earlier section, attention has shifted to the mi-
crovasculature, which not only may be the most exquisitely sensitive 
component of many whole organs but which also ensures (when in-
jured) a perpetuation of parenchymal ischemic injury. For example, 
in studies of canine kidneys, Ueda and associates have demon-
strated with a microphil technique the remarkable "pruning" of the 
terminal arter'ies and arterioles that can occur within 60 minutes af-
ter restoration of the renal arterial supply of inadequately preseIved 
kidneys.i6? A devascularization is the consequence that is far less ex-
treme in kidneys preserved with UW solution than in kidneys pre-
served with the Euro-Collins solution (Fig 39). 
The sinusoidal endothelium of the liver is a unique microcircula-
tOly bed. It lacks a well-defined basement membrane, is structurally 
specialized, forming large fenestrae to allow exchange of metabo-
lites between the blood and hepatocytes, and is in close proximity to 
the Kupffer cells.16B The cell swelling and subsequent damage that 
occurs during hypothcrmia are thought to be responsible for thc fo-
cal areas of sinusoidal lining cell denudation observed ultrastructur-
ally after cold preservation. 
Destruction of the liver that occurs after reimplantation by the 
"I'cperfusion" mechanism is thought to be caused by two different 
but interrelated eventsK1R~K 169 In the first, loss of the sinusoidal lining 
cells disrupts the architectural framework of the hepatic microvas-
culature, preventing adequate restitution of the blood flow. Instead 
of the antithrombogenic environment normally present in the siml-
soids, exposure of the blood to coagulation stimulants results in fi-
brinogen activation and local clotting with trapping of red blood 
cells and leukocytes.159, 169 This contributes to the circulatory block-
ade and fosters the accumulation of leukocytes. These cells likely 
seI\'e as sources of tissue damaging oxidant lfree radical) molecules, 
which is the second proposed pathway of destruction during reper-
fusion injury. 
Pl'Otocol biopsies of human liver allografts obtained during back-
table preparation and 1 to 2 hours after rcvascularization in the re-
Cipients have detailed the sequential histologic events that occur af-
ter repeIfusion.uig As would be expected, the vast majority of back-
table biopsy specimens are essentially normal by light micl'Oscopic 
examination except for hydropic cell swelling. Sinusoidal lining cell 
integrity cannot be reliably evaluated on immersion-fixed, paraftin-
embedded, and routinely stained sections. However, ultrastructural 
examination of the same biopsy specimens may show severe sinusoi-
dal lining cell damage and denudation (Fig 40) like the changes ob-
seIved in animalsK1RS-1R~F However, no specific histologic feature on 
the back-table biopsy specimen is able to predict postoperative or-
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FIG 39. 
Dissecting photomicrographs of renal vascular architectures filled with silicon rubber com-
pound 1 hour after reperfusion of the grafts (x 40). A, 72-hour Euro-Collins group. Notice 
complete filling defect of subcapsular cortex and medulla. Patchy distribution of a vascu-
lar area, irregular and deformed pattern of interlobular artery and glomerulus can be seen. 
B, 72-hour UW group. The capillary networks of both cortex and medulla are fully filled 
with silicon rubber. (From Ueda Y, Todo S, Imventarza 0, et al: Transplantation 1989; 
48:913-918. Used by permission.) 
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FIG 40. 
A, plastic-embedded sections of donor livers reveals that the sinusoidal lining cells bear 
the brunt of cold preservation injury. Note the endothelial cell denudation (arrows) with 
loss of the space of Disse Hepatocytes usually show mild reversible changes such as a 
fatty vacuolization and bleb formation (arrowhead). e, ultrastructural analysis confirms the 
loss of sinusoidal endothelial cells, and leukocytes become directly adherent to hepato-
cytes (EL = endothelial cell; L = lymphocyte; N = neutrophil; H = hepatocyte) (From Kak-
izoe S, Yanaga K, Starzl TE, et al: Hepatology [in press]. Used by permission.) 
gan function other than those that preclude organ use (see earlier 
discussion) . 
Within hours after repenusion, livers that were minimally dam-
aged during preservation show surprisingly few pathologic alter-
ations. By contrast, zonal coagulative hepatocellular necrosis, either 
in the perivenular or periportal regions, accompanied by a brisk 
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neutrophilic exudate, and acidophilic bodies scattered throughout 
the lobule are signs of serious graft injury and harbingers of poor 
postoperative function in many instances (Fig 41). The evaluation of 
postperfusion injury can be influenced by the site of biopsy. It must 
be remembered that core needle biopsy specimens taken from the 
periphery of the organ may show more severe injury than the 
deeper parenchyma, and as always, the pathology findings should 
be interpreted in context with the complete clinical profile. 
Once the liver is revascularized, quick assessment of its quality 
from metabolic studies is far more practical than a postperfusion 
biopsy. Measurements of blood amino acids clearance and study 
of other products of intermediary metabolism have been used 
to distinguish those patients whose new livers can and cannot 
be expected to recover.170-173 However, one of the simplest of all 
signs, namely, bile production by the new liver, has long been 
recognized as the most important predictor of success after revas-
cularization. Recent studies in animals174, 17.'> and humans 176 have 
shown an almost perfect correlation between bile production, the 
rapidity of restoration of liver ATP levels after revascularization, and 
survival. 
Next to bile production by the graft, restoration of good clotting in 
the recipient95-101 and absence of lactic acidosis116,17o.171 are pre-
dictors of success. The coagulopathies that occur intraoperatively 
during liver transplantation are characterized by fibrinolysis, defi-
ciencies of specific clotting factors and platelets, and consumption 
FIG 41. 
Zonal hepatocellular necrosis in a reperfusion biOPSY, particularly when periportal in distri-
bution (arrows), is a harbinger of poor postoperative function in many cases (PT = portal 
tract; CV = central vein), (From Kakizoe S, Yanaga K, Starzl TE. et al: Hepatology [in 
press]. Used by permission.) 
54 
FIG 42. 
A, in the first few weeks after transplantation, grafts with mild ischemic injury show centri-
lobular hepatocyte swelling and hepatocanalicular cholestasis (PT = portal tract; CV = 
central vein). e, when the initial injury is more severe or periportal in distribution, cholang-
iolar proliferation and acute cholangiolitis are seen and represent attempts at repair, 
which, in most cases, is successful (see text). C, the structural changes and cholangiolar 
bile plugs (arrows) may persist for 1 to 2 months while the serum bilirubin level slowly de-
clines. 
of the clotting components.63, 95-101,147,177,178 Standard liver func-
tion tests during the following days almost always verify the accu-
racy of the simple intraoperative assessments of bile production and 
clotting. 
Even organs severely damaged from preservation have the ability 
to completely recover after transplantation, both functionally and 
structurally. Biopsy specimens are often obtained at several-day 
intervals or weekly during the first 1 or 2 months in such patients, 
because clinically they can develop a prolonged cholestatic syn-
drome that does not resolve with increased immunosuppressive 
therapy.144,179 A fairly ordered sequence of events may be seen in 
such specimens. 
The histologic evolution of repair depends on the degree of de-
struction.144.145 If the initial damage was relatively mild, lobular re-
generation, as evidenced by hepatocellular mitoses and twinning of 
the plates, starts 2 to 3 days after transplant and is complete by 7 to 
10 days, Mild perivenular hepatocanalicular cholestasis and cell 
swelling are also common features (Fig 42). If the damage is severe, 
and particularly if it is periportal in nature, florid cholangiolar prolif-
eration ensues, which is invariably accompanied by neutrophils (i.e., 
cholangiolitis) and the hepatocellular regenerative changes men-
tioned earlier. These biopsy specimens are also marked by extensive 
cholestasis, both hepatocanalicular and cholangiolar, simulating 
large duct obstruction (see .Fig 42). Total or near-total restitution of 
the liver is the usual outcome if the patient is well enough otherwise 
to permit the liver time enough to recover; this may take up to 2 
months.144,145 
For the pathologist, the major differential diagnoses for the find-
ings associated with preservation injury include large bile duct ob-
struction, sepsis, and hyperalimentation-induced injury. The histo-
logic features used to rule out duct obstruction are reviewed in the 
section on biliary tract obstruction. Sepsis may be virtually impossi-
ble to separate with certainty. Finally, coexistent rejection is not un-
common in these patients and is recognized pathologically by the 
appearance of a predominantly mononuclear portal infiltrate with 
evidence of venous endothelial and bile duct damage (see the dis-
cussion of acute rejection pathology). 
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PERIOPERATIVE IMMUNE EVENTS 
If other explanations for primary nonfunction or dysfunction of 
the liver graft have been exhausted, host immune factors may be re-
sponsible. It is well known that human kidney180,181 and heart 
grafts182-184 can be destroyed almost immediately by humoral anti-
bodies in a process called hyperacute rejection. There have been no 
unequivocal examples of hyperacute rejection after clinical hepatic 
transplantation, supporting the widely held opinion that the liver is 
resistant to this kind of antibody mediated injury. Because of this re-
sistance, liver transplantation has often been performed in spite of 
positive cytotoxic crossmatches against the donor185-189 and in spite 
of ABO incompatibilities/90-193 which because of the antigraft spec-
ificities of the ABO isoagglutinins would preclude renal or cardiac 
transplantation. Although the liver is resistant to humoral rejection, 
it is probable that humoral antibodies can cause severe graft damage 
in humans. 
WITH ABO-COMPATIBLE DONORS 
The role and importance of cytotoxic antilymphocyte antibodies 
in causing non function of liver grafts are not well delineated. These 
antibodies with antigraft specificity in kidney recipients are highly 
predictive of hyperacute rejection, particularly if the antibody is of 
the "warm" IgG variety?94 The central event of hyperacute rejection 
of the kidney is occlusion of the graft microvasculature by rapidly 
sequestered formed blood elements and by clotting factors.19S-19B A 
striking feature of hyperacute renal rejection if this does not go 
promptly to completion can be the development of a consumption 
coagulopathy and, sometimes, fibrinolysis.196, 197, 199,200 
The association of hyperacute kidney rejection with cytotoxic an-
tibodies directed against donor lymphocytes was first described by 
Terasaki and associates180 and confirmed by Kissmeyer-Nielsen and 
co-workers.181 At first, the simplistic view was that the cytotoxic an-
tibodies themselves were directly responsible for injuring the endo-
thelium of the microvasculature. However, it was soon realized that 
the process was far more complex, that the end result resembled the 
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Schwartzman reaction that can be produced in the kidneys of ani-
mals injected with endotoxin,195 and that destruction of the organ 
probably took place through the action of mediators. At the time, lit-
tle was known about soluble mediators of the inflammatory re-
sponse, and most of these biologically potent substances had not yet 
been discovered. The possible role of these mediators in hyperacute 
humoral rejections has been summarized from a modern perspec-
tive by Makowka and colleagues,201 and in a following section, a pos-
sible additional association of these mediators with recipient endo-
toxemia will be mentioned. 
Hyperacute rejection of the liver was suspected after one of the 
first clinical attempts of orthotopic liver transplantation in a child 
whose graft developed hemorrhagic necrosis a few hours postoper-
atively.202 The gross description of this liver was similar to the find-
ings described many years later in rats20:1 and in rhesus monkeys2114 
sensitized with skin homografts and blood transfusions before or-
thotopic liver transplantation. However, experiments in rodents have 
also demonstrated the difficulty of inducing intense enough sensiti-
zation to reduce hepatic graft sUIviva120S, 206 or else have shown that 
liver heterografts are rejected by heterospecific antibodies later and 
less violently than the heart and presumably other organs.206, 207 
Such is the resistance of the liver to cytotoxic antibodies that a 
positive cytotoxic crossmatch should not preclude an effort at liver 
transplantation. It also is becoming evident that accelerated (possi-
bly humoral) rejection of liver grafts can occur.208-210 However, the 
process develops more slowly than with the kidney and presumably 
other organs, it may be reversible, and it is not strongly associated 
with the antigraft antibodies that are being measured in routine typ-
ing laboratories.208 A progressive and severe coagulopathy develop-
ing shortly after hepatic revascularization should arouse suspicion 
of an accelerated rejection, even if there has not been a positive cy-
totoxic antibody crossmatch.208 
The resistance of the liver to hyperacute rejection from lymphocy-
totoxic antibodies is thought to be the result of several factors. The 
most important of these may be the dual afferent blood supply, a si-
nusoidal network coated with Kupffer's cells rather than a capillary 
microvasculature/68 secretion of soluble major histocompatibility 
complex (MHC) antigens into the circulation,211-213 and nontoxic 
absorption of alloantibodies or immune complexes by the Kupffer 
cells ,169, 214-219 The liver receives an afferent blood supply from both 
the hepatic artery and portal vein, and compromise to either results 
in compensatOIY flow in the other, presumably protecting the liver 
from ischemic injury.168 Most of the microvasculature network of the 
liver is sinusoidal, which is lined by widely spaced (fenestrated) en-
. dothelium with no underlying basement membrane.168 In contrast, 
both the heart and kidney have an arterial end organ blood supply 
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with only a capillary microvasculature, which, when occluded, re-
sults in ischemic necrosis. The only capillary microvasculature of 
the liver is that which derives from the hepatic artery and exclu-
sively supplies the hilar structures and biliary tree. Occlusion of this 
system may result in a more limited fOID} of graft injUIy (bilimyJ 
rather than total organ failure. 
The lymphocytotoxic antibodies present in human or animal re-
cipients of liver grafts disappear from the serum shortly after liver 
grafting.214. 215, 217. 219 In fact, Houssin and associates214 quite ele-
gantly demonstrated in rats that prior liver allografting is able to pro-
tect extrahepatic (heart) grafts from undergoing hyperacute rejec-
tion.214-216 Both a strong donor-specific and weaker nonspecific 
third party protective effect is seen.214-216 Fung and colleagues have 
shown that liver allografts can protect kidney allografts from the 
same donors in presensitized humans and prevent hyperacute re-
jection.217 They documented the disappearance of donor-specific 
anti - class I lymphocytotoxic antibodies from the recipient circula-
tion shortly after transplantation.217,219 However, this protective ef-
fect is not always seen and can be overridden in animals203.204 and 
possibly humans. IM,208 In animals, it was noted that intense sensiti-
zation protocols are required to overcome this effect.203.204 In hu-
mans, at least two recipients have hyperacutely rejected kidney 
grafts after they had received liver allografts ti'om the same donor 
less than 1 day prior.208 These cases have served as prototypes for 
the recognition of antibody-mediated rejection in the liver. 
It is known that human and rat livers secrete soluble (class I MHC) 
antigens that presumably bind to and neutralize the circulating an-
tibodies.211-213 Gugenheim and co-workers have also shown in rats 
donor specific absorption or binding of the lymphocytotoxic anti-
bodies and donor-specific cytotoxic T lymphocyte (CTLl by non-
parenchymal cells of the liverz15 216 Kupffer cell blockade sup-
presses this protective effect. It also appears that Kupffer's cells may 
be involved in the neutralization of lymphocytotoxic antibodies in 
humans, Hi9. 218 either directly or indirectly, by binding immune com-
plexes. Therefore, the liver probably acts as a "sink" for the deposi-
tion of the lymphocytoxic antibodies, immune complexes, and per-
haps CTLs. Whether this deposition is toxic or not may depend on 
the antibody class and titer and on the activity of the Kupffer cells at 
the time of challenge. 
Knechtle and associates have recently shov.rn that hyperimmu-
nized rats hyperacutely reject livers within hours after transplanta-
tion.203 Rat transplantation may not be the ideal model to study this 
phenomenon since, in most instances, no attempt is made to recon-
struct the arterial supply. Gubernatis and colleagues were able to 
demonstrate early antibody-mediated rejection in presensitized 
rhesus monkeys.204 The sensitized animals rejected the livers at an 
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average of 2.5 days compared with the mean graft survival of 26 days 
in unsensitized controls. Routine and immunopathologic studies of 
these grafts that had been rejected in an accelerated fashion demon-
strated immunoglobulin deposits, arteritis, and ischemic necrosis, 
typical of that seen with hyperacute rejection of other organs. How-
ever, an extreme level of pre sensitization was required (multiple skin 
grafts and donor blood transfusions), which may not reflect most 
clinical situations where a positive lymphocytotoxic crossmatch is 
encountered. Furthermore, the antibodies apparently causing the 
damage in the animal experiments mentioned earlie~oPI Z04 were not 
well characterized. Whether this protective effect can be overridden 
by high-titer lymphocytotoxic antibodies in humans is not clear at 
present. If it does occur, routine lymphocytotoxic crossmatch re-
sults are unable to predict the phenomenon beforehand. The only 
apparent correlation between the pretransplant crossmatch and 
early postoperative events is a requirement for an increased number 
of platelet and blood transfusions.zzo 
WITH ABO-INCOMPATIBLE DONORS 
Although ABO-incompatible liver transplantation can be done in 
the event of extreme needIt~Fl-le:o the risk is increased?90-193, ZZl, 2ZZ 
Isoagglutinin fixation has been demonstrated in the microvascula-
ture of ABO-incompatible liver grafts in a collection of cases in 
which hemorrhagic infarction occurred five times more frequently 
than with ABO-compatible grafts.ZZ1 There have been several similar 
case reports of hemorrhagic infarctionKl~FPI ZZZ Minor blood group an-
tibody systems (Lewis) do not appear to influence graft survival.zz3 
Unexpectedly, ABO-identical grafts have done better than ABO-com-
patible but nonidentical organs, and a recipients did better in both 
the incompatible and nonidentical situations.190, ZZ4 
The prototype of antibody-mediated rejection of the liver is often, 
but not invariably, encountered when the major ABO blood group 
barriers are breached.2Z1 The syndrome that occurs is the liver 
equivalent of "hyperacute rejection," but in most instances it devel-
ops more slowly than is seen in heart or kidney grafts. The organs 
initially reperfuse well and produce bile. A change in the color or 
consistency mayor may not be noted by the operative surgeon be-
fore abdominal closure, and difficulty in achieving hemostasis is not 
uncommon. During the first several posttransplanl days,Z21 the pa-
tients experience a relentless rise in liver injury test results. Angio-
grams performed to rule out arterial thrombosis may reveal diffuse 
luminal narrowing, consistent with vascular spasm. Eventually, he-
patic failure ensues, which is manifest by wound site bleeding and 
encephalopathy, and retransplantation becomes necessary. Appear-
ance of the organ at the time of reoperation is similar to that of other 
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organs undergoing hyperacute rejection. They are often enlarged, 
cyanotic, and mottled with areas of necrosis. The capsule may be 
ruptured and bleeding from the liver surface can be obselved. 
Needle biopsy evaluation during the development of antibody-me-
diated rejection demonstrates a progression of findings (Fig 43*).221 
Samples taken within hours after reperfusion show prominent red 
blood cells sludging, clustering of neutrophils, and fibrin deposition 
in the sinusoids. Focal hemorrhage into the space of Disse, hepato-
cellular cytoaggregation, and single-cell acidophilic necrosis then 
follow. Small clusters of hepatocytes undergoing coagulative necro-
sis, red cell congestion, and hemorrhage appear in samples taken 1 
to 2 days later. The areas of necrosis may not demonstrate any par-
ticular zonal distribution. Portal and central veins often shown par-
tial fibrinoid degeneration of the wall, with the attachment of a fibrin 
aggregate, which extends in a flamelike fashion into the lumen. Ar-
teries are usually less severely affected than the veins; endothelial 
cell hypertrophy, endothelial denudation, and focal fibrin thrombi 
are common findings. Intimal neutrophilic or necrotizing arteritis 
(or both) with medial inflammation can be seen on occasion (see Fig 
43). Cholangiolar proliferation as a sign of regeneration is recogniz-
able by 2 to 3 days, and the histologic features at this point may be 
quite difficult, if not impossible, to separate from preseIvation injury. 
Thereafter, progressive patchy hemorrhagic infarction of the organ 
occurs. 
Immunofluorescence and immunoperoxidase staining done dur-
ing the development of the syndrome will often reveal diffuse sinu-
soidal, venous, and arterial deposition of IgG and IgM, Clq, C3, and 
occasionally C4 (see Fig 43). However, only focal patchy deposition of 
IgM and CIQ will be detected in the failed organs. This change in 
the distribution of deposition is presumably because of rapid catab-
olization of the immune deposits. 
A similar clinicopathologic syndrome may occur in ABO-compati-
ble situations when no preformed lymphocytotoxic antibodies are 
present.208, 221, 225 It is likely that other immunologic and nonimmu-
nologic insults are capable of triggering intravascular coagulation 
and the cascade of events that occur within the liver, which result in 
hemorrhagic necrosis.184 Therefore, a diagnosis of hyperacute or hu-
moral rejection in the liver should be based on a complete clinico-
pathologic evaluation of a suspicious case, during which other non-
immunologic causes of graft failure are reasonably excluded.221 In 
addition, several other criteria should be fulfilled (Table 2),t includ-
ing demonstration of a presensitized state in the recipient, consis-
tent light and immunofluorescent microscopic findings, and the 
'Figures 1-42 appear in Part I. 
tTable 1 appears in Part I. 
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FIG 43. 
Sequential histopathologic events during antibody-mediated liver allograft rejection. A, im-
mediately after reperfusion, RBCs and neutrophils stuff the sinusoids. B, 1 to 2 days later, 
small clusters of hepatocytes undergo coagulative necrosis, and portal neutrophilia may 
be seen (arrow). C, immunoglobulin and complement components are usually detected 
diffusely throughout the hepatic vasculature early in the course of events, as shown here 
(immunoperoxidase for IgM), but may be harder to find later on. D, partial fibrinoid degen-
eration of the veins and arteries with intraluminal thrombi are the most characteristic vas-
cular findings. E, eventual graft failure IS due to widespread hemorrhagic necrosIs without 
much of an inflammatory Infiltrate (pt = portal tract; cv = central vein). F, necrotizing andl 
or neutrophilic arteritis (arrow) can be seen, as illustrated here but is found in a minority of 
cases. (From Demetris AJ, Jaffe R, Tzakis A, et al Am J Patho/1988; 132:489-502. Used 
by permission.) 
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TABLE 2. 
Criteria for the Diagnosis of Hyperacute 
IHumoral) Rejection of Human Liver 
Allografts 
1. Early graft failure (usually 1-2 weeks 
after transplant) with no alternative 
clinical or pathologic explanation 
2. Consistent routine light and 
immunofluorescence microscopic 
findings 
3. Demonstration of a presensitized state in 
the recipient" 
4. Pn,sence of donor-specific antibodies in 
an eluate from the tailed graft 
"Not necessarily lymphocytotoxic antibodies de-
tected in conventional assays. 
presence of donor-specific antibodies in an eluate from the failed 
graft. Fulfillment of such a "Koch's postulate" for hyperacute rejec-
tion may be overly restrictive, since there are antibody systems out-
side the ABO and lymphocytotoxins that have been associated with 
hyperacute rejection.183 However, adherence to these criteria will 
add to the predictive value of screening for antibody systems in the 
future. 
Primary nonfunction of a liver homograft without an obvious ex-
planation should suggest that the new organ may have placed into 
an environment that is hostile because of immunologic or perhaps 
nonimmunologic factors. The prompt destruction of hepatic retrans-
plants in patients whose first liver grafts have been lost for inade-
quately explained reasons has been seen in several centers with 
large experience, causing the word of mouth descriptive term "liver 
eaters" to be applied to such recipients208 in the absence of an ex-
planation for their behavior. 
THE QUESTION OF ENDOTOXEMIA 
The inability to predict the perioperative outcome after liver trans-
plantation with prognostic premonitors such as quality of donor, 
time of ischemia, and even the presence of antidonor cytotoxic anti-
bodies has led to a search for other factors. Endotoxemia is one of 
the most interesting of these possible factors. 
Endotoxin is a macromolecular component of the cell wall of 
gram-negative bacteria. Its most specific and active component is 
lipid A.226 However, it has been increasingly recognized that protein 
and polysaccharide components of the molecule can influence its 
potency and specificity.227,228 Because gram-negative bacteria are in-
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digenous to the gastrointestinal (GI) tract, an enteric source must be 
suspected when symptomatic endotoxemia is diagnosed.228 
Them is evidence that small quantities of endotoxin can cause se-
rious or lethal syndromes in animals and humans.229, 230 However, a 
cause and effect relationship may be difficult to establish in specific 
situations.231 One reason is that the presence of endotoxin, even in 
large amounts, may not necessarily be associated with symptorns.232 
Another reason is that the responses elicited by endotoxin am not 
specific or unique.227, 233 Endotoxin can induce the release of a com-
plete spectrum of biologically active substances, including soluble 
mediators of the inflammatory response and cytokines (Table 3). Ac-
tivation of the individual mediators, including the cytokines, is in-
duced by a direct efTect of the endotoxin on complement, macro-
phages, monocytes, and other formed blood elements, including 
lymphocytes and endothelial cells (see Table 3). 
The soluble mediators that can be released into the circulation or 
locally theoretically could have devastating physiologic effects (see 
Table 3), including fever, shock, vasodilatation, vasoconstriction, co-
agulation disorders, smooth muscle contraction, endothelial injury, 
chemotaxis, tissue necrosis, and even neuropsychiatric changes. In 
addition, the majority of the mediators have immunoregulatory func-
tions, predominantly augmenting either cellular or humoral immu-
nomactivity, or both (see Table 3). This latter feature of the soluble me-
diators may be particularly important in the context of transplanta-
tion. What results from exposure to endotoxin could be a combina-
tion of the efTects of many or even all of the mediators. The difficulty of 
interpretation is compounded by the fact that many factors other than 
endotoxin can activate the mediators and by the variable functional in-
teractions between the mediators themselves.227,234 Immune re-
sponses could be interlocking with or simulate endotoxin, as was 
speculated nearly 20 years ago in a report on hyperacute rejection of 
the kidney?9S In that article, the possibility was discussed that endo-
toxin might be able to destroy kidney grafts in a way analogous to the 
hyperacute rejection caused by cytotoxic antigraft antibodies. At that 
time, little was known about soluble mediators and cytokines. Now, it 
is easy to conceive that these substances, including those that are im-
munoregulatory (see Table 3), could participate in an endotoxin-initi-
ated injury, a humoral immune reaction, or a combination of these. 
The liver plays a control role in the modulation of endotoxin. In-
travenous (IV) endotoxin is removed mainly by the Kuppfer cells of 
the liver.2I8, 235, 236 Not only is this detoxification system absent dur-
ing the anhepatic phase of transplantation, but there is a subse-
quent transformation in the graft whereby donor Kuppfer's cells are 
replaced with macrophages of recipient origin237,238 that may be 
accelerated in pathologic states.239 In addition, the transplanted 
liver is exposed to intestinal bacteria that reach the liver in splanch-
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FIG 44. 
Endotoxin levels in picograms per milliliter in 16 consecutive dogs submitted to orthotopic 
liver transplantation, Note that every animal had an endotoxin level increase by the end of 
the an hepatic phase (groups A and B) and that this was less in animals who had an anti-
biotic bowel prep in advance (group B) compared with those who did not (group A), The 
endotoxemia lasted for many hours or even days afterward, (From Miyata T, Todo S, Im-
ventarza 0, et al: Transplant Proc 1989; 213861-3862, Used by permission,) 
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nic blood and through the biliary tract and then "leak" through to 
the systemic circulation.24Q ,241 For all of these reasons, endotoxin 
would be a prime suspect in looking for causes of perioperative 
morbidity. 
However, the obvious possibility that endotoxin was responsible 
for perioperative problems after liver transplantation was not inves-
tigated until recently. The detection of endotoxin in plasma was un-
reliable,242, 243 and only a qualitative assay was available.244 The chro-
mogenic substrate method developed by Iwanaga and colleagues24S 
in 1978 paved the way to a sensitive quantitative assay of endotoxin. 
Using this principle, Obayashi and associates introduced a novel 
method based on the combination of plasma treatment with per-
chloric acid and the chromogenic substrate method,246,247 making 
possible meaningful correlations between endotoxemia and clinical 
syndromes such as coagulopathy with hemorrhage, cardiovascular 
collapse, primary non function of hepatic grafts, acute renal failure, 
respiratory insufficiency, and multiple-organ failure. 
The first studies of endotoxemia in liver transplantation were re-
ported by Miyata and co-workers in 1989, using the new analytic 
techniques to study 16 normal healthy dogs before and after liver re-
placement,248 Nine of the animals had a preoperative bowel prep 
with oral neomycin, After operation, all of the dogs were treated 
with cyclosporine. All 16 of the animals had a significant increase in 
plasma endotoxin levels, which peaked at the end of the anhepatic 
period and remained elevated for several days. The magnitude of the 
rise was significantly lower in dogs with an antibiotic bowel prep 
(Fig 44), and these dogs had better sUIvivaL 
In addition, plasma endotoxin levels in nearly 100 liver transplant 
patients were measured before transplant, at the end of the anhe-
patic phase, and on postoperative days 1, 3, and 7. In this study by 
Yokoyama and colleagues, the presence of high endotoxin levels pre-
operatively and at the end of the anhepatic period was associated 
with graft failure and a high mortality (Fig 45) ,249 
Patients with primary nonfunction of their transplants typically 
had severe endotoxemia. In nine patients with primary nonfunction, 
most of the endotoxin levels were only moderately elevated preoper-
atively. However, large further increases occurred in the plasma in 
seven of the nine patients by the time the new livers were revascu-
larized. The livers acted as if they had been revascularized in a hos-
tile environment. Only two of the nine patients had positive cyto-
toxic crossmatches with their donors, but all nine of the livers be-
haved as if hyperacute rejection had occurred. 
Thus, en do toxemia could be a cause rather than an effect of peri-
operative graft loss, serious morbidity, and increased mortality. With 
the Cox proportional hazards model, the most powerful indepen-
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FIG 45. 
Correlation of endotoxin level at the end of the anhepatic phase with graft survival for 68 
primary transplantations. (From Yokoyama I, Todo S, Miyata T, et al: Transplant Proc 1989; 
213833-3841. Used by permission.) 
dent factors associated with graft death in the study by Yokoyama 
and colleagues were endotoxemia greater than 100 pg/mL at the end 
of the anhepatic period, lactate level greater than 10mM/L at the 
same time, and serum glutamic pyruvic transaminase (SGPT) level 
greater than 200 lUlL preoperatively.249 These exceeded in impor-
tance the degree of recipient illness, graft ischemia time, duration of 
anhepatic phase, cytotoxic crossmatch, and amount of blood trans-
fusion. 
In a further study of the patients who undervvent primary trans-
plantation, Miyata and associates showed that there was a strong 
correlation between the en do toxemia at the end of the anhepatic 
phase and the need for perioperalive platelet transfusions, ventilator 
dependency postoperatively, and 1-month mortality.250 
If endotoxemia can be shown to be a negative factor in the 
transplantation of the liver or other organs, therapeutic strategies 
might be devised to prevent this complication. Possibilities could 
include the use of antiendotoxin monoclonal antibodies251 or, less 
specifically, the control of the gram-negative intestinal flora with 
antibiotics as described by Weisner and co-workers.252 Polymyxin B 
is an antibiotic with a strong antiendotoxin activity.2s:l An alterna-
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tive way to use polymyxin B would be as part of an impregnated 
matrix254 to which blood from the extracorporeal bypass could be 
exposed. 
The studies done so far have been concerned primarily with recip-
ient endotoxin. However, endotoxin also could adversely affect the 
liver and other organs of brain-dead donors, particularly if these are 
victims of severe tmuma.229 In a small group of six cadaveric donors, 
plasma endotoxin levels in two of the six were abnormally elevated, 
in the 10 to 20 pg/mL range.249 More investigations on the matter of 
donor endotoxin are planned. 
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PREVENTION OF REJECTION 
At the time orthotopic liver transplantation was first studied in 
Boston6 and Chicag08 beginning in the summer of 1958, the only 
known technique for immunosuppression was with total body irra-
diation. Attempts were made in 1959 to influence rejection by irradi-
ating either the canine liver donors or their recipients with 1,400 rad. 
Neither approach was helpful, and in fact, recipient irradiation led 
to 100% mortality. The results were so poor that they were not pub-
lished until 1962.255 
The possibility that there was an immune barrier to successful 
transplantation of tissues and organs apparently was not part of the 
consciousness of early clinicians or, for that matter, of most basic 
scientists. This realization awaited the classical studies of Medawar 
with rabbit skin grafts.256 Appreciation by Medawar that rejection 
was an immunologic phenomenon made inevitable almost every-
thing that followed. The deliberate depression of immunologic reac-
tivity became feasible theoretically when total body irradiation257, 2.'i8 
and adrenal cortical steroids259 were shown to be immunosuppres-
sive. The next great step was the introduction of thiopurine com-
pounds, 6-mercaptopurine and its imidazole derivative azathioprine, 
which inhibited heterohemagglutinin formation in mice,26o respon-
siveness to foreign proteins in rats,261 and rejection of skin and renal 
grafts in rabbits, rats,262,2(i3 and dogs,ZB4'265 respectively. 
The foregoing laboratory research proved inapplicable to organ re-
placement in humans. Complete control of rejection with a single 
agent rarely was achieved without lethal side effects in either ani-
mals or humans, as exemplified by the historically important trials 
with total body irradiation266 as well as by early trials with 6-mer-
captopurine and azathioprine.267-271 Hopeful signs from the clinical 
experience through 1962 were footnotes to an otherwise dreary cat-
alogue of failures. In 1961, Burnet, a Nobel laureate with Medawar 
the preceding year, wrote in the New England Journal of Medicine272 : 
Much thought has been given to ways by which tissues or organs not ge-
netically and antigenetically identical with the patient might be made to 
survive and function in the alien environment. On the whole, the present 
outlook is highly unfavorable to success .... 
71 
THE HUMAN KIDNEY TRANSPlANT PROTOTYPE 
Liver transplantation at first was a passive partner in the develop-
ment of immunosuppressive techniques. Whatever the current prac-
tice was in clinical renal transplantation was passed on for second-
my application to the extrarenal organs. The modern era of trans-
plantation was entered when it was realized that azathioprine and 
prednisone had at least additive, and possible synergistic, effects.273 
With the use of living-related donors, renal transplantation became 
overnight a practical means of treating renal failuI"C.273, 274 There are 
only 23 patients left in the world from this early era (Table 4), all hav-
ing been given kidneys from blood relatives.m ; Other multimodality 
techniques followed. 
The most important new variable between 1962 and 1978 was the 
adjuvant use of antilymphocyte globulin (ALG) added to azathio-
prine (or to cyclophosphamide) and steroids.27H Ultimately, it be-
came possible to produce more potent and specific ALGs277 with the 
hybridoma techniques discovered by Kohler and Milstein.278 How-
ever, from 1963 to 1979 with any of the methods available, truly ac-
ceptable results were obtained only with renal transplantation from 
consanguineous donors. Candidates for liver transplantation were 
faced with the bleak prospect of receiving a nonrelated (cadaveric) 
graft. 
The situation changed drastically for recipients of all kinds of ca-
daveric organs, including the liver (Fig 46), with the disclosure by 
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TABLE 4. 
Renal Transplant Recipients Treated Befm'e 
31 March 1964, Surviving in September 1989* 
No. of Original 
Patients Graft 
University of Colorado 14 10 
Medical College of 3 3 
Virginia 
University of 2 2 
Minnesota 
Necker Hospital (Parisi 1 0 
Peter Bellt Brigham 1 1 
Hospital (Boston) 
Western General 1 0 
Hospital (Edinburghl 
Cleveland Clinic 1 1 
Total 23 17 
'Data presented at the Sixth Capri Conference of 
UrCInia. From Starzl TE) Schroter GPJ} Hartmann 
NJ, et a1: Long lelm 125 years) sUIvival after re-
nal honlotransp]antation-The wOT'ld exppriencc. 
Tral1spianl Proc 1990, lin press I. 
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FIG 46. 
Patient survival rates (life table method) for children (patients less than 18 years of age 
when they received their primary liver graft) and adults (patients 18 years of age or older 
when they received their primary liver graft). Eighty-five patients less than 18 years of age 
were treated with azathioprine (AZA) and steroids, and 438 were treated with cyclosporine 
(GYA) and steroids. Eighty-five patients 18 years of age or older were treated with azathi-
oprine and steroids, and 1,031 were treated with cyclosporine and steroids. 
Borel and associates of the phenomenal immunosuppressive quali-
ties of cyclosporine,279 with the initial clinical trials of this agent for 
cadaveric renal transplantation by Calne and co_workers,28o,281 and 
with the systematic combination of cyclosporine with steroids and 
other immunosuppressive measures.282,283 Although cyclosporine 
and steroids are the baseline drugs, azathioprine is often used as a 
third maintenance agent to reduce the required dose of cyclospo-
rine,284-289 or it has been used in some cases to replace cyclospo-
rine altogether after a few months or longer. Antilymphocyte globu-
lin preparations,284 including the monoclonal antibody OKT3,290-293 
have been given prophylactically, later in the postoperative period 
for the specific indication of rejection, because nephrotoxicity of cy-
closporine necessitated its use in low doses, or both. 
Cyclosporine and Its Limitations 
Cyclosporine has been the single most important factor in making 
liver transplantation a practical way of treating hepatic disease (see 
Fig 46), However, the drug's principal side effect of nephrotoxi-
cilf80, 281, 294 puts a cap on its permissible dosage. Even with the 
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multiple-drug regimens mentioned in the preceding section, rejec-
tion has remained a common reason for early or late graft 10sses.67, 113 
Furthermore, it has not been possible to completely eliminate neph-
rotoxicity by using smaller doses of cyclosporine in drug cocktails. 
In human recipients of livers294-299 and hearts,300-302 evidence of re-
nal dysfunction has included azotemia, hyperkalemia, and hyper-
tension. Because the morphologic changes in the kidneys nf these 
patients may not be reversible,297,302-304 the extent of the eventual 
liability of either short- or long-term cyclosporine therapy has yet to 
be determined. 
When cyclosporine was first used clinically in 1978 through 1981, 
assays were not available to monitor blood or plasma levels. Renal 
function was used to guide dosage, the objective being to give cy-
closporine to the limit imposed by its nephrotoxicity.298, 305, 306 There 
is much to be said for this approach even today. However, there is a 
tendency to guide cyclosporine doses by frequent measurements of 
blood or plasma trough concentrations with radioimmunoassay 
(RIA)/07 high-performance liquid chromatography (HPLC),308 or fluo-
rescence polarization immunoassay EcmfAFKPM~F A trough whole blood 
cyclosporine concentration of 250 to 450 nglmL (HPLC), 800 to 1,200 
ng/mL (RIA), or 1,000 to 1,600 ng/mL (FPIA) is normally considered to 
be therapeutic.309 However, these so-called normal concentrations 
vary greatly from center to center. In addition, therapeutic concen-
trations for cyclosporine are dependent on the other immunosup-
pressive drugs used and may decrease with time after transplanta-
tion.3IO,311 Although some patients maintained at "therapeutic con-
centrations" have exhibited cyclosporine toxicity, others above the 
"therapeutic concentration" may not manifest any toxic symptoms at 
all. The maintenance of stable cyclosporine concentrations in liver 
transplant patients is more difficult than in recipients of other 01'-
gans.312 The changing quality of graft function postoperatively,313 
biliary duct obstruction or the presence or absence of T-tube 
drainage,3l4 bile fistulas,315 and numerous other factors common in 
or specific to liver transplant patients3Hl make cyclosporine monitor-
ing even more important than it is for kidney and heart transplant 
recipients,317 providing reliable in-center standards are established. 
Cyclosporine and Liver Regeneration 
The ability of the liver to regenerate after being injured is an im-
portant consideration in any kind of major hepatic operation, but 
especially after liver transplantation where recovery from ischemic 
injury or from rejection is required in most cases. In addition, many 
chemotherapeutic agents inhibit regeneration, including doxombi-
ci.n (Adriamycinl,3111,3Hl which might be given to patients undergoing 
liver replacement for hepatic malignancies under cyclosporine im-
munosuppression. Consequently, it was important to know what ef-
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fect cyclosporine has on regeneration. Earlier studies in rats showed 
that cyclosporine actually enhances the regeneration response after 
partial hepatectomy,320 an unexplained effect that has been con-
firmed by other workers.321. 322 The mechanisms of this seeming he-
patotrophic effect will be important to determine for another reason, 
not only for cyclosporine but for other drugs. It is now known that 
the transplanted liver promptly goes through a period of volume ad-
justment, shrinking or enlarging to conform to an appropriate size 
for the particular recipient.323.324 It may be speculated from non-
transplant experiments325 that control of liver size is hormonal, with 
the most dominant factor being endogenous insulin. Interference or 
distortion of the hepatocellular growth control that is responsible 
would have practical implications. 
The demonstration that cyclosporine enhances regeneration has 
prompted further experiments to elucidate its hepatotrophic prop-
erties. The model has been the dog submitted to end-to-side porta-
caval shunt (Fig 47).3 The livers in animals with Eck fistula undergo 
acute atrophy and organelle disorganization within 4 days. The most 
specific organelle change caused by Eck fistula is disruption of the 
rough endoplasmic reticulum with depletion of its ribosomes.3.325 
At the same time, the rate of hepatocyte mitoses per 1,000 hepato-
cytes increases from 1.5 to 4.5.3 
Pump 
FIG 47. 
The use of an Eck fistula (portacaval shunt) model for the study of drugs such as cyclo-
sporine (CsA). The model, in effect, splits the liver into two fragments that differ only by 
what is infused into the tied-off left portal vein branch. Each experiment serves as Its own 
control, since the directly treated (left lobar) and control hepatocytes that are exposed to 
recirculate a drug (right lobar) are present in the same liver. (Redrawn from Starzl TE, Por-
ter KA, Watanabe K, et al: Lancet 1976; 1 :821-825. 
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If insulin is perfused into the tied-off left portal vein (see Fig 47), 
the atrophy is prevented in the liver normally supplied by this 
branch, the organelle damage is prevented, and the rate of hepato-
cyte mitoses triples or quadIuples. The contralateral hepatic lobes in 
these dogs are not aft'ected by the insulin infusions, meaning that 
the insulin largely is consumed or inactivated with the first trans-
hepatic passage.325 
This same experiment has been perfom1ed with infusion of cy-
closporine instead of insulin into the left portal vein.326 The cyclo-
sporine in appropriate doses prevents hepatocyte atrophy com-
pletely and increases proliferation slightly on the side of infusion. In 
contrast to insulin, the cyclosporine effect is almost as pronounced 
in the contralateral (right) liver lobes as in the infused ones. The fact 
that the cyclosporine hepatotrophic effect is not removed on first 
passage through the liver is of considerable interest, particularly 
since the liver is thought to be responsible for more than 90% of the 
degradation of this dmg. A predominantly first passage removed of 
its hepatotrophic effect might have implied that cyclosporine is a 
liver-specific drug in other biologic actions as well, not excluding 
immunosuppression. The Eck fistula model ",,;jth selective portal 
branch infusion may be a useful experimental device to study the 
effects of other orally administered drugs on the liver and to see 
how the liver alters these agents as they are picked up from the 
splanchnic venous bed during intestinal absorption and brought to 
the liver. 
A NEW DRUG: FK 506 
Until recently, only four drugs had been demonstrated to prolong 
liver graft survival in large animals: (1) azathioprine,327 (2) antilym-
phocyte selum and its globulin derivative (ALG),276 (3) cyclosporine,328 
and (4) the cyclosporine analogue Nva2-cyclosporine.32fl Recently, the 
efficacy of a new agent, FK 506, was demonstrated after canine liver 
transplantation.330, ,{;n This agent might permit refinements of clinical 
immunosuppression. FK 506 was discovered in Japan less than 5 years 
ago and reported in the literature for the first time in 1987.330,332- 335 A 
reasonably clear picture of the conditions that will permit the most ef-
fective and safest use of FK 506 has emerged from these studies. The 
practicality of combining FK with other conventional agents was 
shown with canine kidney and liver transplantation,331 in which sub-
therapeutic doses of FK, cyclosporine, and steroids provided as good 
results as have ever been reported in dogs with any drug regimen. 
The concept of dmg synergism for immunosuppression is an old 
one273 but difficult to prove until recently. Now, the interaction of 
drugs can be studied with great precision by measuring their effect 
on mixed lymphocyte culture systems.336,337 These techniques have 
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+IL2 
FIG 48. 
Propagation of activated lymphocytes from human biopsy specimens with interleukin (IL2). 
(From Starzl TE Transplant Proc 1988; 20[suppl 3]:356-360. Used by permission.) 
made it possible in tissue culture experiments to dissect the mech-
anisms of drug action as these affected lymphocyte populations, to 
study the intrinsic cytotoxicity of the agents on cell cultures, and to 
measure in highly quantifiable test systems the interactions (includ-
ing synergism) of different drugs. It has been possible with a few 
days of effort to acquire information that previously was completely 
inaccessible or that required years to accumulate. 
Zeevi and associates/37.338 Fung and colleagues,339 and Duques-
noy and co-workers340 in Pittsburgh have referred to these tech-
niques as minitransplant models. From biopsy specimens of hearts 
and livers, they obtained cultures of primed lymphocytes that had 
been exposed to donor-specific antigen by virtue of transplantation 
(Fig 48). When donor spleen, which is saved at the tiIne of organ har-
FIG 49. 
PRIMED 
CELL 
Lymphocyte culture technique in which human lymphocytes obtained from biopsy speci-
mens are cultured and exposed to donor cells. Clonal expansion results. (From Starzl TE: 
Transplant Proc 1988; 20[suppl 3]356-360. Used by permission.) 
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FIG 50. 
PRIMED 
CELL 
INHIBITION OF 
EXPANSION 
Prevention or inhibition of clonal expansion in primed human lymphocyte cultures by addi-
tion of cyclosporine (CyA) or other drugs. (From Starzl TE: Transplant Proc 1988; 20[suppl 
3]:356-360. Used by permission.) 
vest and preserved, is added to the recipient lymphocyte culture, 
the "primed" recipient lymphocytes proliferate (cell expansion! with 
vel)' little delay (Fig 49). The mechanisms of the expansion can be 
studied qualitatively and quantitatively by collecting IL-Z or other 
lymphokines from the culture medium and adding them to IL-Z-de-
pendent cells. The proliferation or other response characteristics of 
these IL-2-dependent cells provide an end point for a biologic assay. 
The ability of cyclosporine or other drugs to prevent this expan-
sion of a human lymphocyte popUlation is illustrated in Figure 50. In 
the liver or heart hiopsy specimens of patients undergoing severe or 
even intractable rejection, clones of cyclosporine-resistant lympho-
cytes have been found side by side with sensitive clones (Fig 51) .341 
In such cases, FK 506 used alone or added to cyclosporine can 
eliminate the rogue clones (Fig 52).:142 Cyclosporine, azathioprine, 
ANTIGEN 
FIG 51. 
CyA 
PRIMED 
CELL 
~ 
CyA .. RESISTANT" 
CyA ., SENSITIVE" 
Development of cyclosporine (Cy A)- resistant clones in liver or heart biopsy specimens 
that were undergoing clinical rejection. (From Starzl TE: Transplant Proc 1988; 20[suppl 
3):356-360. Used by permission.) 
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FIG 52. 
CyA + FK 506 
SYNERGISM 
1 A~:--~-~ 
CELL • 
INHIBITION OF 
EXPANSION 
Disappearance of "rogue" clones by the addition of the experimental drug FK 506 and 
cyclosporine (GyA). (From Starzl TE: Transplant Proc 1988; 20[suppl 3]:356-360. Used by 
permission.) 
and FK 506 all are synergistic with each other with in vitro 
models.:142.343 
In vivo synergism of FK 506 and cyclosporine has been demon-
strated equally clearly with heterotopic heart transplantation in 
rats.3•• The synergism of FK 506 and cyclosporine is of special 
interest, since the two drugs have similar, if not identical, ac-
tions.:134. 33(;. 3:17 
FK 506 is remarkably nontoxic at therapeutic dose ranges in 
rats.335. 344. 345 It can cause convulsive vomiting and lethal emaciation 
in dogs.330.3.16-348 Widespread arteritis was described in the organs 
of dogs,347. 348 but in subsequent studies, these lesions were found in 
untreated control animals as well as in those given cyclosporine, ste-
roids, or both.331 Although one group has described alarming side 
effects of FK 506 in baboons/49 further studies have been reassur-
ing.331.350 In appropriate doses, the drug use alone in outbred ba-
boon recipients has allowed nearly uniform survival of kidney ho-
mografts with minimal toxic side effects.350 
Clinical trials with FK 506 recently were started in Pittsburgh, and 
the first dose was administered to a human on 28 February 1989. 
The patient is a 28-year-old woman who had been given three liver 
grafts over a period of 3 years. In addition to losing the first two liv-
ers to chronic rejection (Table 5), the recipient had developed renal 
failure to which cyclosporine nephrotoxicity was thought to have 
contributed. After FK 506 was started, rejection of the third liver graft 
was promptly controlled by histopathologic criteria (Table 6), with 
concomitant improvement of the liver chemistries (Table 71. How-
ever, her renal failure was not improved, and on March 27, 1989, ca-
daveric renal transplantation was canied out with immediate and 
sustained good renal function (Table 8). In this and all subsequent 
cases treated chronically, cyclosporine was eventually discontinued. 
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TABLE 5. 
First Eight Liver Allograft Recipients Receiving FK 506 
Patient I.D. Age Weight 
No. (yrJ IkgJ FK 506 Start OLTX No. Date Cause of Liver Failure 
1 28 50 0 Cryptogenic cirrhosis 
1 7/2/85 Chronic rejection 
2 12128/87 Chronic rejection 
2;"28189 3 6/29/88 
2 38 53 0 Sclerosing cholangitis 
] 11/9183 PrimalY nonfunction 
2 11114/83 Chronic rejection 
3 12/6/85 Hepatic arteIY thrombosis 
4 2/16/86 Chronic rejection 
3/25/89 5 111189 Hepatic artery thrombosis 
(late) 
6 7/2189 
3 30 55 0 Autoimmune cirrhosis 
1 6/26/84 Chronic rejection 
4/4189* 2 11118/87 
4 43 52 0 Polycystic liver and 
kidney 
4/8189 1 11121188 
5 42 65 0 Clyptogenic cirrhosis 
6/2/89 4/30/89 
6 38 49 0 Clyptogenic cirrhosis 
6/29/89 1 12/2/82 
7 47 100 0 Sclerosing cholangitis 
711189 1 6115/86 
8 18 63 0 Clyptogenic cirrhosis 
1 5/13/86 Chronic rejection 
7/8189 Z 7/18/86 
'Because the allocated supply of IV FK !iOn had been deplet"d, FK 5U6 was stopped on 8/5/89 Iday 124), 
and cyclosporine was resunwd. 
When FK 506 and cyclosporine were used together, cyclosporine 
blood levels tended to rise with consequent aggravation of cyclospo-
rine nephrotoxicity. The cadaveric kidney graft of patient no. I, 
which has never been exposed to any baseline drug except for FK 
506, has had no evidence of nephrotoxicity. 
The same improvement in liver function has been noted in every 
patient except one (patient no. 4), whose initial diagnosis of rejection 
4.5 months after combined liver and kidney transplantation proved 
to be incorrect. Within a few days, it was realized that this patient 
had fulminant hepatic failure due to B virus hepatitis, and the FK 
506 was stopped. Despite retransplantation, the patient died. 
The remarkable effectiveness of FK 506 in patients for whom all 
previous therapy had failed, as well as the seeming lack of toxicity in 
these patients, has been noteworthy. From the preliminary observa-
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TABLE 6. 
Description of Liver Biopsy Results Before and After FK 506* 
Patient I.D 
No. Day Cellular Infiltrate Ductal Damage Duct Loss Fibrosis 
0 1+ 1+ 0 0 
15 0 0 0 0 
69 0 0 0 0 
2 0 1+ 1+ 0 0 
12 1+ 0 0 0 
34 0 0 0 0 
94 0 0 0 0 
3 0 2+ 1+ 0 0 
14 0 () 0 0 
31 0 0 0 0 
4t 0 1+ 1+ 0 0 
5 () 3+ 2+ 0 2+ 
14 1+ 1+ () 2+ 
51 0 0 1+ 1+ 
6 0 1+ 3+ 0 0 
12 +1- 2+ () 1+ 
7 0 1+ 1+ 1+ () 
18 0 1+ 0 0 
8 0 2 2+ 1+ 1+ 
16 1 1+ 1+ 1+ 
*Scale from 0-3+, with 0 being no injlllY and 3+ being extensive injUlY. 
"'Initial diagnosis of cellular rejection was incorrect; special staining for hepatitis B core and sUIface 
antigen was positive. Patient no. 4 progressed to fulminant hepatic failure, although FK 506 was 
stopped. 
TABLE 7. 
Rcsponse of Liver Function Tests to FK 506* 
Patient LD. TBlL SGOT SGVr Alkaline Phosphate GGTP 
No. Day ImgldL) (lUlL) I lUlL) 11U1L1 I lUlL) 
1 0 0.6 49 47 160 71 
7 0.6 24 24 145 45 
14 0.5 31 36 131 42 
28 0.2 11 10 75 24 
56 0.2 17 17 111 37 
143 0.2 20 19 94 22 
156 0.3 29 27 90 17 
2 0 1.3 109 142 345 167 
7 0.7 46 109 277 172 
(Continued.) 
81 
TABLE 7 (cont.). 
Patient l.D. TBIL SGOT SGPT Alkaline Phosphate GGTP 
No. Day imgldL) (lUlL) (lUILI IIU/L) IHJ/LI 
14 0.8 50 77 214 146 
28 0.5 29 30 145 83 
56 0.4 29 36 70 53 
109t 3.6 33 105 514 1,091 
116t 1.9 110 171 858 1,267 
123t 1.2 35 29 311 265 
130t 0.7 28 31 3S2 256 
143t 0.9 46 71 394 284 
3 0 0.6 32 32 121 82 
7 0.5 41 31 117 88 
14 0.4 26 24 96 76 
28 0.2 11 10 99 64 
56 0.6 26 9 81 33 
102* 1.7 .'iiI 20 192 174 
124* 1.9 56 49 297 370 
4 0 2.3 2117 312 144 lOll 
5 0 20.5 63 T~1 417 437 
7 13.6 60 72 386 498 
14 ~gKP 47 60 257 361 
28 3.8 38 61 305 350 
56 1.9 :n 38 229 215 
63 1.5 9 39 194 185 
69 1.5 13 38 17:, 112 
6 0 2.5 339 634 348 2)756 
7 0.7 33 107 283 1,536 
14 0.5 46 95 5.'i7 2,742 
28 O.S 93 114 409 2,457 
46 0.5 S2 75 241) N.D. 
7 0 2.1 198 550 304 1,351 
7 1.6 40 236 250 876 
14 1.2 135 600 S23 1,287 
28 0.7 94 324 501 l,5H:1 
41 1.8 114 408 555 1,306 
8 0 3.7 713 609 268 1,348 
7 1.2 :nll 284 176 7.')1 
14 1.1 175 128 119 433 
28 0.8 84 90 106 254 
38 0.5 74 86 142 192 
"TBIL = tota] bilirubin; SCOT = SCIUlll glulalllic oxaloacetic transaminase; GGTP = gamn1a glutmnyJ 
transp"ptidasc. 
tNew liver allograft Isee texti. 
:fOn IV hyperalinleiltatioll (see text); FK 506 stupped on day 124. 
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TABLE 8. 
Renal Function, Cyclosporine, and FK 506 
Cyclosporine Oral Dose Level FK 506 Oral Dose Level 
Patient I.D. BUN' Creatinine 
No. Day mgld nglmL mgld nglmL (mgldLi (mgldLi 
1 0 900 685 0 0 50 2.5 
7 150 737 18 0.4 98 4.1 
14 0 281 18 0.7 81 4.1 
28 0 0 18 O.:i 51 2.8 
56 0 0 18 0.5 38 1.4 
143 0 0 18 0.4 29 1.4 
156 0 0 18 0.4 23 1.3 
2 0 1,600 255 0 0 37 1.7 
7 100 810 18 0.4 50 2.0 
14 0 0 18 0.7 61 2.5 
28 0 0 18 0.2 45 2.4 
56 0 0 9 0.3 38 2.4 
109 0 0 6 t 1.1 111 3.6 
130 0 0 3 t 0.4 63 1.7 
143 0 0 9 t 0.9 65 2.6 
3 0 150 214 0 0 84 5.4 
7 0 0 18 1.0 95 {j.5 
14 0 0 18 1.0 88 5.8 
28 0 0 12 0.7 60 5.8 
124* 50 < 50 0 0.1 34 :i.2 
4 0 800 1,621 0 0 75 2.4 
5 0 2,000 967 0 0 25 0.6 
7 150 1,373 20 4.0 49 1.4 
14 150 148 18 1.2 49 1.7 
28 150 190 20 1.9 46 1.4 
56 150 324 20 0.6 40 1.5 
69 0 0 20 1.2 40 1.6 
6 0 100 154 0 0 55 2.3 
7 100 160 16 1.2 65 2.7 
14 0 76 16 0.9 82 3.8 
28 0 0 16 NA 55 4.0 
46 0 0 16 2.1 58 3.5 
7 0 250 482 0 0 38 2.1 
7 100 615 30 NA. 37 2.5 
14 100 292 30 3.9 41 2.4 
28 0 0 30 1.8 57 2.9 
41 0 0 30 2.1 49 3.1 
8 0 440 845 0 0 29 1.1 
7 100 444 18 3.1 40 2.6 
(Continued.) 
83 
TABLE 8 (cont.). 
Cyclosporine Oral Dose Level FK 506 Oral Dose Level 
Patient I.D. 
No. Day mgld 
14 0 
28 0 
38 0 
'IlUN = blood urea nitrogen. 
tFollowing liver transplant (see textl. 
tValue on hemodialysis. 
ng/mL 
129 
o 
o 
mgld 
18 
18 
9.5 
ng/mL 
3.0 
NA. 
3.9 
BUN' Creatinine 
(mgldLJ Img/dLJ 
40 3.6 
66 3.1 
29 2.9 
tions made with FK 506 as a salvage drug, its efficacy and safely 
seem beyond question even at this early stage. A trial of FK 506 as 
the primary drug in liver transplantation was started in August 1989. 
A VeIY important observation in the patients with FK 506 has been 
almost immediate relief from the severe hypertension from which 
each of the patients except patient no. 4 were suffering. The antihy-
pertensive therapy was greatly reduced or stopped altogether in 
these patients. 
At the annual meeting of the European Sociely of Organ Trans-
plantation, which was convened on October 31,1989, a complete re-
port of FK 506 was given, including exposition of the Pittsburgh clin-
ical trials. The FK 506 has been synthesized, and its binding site has 
been identified by Dr. Stuart Schreiber of Harvard Universily. This 
binding site, which has been called Flljiphilin, is different than the 
cyclophilin binding site for cyclosporine. 
In the meanwhile, an additional drug with a veIY similar chemical 
structure has been isolated by workers of the Ayerst Pharmaceutical 
Corporation from the fungus Streptomyces hygroscopicllp~f:;l and 
called rapamycin. This drug has been described as having poweIful 
immunosuppressive qualities in rodents and dogs.352 It seems clear 
that the FK 506 is the forerunner of a new and extremely interesting 
class of drugs that may have a potency and safety profile good 
enough to make them competitive with or possibly superior to cy-
closporine. 
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DIFFERENTIAL DIAGNOSIS OF 
GRAFT DYSFUNCTION 
When a liver graft fails intraoperatively, nonimmunologic factors 
are the primary suspects, even though there may be exceptions, as 
described in the previous section. The frame of reference quickly 
changes thereafter. Immunologic rejection as an explanation for 
later graft dysfunction becomes increasingly probable with each 
passing day after transplantation, particularly if the new liver 
seemed to be satisfactory at the outset. Nevertheless, nonimmuno-
logic explanations for delayed graft failure or dysfunction must be 
systematically ruled out. During the fIrst several postoperative 
months, the diagnostic possibilities include suboptimal revascular-
ization, as already discussed; defects in bile duct reconstruction 
causing obstruction or fIstula; opportunistic viral infection with cy-
tomegalovirus ICMV),353,354 herpes simplex virus (HSV) or viruses,354 
Epstein-Barr virus IEBV),355 or adenovirus IADv)356, 357; infection by a 
variety of bacterial or fungal pathogens:351l ; toxicity from hyperali-
mentation or sepsisl44,145; and hepatotoxicity of the drugs used to 
prevent rejection359,360 or for other purposes.3 G1 Graft dysfunction 
occurring at a somewhat later time can be caused by recurrence of 
the disease that destroyed the native liver, infection of the transplant 
by one of the hepatitic viruses, defects of bile duct reconstruction, or 
chronic rejection. Each general cause of graft dysfunction except 
those already covered will be expanded on in the following sections. 
REJECTION AND TOLERANCE INDUCTION 
Like other immune responses, rejection can be separated into 
three distinct but overlapping phases: (1) recognition of the antigen 
I induction) , (2) development of response capable of neutralizing the 
antigen (effector), and (3) regulatory mechanisms that restore ho-
meostasis to the organism.362, 363 It is likely that there are several dif-
ferent inductor, effector, and regulatory pathways involved in each 
phase.362,303 Clinically, effector mechanism receive the most atten-
tion, since recognition and attempts to control this process are the 
85 
mainstays of recipient management. Inductive and regulatory path-
ways remain largely in the realm of experimental transplantation 
and at present seeln to be the least understood?G4-3(;G 
Aside from its resistance to humoral rejection (see earlier section), 
the liver displays some special properties as a solid organ allograft in 
both animals and humans and therefore serves as an especially 
good model to study each phase of the rejection response. Shortly 
after the initiation of human liver transplantation, Cordier and asso-
ciates:167 as well as others3GI< discovered that liver allografts in pigs 
do not follow the normal laws of transplantation. They found that 
porcine hepatic grafts experienced prolonged survival with little or 
no inuJ1uI1osuppression. CaIne and co_workers369-371 denlonstrated 
that along with the immunologic "privileged" status, porcine liver al-
lografts also induced a state of hyporesponsiveness to other tissues 
from the same donor. In contrast, no spontaneous long-term liver al-
lograft survival was seen in the dog, baboon, rhelms monkey, or hu-
mans, all of whom required immunosuppressive therapy to main-
tain graft viability.:l72 Later, Zimmerman and colleagues373 and Ka-
mada and others273.374-:l7fi demonstrated that inbred strains of rats 
experienced a phenomenon similar to that seen in pigs. Since then, 
the rat has seIVed as an invaluable animal model for the study of 
liver transplantation.213, ;176 The resistance of the liver allograft to hy-
peracute rejection has already been discussed. 
Tolerance Induction and Immunosuppression Induced by Rat Liver 
Transplantation 
As mentioned previously, liver allografts are permanently accepted 
without immunosuppression between certain strains of rats (e.g., DA 
to PVG), whereas in others, the liver is acutely rejected.213, :176, 377 The 
class II MHC antigens appear to be the most influential in determin-
ing the rejector status of the strain combinations.213, :171<, PT~1 However, 
even across full RTl haplotype mismatches, liver allografts are toler-
ated in these nonrejector combinations, whereas other organs (e.g., 
skin) heart, and kidney) are acutely rejected.374-376 The liver grafts 
also induce a state of donor-specific unresponsiveness in the 
recipient that permits subsequent transplantation of the skin, heart, 
or kidney grafts.213, 375, 37G Liver grafts perfOimed on the same day as 
the kidney or heart graft can prevent subsequent rejection of either 
of these extrahepatic organs.374 However, a period of at least 5 days 
is required between the liver and skin grafts to achieve any 
acceptance.:174 Liver grafts are even able to reverse cellular rejection 
in cardiac grafts transplanted 5 to 6 days before the liver.213, 37(; This 
potent tolerance-enhancing effect is also capable of reversing a pre-
sensitized state (i.e., removing circulating allogeneic antibodies and 
memory cellsl.213, :l7(i However, when liver grafts are transplanted to 
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presensitized recipients, the acceptance rate falls from 95% to 50% 
(see the discussion of antibody-mediated rejection).213, 376 
This tolerance-enhancing and immunosupressant effect seems to 
be dependent on removal of the recipient liver.38o, 381 Auxiliary grafts 
are almost invariably rejected, and the recipient becomes sensitized 
as a result.38o,381 The reasons for these observations are largely un-
known; howevec the immunogenecity of the liver seems to reside 
largely in the nonparenchymal cell fraction. Sensitization rather 
than tolerance develops following infusion of unfractionated liver 
cell suspensions that contain both parenchymal and nonparenchy-
mal elements.:l8o Lautenschlager and others382,383 infused crude 
subfractions of liver-derived cells in an attempt to prime recipients 
for rejection of subsequent heart grafts. They found little immuno-
genecity associated with the fraction enriched in hepatocytes,382. :183 
whereas the Kupffer cell fraction, which may also have contained 
dendritic cells, was potently immunogenic. 
Possible Mechanisms Underlying the Unique Properties of Liver 
Allografts in Rats 
Genetic control of the allogeneic immune response is the most ob-
vious reason for the nonresponder status in rats, since the phenom-
enon described earlier occurs only between certain strain combina-
tions. As might be expected, in rat liver transplantation the alloge-
neic response appears to be under the control of primarily the im-
mune response gene (Ia or class II MHCJ, but minor polymorphic 
MHC loci may also influence the reaction.2U, 376, 379,384 Although no 
unifYing concept has been described to explain the peculiarities as-
sociated with rat liver transplantation, many of the effects observed 
are similar to those seen when attempts are made to regulate other 
immune responses. Kamada and Wight,374 Zimmerman and col-
leagues,373 and Houssin and associates214 reported that rat liver al-
lografts secrete soluble MHC antigens in the circulation where they 
bind to antigraft antibodies, rendering them nontoxic. However, it 
has been difficult to detect circulating immune complexes. Human 
liver allografts also secrete these MHC products/ll and their binding 
to preformed antibodies is one mechanism whereby the liver is 
thought to be relatively resistant to the effects of preformed lympho-
cytotoxic antibodies. 
Kamada and associates385 have also shown that serum from liver 
graft - tolerant (LGT) rats can cause donor-specific enhancement of 
heart grafts, and the enhancing activity has been localized to the 
anti-Ia antibody subfraction.386 Lymph fluid from LGT rats exhibits a 
similar effect but requires daily administration.213,376 
Although liver grafts are eventually tolerated between nonrejec-
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tor strain combinations in rats, they under'go a histologically and 
biochemically documentable episode of acute cellular rejec-
tion.213, ~TSI 387 This initial reaction is associated with infiammatOIY 
cell infiltration of the graft and a low transient elevation of 
anti - class I antibodies.213, 376, 388 Thereafter, graft infiltrating cells 
subside, and the class I antibodies return to baseline.388 Persistent 
high-titer anti-class II antibodies subsequently appear and may be 
partially responsible for maintenance of the graft.213, 376, 387, 368 Im-
munophenotypic analysis of graft infiltrating cells during the tran-
sient rejection episode in nonrejector rats reveals a profile of cells 
quantitatively similar to that in rejector strain combinations.389,390 
Qualitatively, however, the ratio of T cells to non-T cells and T-
helper cells to T-suppressor/cytoxic cells are increased over time in 
nonrejector combinations compared with the rejector strains.389. 3 !Jo 
In addition, eventual hepatocyte necrosis with architectural col-
lapse, which presumably is the result of the vascular insufficiency, 
never develops in grafts that are eventually tolerated (unpublished 
observations) . 
Adoptive transfer of thoracic duct lymphocytes of LGT rats has no 
effect in the immunologically crippled host.21 ;1.37(; However, transfer 
of graft-infiltrating lymphocytes restores the alloreaction, suggesting 
that clonal deletion of donor-specific effector cells occurs within the 
liver graft.375, 376 Despite the inability of the animal to reject the liver, 
in vitro, lymphocytes from LGT rats proliferate in response to donor 
lymphoid cell and generate CTLs.213, 371i Also, in vivo localized graft-
vs.-host (GVH) lymph node reactions remain intact. This phenome-
non has been temled split tolerance.2 13. :176 Splenic suppressor cells 
have also been identified?!)1 Similar immunologic findings have been 
reported in nonrejector pig strain combinations392 and in some hu-
man liver allograft recipients.393 
The immunologic observations in LGT rats are similar to those 
seen in antibody enhancement studies. The antigen reactive cell 
opsinization (ARCO) hypothesis has been used to explain the rela-
tionship between delayed-type hypersensitivity responses, which 
are thought to be important in rejection, and antibody reactions.394 
This hypothesis incorporates a role for antigens and antibodies, sup-
pressor cells, splenic sequestration, and clonal deletion of alloreac-
tive cells in the liver, all of which are reportedly seen in LGT rats. 
The position of the liver in the circulation and the function of the 
intrahepatic reticuloendothelial system may be important in this re-
gard. Several groups have reported prolonged survival of various al-
lografts following portal venous inoculation of allogeneic cells.395, :196 
However, others have been unable to reproduce this phenomenon, 
and Starzl and colleagues have questioned the experimental basis 
and rationale of this approach.:l 
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Inductive Pathways 
We will now return to consideration of rejection as an allogeneic 
immune response and its clinicopathologic manifestations. As was 
shown by Medawar,z56,397 recipients reject foreign tissue allografts 
because of an immunologic reaction elicited by a genetic disparity 
between the donor and recipient, which demonstrates both speci-
ficity and memory. The response is largely T-cell dependent and is 
provoked by the cell surface glycoproteins encoded by the MHC 
complex on chromosome 6 in humans. Not only are these antigens 
the principal targets on the transplanted tissue, but they assist in 
the regulation of the recipient rejection response.398 Other antigens 
of importance in the rejection response include the major ABO 
blood group system, mino)" MHC antigens, and possibly tissue-
specific antigens?(;Z, :\63 
Despite the observation that MHC antigens provoke strong rejec-
tion responses when they are part of an allograft, as isolated anti-
gens, they are, in general, considered to be relatively weak immuno-
genes within species.362 , 363, 399 A strong in vivo cytotoxic T-Iympho-
cy1e response to these antigens requires not only the antigen but 
also a secood signaL or costimulus, which is provided by a viable 
donor cel1.399 
Donor accessory, especially "dendritic" or passenger leukocytes 
are capable of presenting both the foreign MHC antigen and provid-
ing the second signal, or costimulus.:199, 400 The ability to respond de 
novo to alloantigens has been attributed to the diversity and cross-
reactivity within the antigen and MHC restriction element sites on 
the T-cell receptor complex.401-4u4 Clones that normally recognize 
self-antigen X (e.g., viruses) complexes can cross-react with alloanti-
gens.401-404 Alternatively, the donor MHC antigens may be pro-
cessed by recipient antigen-presenting cells, similar to other types of 
foreign antigens.362,363 
The structures within the allografts that trigger the alloreaction 
have not been identified "vith certainty, nor is it known whether the 
inductive phase occurs within the graft, systemically, or both. Liver 
grafts offer a unique opportunity to study the sites of sensitization 
because of the strict structural anatomy of the organ. In a "noI1llal" 
untransplanted liver, such as a donor liver prior to transplantation, 
there is strong expression of the major ABO blood group antigens on 
arterial venous and capillary endothelium and bile duct ce11s.405 He-
patocytes do not express any of these antigens. The class 1 MHC an-
tigens are expressed strongly on the bile ducts and somewhat more 
weakly on the sinusoidal cells and endothelial cells. Class I MHC an-
tigens are barely detectable on hepatocytes. Class II MHC antigens 
(DR, DO, and DP) are expressed only on capillary endothelium, 
sinusoidal cells and dendritic-shaped cells within the portal tri-
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ads.Z :IS, 3S:\, 4MR~InP The presence of l'vIHC antigens on the cell surface, 
however, is a dynamic process influenced by disease, drugs, inflam-
mation, and circulating immune mediators and is altered after trans-
plantation, which will be discussed later, 
Until recently, little attention has been given to the possible role of 
dendritic cells (DCs) in liver allograft rejection.409.414 Dendritic cells 
have been shown to be the most potent stimulators of the mixed 
lymphocyte response and spontaneous DC-allogeneic lymphocyte 
clustering is observed within hours after the initiation of a mixed 
lymphocyte culture.40Q,H5 In the liver, DCs are thought to be local-
ized almost exclusively within the portal traids,409, 414 although more 
definitive work is needed in this area. 
Daily histopathologic examination of rejector strain combination 
animal or some human liver allografts reveals what may be the mor-
phologic correlate of the inductive phase of the immune response. 
Two to 3 days after graft implantation, mononuclear cells begin to 
sludge and cluster in the capillaries and interstitium of the portal 
tract. At this Lime, mitotic figures can easily be identified in these ac-
cumulating lymphoid cells (Fig 53), which suggests that at least 
some degree of sensitization occurs within the liver. Structures lo-
cated at this initial site of accumulation and likely responsible for 
triggering the immune reaction include the donor DCs,409, 414 capil-
laI)' and lymphatic endothelia, and other connective tissue cells. 
Thereafter, infiltration and damage to target structures signal the be-
ginning of the effector phase (see Fig 53). 
Effector Pathways 
Several pathways have been implicated in the effector phase of the 
alloreaction: direct antibody and complement mediated damage, 
delayed-type hypersensitivity responses, cytotoxic T lympholysis, 
and antibody-dependent cell cytotoxicity mediated through killer 
cells.36z, 3(,3, 41d~4OO All of these effector pathways are dependent on T 
lymphocytes.362. 363, 41d~4OO 
These pathways roughly correspond to clinical classification of re-
jection.:162,363 Direct antibody and complement-mediated damage is 
largely responsible for triggering the cascade of events resulting in 
hyperacute rejection. Delayed-type hypersensitivity and allogeneic 
cytotoxic T lympholysis play principal roles in acute cellular rejec-
tion, and chronic rejection most likely represents a vascular directed 
attack by a combination of both cellular and humoral immunity. 
However, the present clinicopathologic classification of rejection 
into hyperacute, acute, and chronic rejection is not ideal, particu-
larly with regard to the liver, and is probably in need of revision. 
Nevertheless, we will adhere to conventional terminology in the 
present review. 
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FIG 53. 
Early histologic events in rejecting rat liver allograft EBk~aAFK A, the early evidence of 
the alloresponse occurs at 2 days and consists of mononuclear cell sludging in the capil-
laries (inset) and interstitium of the portal tracts. e, closer examination of this population 
reveals mitotic figures (arrows), suggesting that some senSitization may occur within the 
graft. C, by 4 days, the infiltrate begins to tunnel beneath the portal vein endothelium (ar-
row), D, by 5 days, venous damage and Infiltration into the ducts are noted (arrows). E, 
preterminal changes at 12 to 14 days include portal-portal linkage, centrilobular collapse, 
congestion and hemorrhage (pi = portal tract; cv = central veinl. (From Demetris AJ, Oian 
S, Sun H, et al: Am J Surg Pathol [in press]. Used by permission.l 
CLINICOPATHOLOGIC FEATURES OF REJECTION 
Acute Cellular Rejection 
The physiologic and morphologic features of cellular rejec-
tion were worked out long ago in experimental ani-
mals.8 . 9,18,74,81,186,327,423 Improvement in patient survival (and wide-
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spread utilization of liver transplantation) has enabled an expansion 
of some of these basic obseIvations.118, ,J9, 144, 145,179.424-435 In hu-
man liver allograft recipients, acute cellular rejection is the most 
common and principal manifestation of the rejection reaction. Most 
episodes occur between 6 or 7 days and 6 weeks after transplant 
but may be seen as early as 2 or 3 days after the operatiun. Episodes 
occurring later than 2 months usually, but not invariably, are 
associated with decreased levels of immunosuppressive agents. 
The clinical signs of acute rejection include fever, lethargy, graft 
tenderness, leukocytosis, and a change in the color or quantity of 
bile. IS, 66. (;7, 74, 435-437 Peripheral bloud and graft eosinuphilia4:18.439 
and lymphocytosis440 have also been associated with rejection, as 
have increased levels of serum neupterin,441 soluble IL-2 receptors,442 
guanaseID~4P amyloid A protein, and (3z-microglobulin,444 but none of 
these alterations appears to be entirely specific. Serum bilirubin is a 
sensitive marker of dysfunction, and hepatic enzymes indicative of 
liver injury are frequently increased, but neither the absulute level 
nul' the pattern of elevation is specific for rejection.'s. 66. 67, 74. 435-437 
Confirmation of a clinical suspicion rejectiun is usually achieved by 
core needle biopsy evaluation.* 
The histologic diagnosis of acute cellular rejection rests mostly on 
identification of a predominantly mononuclear portal tract inflam-
matory infiltrate, along with evidence of tissue damage (Fig 54).t It 
should be emphasized that portal inflammation alone may be due to 
many causes and therefore is not diagnostic of rejection. The initial 
accumulation of monunuclear cells occurs in the interstitium of the 
portal tracts. Tissue damage becomes manifest as the infiltrate ex-
tends into the walls of the portal vein and bile ducts, associated with 
reactive changes in the target cell populations (endothelium and bile 
ducts) such as hypertrophy and nuclear enlargement. Evidence of 
pyknosis and focal necrosis is also seen. 
Cytologically the rejection infiltrate consists of an admixture of 
large blastic lymphocytes, smaller lymphocytes, plasma cells, macro-
phages, eosinophils, and neutrophils. Eosinophils may predominate 
in some cases during the early phases, simulating an allergic drug 
reaction?44, 145. 428, 438 Immunophenotypic analysis of the rejection 
infiltrate demonstrates a preponderance of T cells with both CD4 + 
or CD8+ subsets; non- T cells, such as macrophages, monocytes, 
neutrophils, and B cells, are also present.Z38, 409, 411, 44S, 446 
Hepatic arteries within the purtal tract are difficult to lucate dur-
ing an acute cellular rejection episode. Endothelial swelling and mu-
ral hypertrophy are the most common obs8Ivation when the arteries 
are found. Necrotizing or neutrophilic arteritis (or both! is rarely 
9Z 
'References 67, 118, 119, 144, 145, 179,423-436. 
tReferrmces 67, 118, 119, 144, 145, 179, 4Z:i-434. 
· . 
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FIG 54. 
Histopathology of acute cellular rejection in humans. Events are almost Identical to those 
seen in the rat (see Fig 53). A, mild acute cellular rejection. B, in moderate acute cellular 
rejection, the infiltrate is somewhat more florid. but no signs of ischemic parenchymal or 
interstitial injury are detected. C, subendothelial infiltration of lymphocytes in the portal 
veins and. D, infiltration and damage of small bile ducts (arrow) are characteristic and di-
agnostic features. E, severe acute cellular rejection is diagnosed when there is evidence 
of acute rejection-related ischemia. such as interstitial hemorrhage. necrosis, and cell 
dropout (pt = portal tract; cv = central vein), or F, inflammatory or necrotizing arteritis. 
(From Demetris AJ. Qian S. Sun H, et al: Am J Surg Pathol [in press]. Used by permIs-
sion.) 
93 
seen (see Fig 54). Lymphocytic arterial inflammation can occur but is 
present in less than 5% of cases of acute cellular rejection.447 Inflam-
matory arteritis may be a component of rejection, but the vessels 
most commonly affected are the second- and third-order branches 
of the hepatic artery in the hilum, which are not accessible to needle 
biopsy evaluation.l44 , 145,424,427,428 The rather low incidence of arteri-
tis detected in needle biopsy samples may therefore be due to a 
sampling problem.144, 145,424,427,428 
Surprisingly little inflammatory cell infiltration into the hepatic 
lobule is seen during rejection. In fact, if significant lymphocytic he-
patocellular injury is detected in biopsy samples, a de novo or recur-
rent viral hepatitis is more likely to be the cause of graft dysfunction, 
The relative restriction of the inflammation to the porial tracts during 
rejection may be the result of the functional anatomy of the organ, the 
localization and concentration of MHC antigens, and possibly the lo-
cation of portal dendritic or capillary endothelial cells.409, 414 
Fine needle aspiration biopsy (FNABJ sampling of the liver has 
been advocated as an adjuvant to the needle core for routine immu-
nologic monitoring.448,449 Although this technique appears to be 
useful, it is diagnostically limited because no information is obtained 
on the architectural integrity of the organ, a problem that is of lesser 
significance in kidney grafts where FNAB is mOI'e routinely used. In 
the liver, there are many more causes of graft dysfunction, complica-
tions, and morphologic manifestation of systemic derangements, 
which require attention to architectural detail. 
The distributions of the MHC antigen in human livers is altered 
after transplantation presumably because of local secretion of lym-
phokines.450,451 Steinhoff and associates411 and Gouw and col-
leagues238 detected a weak expression of class I antigens on hepato-
cytes early after transplantation in the absence of graft pathology. So 
and co-workers attributed this early presence to hepatocyte necrosis 
from harvesting injury,4l2 Weak class II antigen expression was de-
tected locally on bile ducts in the absence of cellular rejection, Dur-
ing rejection, class I antigens are upregulated on hepatocytes and 
bile ducts, and DR, DP, and at times DQ can be detected on biliary 
epithelia and endothelial cells ,238, 409-413 Steinhoff and associates 
were also able to detect weak DR expression on hepatocytes during 
rejection and viral infection."1l Although several investigators have 
detected an association of an altered display of MHC antigen with 
certain graft syndromes, the patterns pel' se were not generally spe-
cific for any particular cause of dysfunction. Alterations have been 
detected during large duct obstruction and hepatic or systemic (or 
both) viral and bacterial infections, in addition to rejection.2:l8,409-4u 
Pathologic grading of acute cellular rejection is a controversial 
area. Several classifications systems have been proposed, but none is 
able to predict the likely response to therapy or eventual outcome 
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based on the initial histologic appearance unless irreversible dam-
age, such as duct loss or obliterative arteriopathy, is already mani-
fest. IIS . 431, 452 Currently, the system in use in Pittsburgh adapts con-
cepts applied to kidney and heart grafts (Table 9).144,145 As in the ex-
trahepatic organs, the separation from mild to moderate acute cellu-
lar rejection is somewhat arbitrary and is based on the exuberance 
of the inflammation, which may have little prognostic significance. 
Severe rejection, on the other hand, is diagnosed when there is his-
tologic evidence of rejection-related vascular compromise (ischemic 
damage), interstitial hemorrhage, and/or arteritis. The problem with 
applying such a system in the liver is that arteritis is rarely observed 
in biopsy samples, and apparent ischemic parenchymal changes 
may be nonspecific or unrelated to rejection. It may be that a se-
quential analysis of serial biopsies demonstrating continual deterio-
ration is more predictive.4:n, 452 
Functional analysis of lymphocyte cultures derived from rejecting 
human liver tissues demonstrates both proliferative and cytotoxic 
reactivity directed at donor MHC antigens.:l:l9 ,453 The concept of in 
vitro expansion of graft-infiltrating lymphocytes, which was dis-
cussed earlier (see Figs 50-54J in connection with drug develop-
ment, is based on the fact that the T cells activated in vivo express 
growth-promoting IL-2 receptors, and in vitro, the addition of IL-2 
to the culture medium selectively expands the activated cells. Both 
the proliferative and cytotoxic activities observed in lymphocyte 
cultures can be blocked by specific monoclonal antibody directed at 
class II or class I antigensKPP~gI 453 Functional analysis of the lympho-
TABLE 9. 
Histopathologic Grading System of Acute Cellular Rejection 
Crade 
1. Consistent with 
2. Mild 
:>. Moderate 
4. Severe 
Histologic Findings 
Mononuclear portal interstitial infiltrate with "blastic" 
lymphocytes but little evidence of tissue damage' 
Mild predominantly mononuclear portal tract infiltrate with 
evidence of bile duct damage with or without subendothelial 
inllammation 
Portal expansion secondary to pl'8dominantly mononuclear 
inflammation with duct damage and spillover into the lobule 
with or without periportal hepatocyte necrosis; no evidence of 
aIieritis, central or bridging necrosis (rejection-related 
ischemia) 
Usually marked but variable portal inflammation with evidence of 
interstitial hemorrhage andlor ischemic hepatocyte necrosis or 
inflammatory arteritis, in addition to findings in no. 2 or 3 
*Diagnosis used "lost often itl the first 3 posttransplant weeks 'when there is clinical and biocheluical 
evidence of w'aft dysfunction but histologiC findings are not diagllostic {see text I. 
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cytes from a needle core sample adds an informational dimension 
that, at present, cannot be gained from a strictly morphologic 
analysis. 
In general, lymphocyte outgrowth from the biopsy specimen cor-
relates well with the histologic diagnosis of moderate or severe acute 
cellular rejection.33ll, 453. 454 However, alloactivated cells can be gener-
ated from biopsy specimens where the etiology of graft dysfunction 
is due to viral hepatitis.45:l The signiflcance of this latter obseIvation 
has yet to be determined. Similar studies have been performed in rat 
liver allografts.455 
Chronic Rejection 
Recipients who develop chronic rejection usually experience a rel-
atively asymptomatic rise in the canalicular enzymes (alkaline phos-
phatase and -y-glutamyl transpeptidase) and eventually become 
jaundiced.* Although the term chronic implies a temporally pro-
longed course, this syndrome can evolve within weeks after trans-
plantation or be the end resulL of acute rejection unresponsiveness 
to conventional therapy. Unfortunately, some of the patients will 
recapitulate the same course after retransplantation of a new 
graft.144, 145. 456, 457 Synthetic function usually remains intact until 
late in the course! although rapid deterioration can occur in 
patients who develop superimposed vascular thrombosis or biliary 
tract stricturing and subsequent cholangitis.145 Clinical suspicions 
of chronic rejection can be confirmed or ruled out after needle 
biopsy evaluation.144, 145,424.456.4,57 
Occlusive arteriopathy and bile duct loss (vanishing bile duct syn-
drome) are the principal structural consequences of this form of im-
munologic graft injury:" Although these cardinal manifestations may 
occasionally appear to occur in isolation, we have shown a close re-
lationship between the degree of arterial luminal narrowing and the 
severity of bile duct loss.458 This dependency is not surprising con-
sidering the arterial system is the only source of blood for the bile 
ducts.146 This led us to suggest that two mechanisms are responsi-
ble for the bile duct loss seen with chronic rejection: direct immu-
nologic damage and ischemia.458 The Cambridge group has also 
shown that disparity at the class I MHC locus (see the discussion of 
the effect of Histocompatibility) and CMV infection were interdepen-
dent predisposing factors for chronic rejection.459.46o In addition. 
patients with a positive pretransplant or posttransplant lymphocyto-
toxic crossmatch more commonly developed bile duct 10ss.4,59. 461 
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The histopathologic features of chronic rejection are somewhat 
'References 67, 144. 145, 423, 424. 433, 434, 456. 457. 
TRcfcrences 144, 145, 423, 424, 433, 434, 456, 457. 
FIG 55. 
Histopathologic features of "chronic" liver allograft rejection. A, in the earliest phases of 
chronic rejection, the portal infiltrate is often unimpressive, but the duct damage is severe 
(arrows) . B, eventually the bile ducts are totally destroyed, a finding recognized by the 
presence of a portal artery without an accompanying bile duct. C, finally, tile artery may 
be destroyed as well, and the portal triad becomes devoid of inflammatory cells. D, lobular 
changes include central hepatocanalicular cholestasis, perivenular fibrosis, cell dropout, 
and mononuclear infiltration with occasional clusters of sinusoidal foam cells (cv = central 
vein). E, large septal arteries (HA = hepatic artery) become occluded, usually by subinti-
mal foam cells, which causes ischemic injury and epithelial sloughing to accompanying 
septal ducts (BD = bile duct). F, fibrointimal hyperplasia similar to the arteriopathy in kid-
ney and heart grafts can also be seen. (From Demetris AJ, Qian S, Sun H, et al: Am J Surg 
Patho/ [in press]. Used by permission.) 
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subtle and easily overlooked if one is not attuned to recognizing its 
features (Fig 55). In contrast to acute cellular rejection, the portal in-
filtrate is often quite sparse and is comprised of lymphocytes, 
plasma cells, and macrophages. Acute inflammatory cells are un-
common. Despite the relative paucity of portal inflammation, epithe-
lial cell pyknosis, disruption of the basement membrane, and com-
plete destruction of small bile ducts ensue. t This response suggests 
that the effector mechanisms are extremely potent, noncellular, or 
ischemic in nature. 
Lobular alterations include Kuppfer's cell hypertrophy, mild 
spotty acidophilis necrosis like that seen in a low-grade lobular hep-
atitis, and eventual central hepatocanalicular cholestasis. Small clus-
ters of intralobular foam cells and perivenular hepatocellular atro-
phy, ballooning or dropout, and hemorrhage with sclerosis, presum-
ably a result of chronic ischemia, are end-stage features. Although 
bridging fibrosis is occasionally seen, a cirrhosis with regenerative 
nodularity is uncommon. 
The obliterative arteriopathy that develops does so most com-
monly in the branches of the hepatic artery in the hilum, vessels not 
routinely sampled in needle biopsies.14.5. 423, 424, 452-458 Most affected 
arteries are narrowed because of deposition of subendothelial foam 
cells in the intima, the majority of which appear to be derived from 
recipient macrophages. However, the presence of T lymphocytes 
and interdigitating reticulum cells can also be seen in the intima 
media and periadventitia,462 suggesting that cellular immunity is in-
volved in the development of these lesions. Concepts from the re-
sponse to injury hypothesis used to describe the development of 
atheroclerosis in the general population46:3 appear particularly rele-
vant to the obliterative arteriopathy that occurs in the transplant 
population. 
Graft-vs.-Host Disease 
Control of the rejection may not be the only requirement for recip-
ient smvival. There has been increasing awareness that hepatic 
grafts can mount a significant attack on their recipient. The most 
likely explanation is the persistence of donor lymphoid tissue in the 
liver grafis.423, 464. 465 The presence and continued viability of such 
donor lymphoid implies the possibility of GVH disease, a potential 
that has been documented by the demonstration of new circulating 
donor-specific Gm types in the recipiene37, 464, 465 and by the hemo-
lysis caused by antihost RBC isoagglutinins, which are produced by 
the lymphoid tissues in ABO-compatible but not identical livers (e.g., 
o donor to A recipient) .466,467 In addition, GVH disease has been 
reported in a recipient whose own tissue contained donor mono-
cytes.46B Intensification of immunosuppression relieved a skin rash, 
fever, and other symptoms of GVH disease. Unexplained wasting of a 
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febrile postoperative liver recipient who has a skin rash should 
cause GVH disease to be expected. A skin biopsy specimen should 
be obtained. Although contim ... _ 1 viability of donor lymphoid cells 
has been documented in the cases cited previously, replacement of 
the donor lymphocytes in grafted hepatic hilar lymph nodes has 
also been shown.-169 
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INFECTIOUS PROBLEMS IN LIVER 
TRANSPLANTATION 
BACTERIAL AND FUNGAL INFECTIONS 
Although liver grafts may possess some immunologic advantage, 
as discussed earlier, the practical reality is that heavy initial immu-
nosuppression and later maintenance therapy are required in the 
same way as with other organs. The balance between immunosup-
pression and infectious disease control is more delicate than with 
cardiac and renal transplantation because the hepatic graft is ex-
posed to the intestinal tract through the biliary tract or by hematog-
enous contamination fi'om the splanchnic venous bed. The devastat-
ing role of consequent graft infection by organisms indigenous to 
the gastrointestinal (GI) tract was delineated in the early clinical tri-
als 18.470-472 as well as those in the cyclosporine era.358, 436, 473-475 Ex-
periments in dogs performed 25 years ago provided an example of 
what now is called bacterial translocation in that the liver graft itself 
became a porous entry site for bacteria indigenous to the GI tract.476 
A liver damaged by rejection becomes unusually vulnerable to inva-
sion by such microorganisms. Effective immunosuppression has 
long been recognized to be the only way to maintain intact tissue 
barriers and to avoid this kind of infection,lll 
There has been recent interest in controlling the bacterial and 
fungal population of the GI tract vvith preoperative nonabsorbable 
oral antibiotics.252,477 These antibiotics selectively suppress patho-
genic gram-negative organisms and fungi but allow survival of anaer-
obes. This has been called selective intestinal decontamination. A 
typical antibiotic regimen consists of polymyxin E, gentamycin, and 
nystatin. The morbidity from infection after liver transplantation has 
been reduced with this approach, but the mortality has not.252 In 
addition to its unproved value, a practical limitation of selective de-
contamination is the inability to find a cadaveric liver at the optimal 
time ordained by the antibiotic preparation. 
Much about the subtle relationships between host defenses and 
invasive bacteria remains to be learned in the liver transplant model. 
The host macrophage system, of which the liver is an important 
component,218 is profoundly altered by transplantation. The possi-
ble role of altered graft Kuppfer's cells in contributing to endotox-
emia was discussed in an earlier section. 
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Liver recipients also suffer frequently from virus infections. The 1'C-
currence of hepatitis viruses in grafts will be discussed in the next 
section. Other virus infections occur at some postoperative time in 
the majority of liver recipients.478 
CLINICOP/1THOLOGIC FEA'l'URES OF ALLOGRAFT VIRAL HEPATI11S 
Clinical symptoms, along with the use of core biopsy, am used to 
establish the diagnosis of allograft hepatitis. In general, the clinical 
features and histologic appearance of allograft viral hepatitidies are 
identical to those observed in other immunosuppressed patients. It 
is helpful, however, to anticipate the relative time of onset of the dif-
ferent viral syndromes, since they tend to occur at characteristic 
times after liver replacement (Table 10).* The following sections are 
separated into discussions of those viruses that are classically asso-
ciated with hepatitis from those that are more opportunistic in na-
ture. 
Opportunistic Viruses 
The most common viral pathogens in the opportunistic categoI)' 
that cause allograft hepatitis belong to the herpes family: CMV, HSV 
types 1 and 2, varicella-zoster (VZ) virus, and EBV. Another cause of' 
allograft hepatitis not commonly seen in the general popUlation is 
adenovirus (ADV). The follmving are presented in order of frequency. 
Cytomegaloviral Hepatitis 
The most common serious infections are with CMV, which 
can cause lesions in many organs.353, 354,478-480 Cytomegalovirus 
is the most common cause of postoperative graft hepatitis and 
is seen most frequently between 3 and 8 weeks after trans-
plant.3s:1, 354. 478--480 Protection from serious CMV infection has been 
reported with hyperimmune globulin.4R' RecoveIY is the rule if im-
TABLE 10. 
Peak Incidence of Graft Syndromes vs. th" Tim" Aft"r Transplant 
Viral Syndromes 
Cytomegalovirus 
Herpps simplex 
Epstein-Barr 
Adenm,irus 
Hepatitis B 
Hepatitis A 
non-A, non-B hepatitis 
Time After Transplant 
3-8 wk, oft,m after treatment of rejection 
Any time after transplant 
Most common in first 2 mo. but may occur anytime thereafter 
3-4 wk ;ifter tmnsplant. 
Onset usually aftel' 4- 6 wk, and graft remains infected 
No expc!~encc to date 
Usually after 4 wk 
'Table 1 appeal's in Part I; Tables 2-9 appear in Pali II. 
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munosuppression is lightened and especially if therapy is given with 
ganciclovir EdancyclovirFK4T~1K 482 However, CMV strains resistant to 
ganciclovir have been reported recently.483 The onset of CMV is often 
temporally related to episodes of rejection, where the patient has 
just received additional immunosuppressive therapy for an acute 
cellular rejection episode.353, 354. 478-480 
Clinically, patients usually present with a low-grade fever and 
mildly elevated liver injury test results. Leukocytopenia, diarrhea, GI 
ulcers, and respiratOlY symptoms are not uncommon.353, 354, 478-480 
The diagnosis of liver involvement is confirmed by needle biop-
sy.144, 145. 353 
Cytomegaloviral hepatitis is characterized by lobular alterations 
(Fig 56).d44, 145,353 Any cell type of the liver may be infected, and 
those that are may demonstrate cytomegalic change, intranuclear 
eosinophilic inclusions surrounded by a halo, and/or small baso-
philic cytoplasmic inclusions. These foci are often infiltrated with 
clusters of inflammatory cells, consisting of neutrophils, macropha-
ges (microabscesses and microgranulomata), or both. Other lobular 
alterations include mild Kupffer's cell hypertrophy. Significant lobu-
lar disarray, massive or submassive necrosis, or even severe liver 
damage from CMV alone is rare. Recognition of any of these changes 
should prompt a careful search for viral inclusions, the use of immu-
Characteristic histologic features of CMV 
hepatitis include Kupffer's cell hypertrophy, 
spotty lobular necrosis (A, arrows) 
accompanied by microgranulomas or 
microabscesses (8); inclusions can be 
found in nearby cells (8, arrow). 
Cytomegalovirus inclusions (C) can be 
found in any cell within the liver, including 
the biliary epithelium (arrow), where it has 
been associated with loss of bile ducts 
(see text). 
* Figures 1-42 appear in Part I; Figures 43- 55 appear in Part II. 
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nohistochemical stains for the detection of the CMV antigens, or 
both. 
Tissues containing rapidly dividing cells, such as young granula-
tion tissue, proliferating cholangioles, edges of infarcts, and ab-
scesses or other defects are fertile soil for CMV growth.144. 145 When 
such tissue is encountered, a more careful search of CMV is war-
ranted.144, 145 
Finally, CMV can be associated .vith a plasmacytoid or blastic in-
filtrate (or both) similar to that seen in EBV hepatitis (unpublished 
obseIvations). Cytomegalovirus inclusions are nut usually detected 
in such cases. Differentiation from rejection and lymphoproliferative 
disease associated with EBV may be difficult and is based on careful 
microscopic examination and immunohistochemical stains to detect 
viral antigens. The clinical profile and various hematologic parame-
ters are also helpful. 
Recently, CMV has been implicated in the pathogenesis of the van-
ishing bile duct syndrome (VBDS).460 Compatibility between the do-
nor and recipient at the DR MHC locus, along with mismatching 
at the class I locus and CMV infection have been identified as inter-
dependant risk factors for the development of bile duct loss.459.46o 
The Cambridge group has suggested that MHC-restricted antigen 
presentation of viral antigens or mismatched class I MHC antigens 
by DR-compatible bile duct cells is responsible for this obseIva-
tion.460 
Herpes Simplex. and Varicella-Zoster Hepatitis 
Both subtypes of HSV (1 and 2) and the VZ virus have been identi-
fied as causes of liver allograft hepatitis. Signs of graft infestation 
have been seen as early as 3 days after transplant and may occur 
any time thereafter. l44, aS4. 4114 The clinical presentation with the HSVs 
includes fever, fatigue, and body pain combined with serologic evi-
dence of hepatic injUIy.144 145.354 Cutaneous manifestations mayor 
may not be present. With the VZ virus, allograft involvement may be 
detected several days prior to the eruption of cutaneous vesicles 
typical of this disorder. Untreated, any of these viruses may rapidly 
lead to massive hepatic necrosis. Therefore, early recognition on 
needle biopsy is particularly crucial since effective medical therapy 
(acyclovir) is available. 
Microscopically, all three viruses produce similar graft pathology 
(Fig 57).144.145,4114 They are characterized by circumscribed areas of 
coagulative necrosis, showing no respect for the lobular architec-
ture. Ghosts of hepatocytes intermixed with neutrophils and nuclear 
debris are seen in the center of the lesions. More viable hepatocytes 
are seen at the periphery, some of which may contain ground glass 
nuclei or characteristic inclusion bodies. Multinucleated cells are 
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A, the HSV and the VZ virus produce 
similar lesions in the liver allograft, 
characterized by large areas of 
coagulative-type necrosis (arrows). B, 
multinucleated cells may be seen at the 
periphery of the lesion, and occasionally 
characteristic Cowdry type A inclusion 
bodies are identified like those shown in 
C (arrows). 
also occasionally present. Immunoperoxidase stains for various viral 
antigens confirm the diagnosis when the pathologist is unsure on 
the basis of the hematoxylin-eosin stains alone. 
Epstein-Barr Virus 
Consequences of primary infection or reactivation of the EBV after 
transplantation run the gamut from an infectious mononucleosis 
syndrome as seen in the general population485 to severe life-threat-
ening lymphoproliferative disease similar to patients with the x-
linked lymphoproliferative disorder486 or acquired immunodefi-
ciency syndrome (AIDS) .487 Lymphoproliferative tumors (B-cell lym-
phomas) have been seen with all kinds of transplantations but most 
frequently in liver recipienls355, 4UU-4~11 and especially in infants and 
children, in whom the risk over the first 2 years after transplantation 
may be as high as 10% .355, 492 The liver graft itself is frequently in-
volved. The most effective treatment measure for any of the EBV syn-
dromes is discontinuance or reduction of immunosuppression,488 to 
which antiviral therapy with acyclovir should be added.493 Regres-
sion of the symptoms, laboratOIY abnormalities, and lymphomas 
usually, although not invariably, follows reduction of immunosup-
pression whether or not acyclovir is given.488, 490, 491 This effect 
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may be achieved even though the hepatic graft is not rejected. The 
regression of these lymphomas, some of which are monoclonal, 
when the recipient immunologic responsiveness is allowed to re-
cover is thought to be an example of immunologic sUIveillance in 
hurnans.4 1>8 
Clinical signs and symptoms of recipients with EBV syndromes at 
the more benign end of the spectrum are similar to those seen with 
infectious mononucleosis, although atypical presentation in the 
fOrIn of fever, rashes, and joint and jaw pain are not uncommon. 
Liver enzyme levels are usually only modestly elevated, but occa-
sionally significan t damage and even submassive or massive necro-
sis may be seen. Those recipients who develop tumors present 
clinically with constitutional symptoms similar to those just de-
scribed in addition to those related to organ system involvement 
with tumorK4UU-D~91 Atypical lymphocytosis in the peripheral blood 
smear is invariably present in all patients. The diagnosis of allograft 
involvement is confirmed by needle biopsy evaluation of the graft. 
FIG 58. 
The EBV causes a spectrum of pathologic lesions in the liver, ranging from mild lobular 
hepatitis with sinusoidal lymphocytosis (A) to granulomatold collections (8) of immuno-
blastic lymphocytes, which can be associated with hepatocyte necrosis (C, arrow). Ep-
stein-Barr virus- driven Iymphoproliferative lesions in the liver (D) are characterized by a 
monomorphic infiltrate that overruns the normal architectural landmarks. (From Demetris 
AJ, Jaffe R, Starzl TE: Pathol Annu 1987; 22347-386. Used by permission.) 
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Like the variety of clinical disorders, involvement of the liver by 
EBV-associated disorders also Iuns the histopathologic gamut from 
typical monohepatitis as seen in the general population to submas-
sive or massive hepatic necrosisl~s or involvement by tumor, com-
prised of malignant lymphoid cells similar to those seen in immuno-
blastic lymphomas (Fig 58). Cases resembling lymphomatous in-
volvement of the liver may be difficult to differentiate from acute cel-
lular rejection145 since subendothelial infiltration of the portal veins 
along with focal bile duct damage may be present. Usually these are 
not as severe or as widespread as those seen with rejection. The key 
to the diagnosis is the monomorphic and atypical appearance of in-
filtrative cells in the EBV-related disorders. Immunohistochemical 
FIG 59. 
A, the ADV causes typical granulomas in the liver. Immunoperoxidase stains can be help-
ful if one cannot identify the inclUSion bodies (arrows). 8, at the periphery of the granulo-
mas, infected cells with intranuclear inclusions appear smudgy. (From Demetris AJ, Kaki-
zoe S, Oguma S: Pathology of liver transplantation, in Williams JW led]: Hepatic Trans-
plantation. Philadelphia, WB Saunders Co [in press]. Used by permission.) 
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staining to detect EBV viral antigens can be performed but requires 
frozen tissue. Immunophenotypic analysis of the infiltrative cells in 
EBV-related disorders usually demonstrates a great number' of 
non-T cells, whereas in acute cellular rejection, the T cells predom-
inate. 
Biopsy of enlarged lymph nodes (most common) or other organs 
infiltrated by tumor is also used to establish the diagnosis of an EBV-
related disorder. In the nodes, the changes vary from those seen 
with infectious mononucleosis4~l4 to a histology indistinguishable 
from immunoblastic lymphoma.489 Immunohistochemical and light-
chain immunoglobulin gene rearrangement analysis are used to es-
tablish the clonality of the tumors, if present.488-491 
Adcnoviral Hepatitis 
Allograft hepatitis due to the ADV has been restricted to primarily 
the pediatric population, although more recently an unequivocal 
case in an adult has been identified.:l56.357 Adenovirus usually oc-
curs within a very narrow time frame, namely, 20 to 30 days after 
transplant, and the patients present with fever and elevated liver in-
jury test results.357 To date, almost all of the cases of ADV in the 
transplant population have been caused by viral subtype 5.357 How-
ever, other viral subtypes (2, 11, and 16) have been associated with 
hepatitis in the general population and could be expected to infect 
allografts.495 The diagnosis is made on needle biopsy sampling of 
the organ,3S7 after which immunosuppression should be temporarily 
stopped. 
Histologically! granulomatoid collections of histiocytic cells are 
randomly located throughout the parenchyma (Fig 59). Hepatocyte 
necrosis may be detected but usually is less severe than that seen 
with HSV. Characteristic "smudgy" intranuclear inclusions can be 
identified in hematoxylin-eosin-stained sections, but experience is 
required to be confident of the diagnosis without the use of special 
stains. In infected cells, the chromatin is crowded toward the nu-
clear membrane, which imparts a muffin-shaped appearance to the 
nucleus. Immunohistochemical stains are confirmatory. 
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HEPATITIS VIRUSES 
HEPATITIS B VIRUS 
Viral hepatitis type B in the posttransplant period is restricted 
largely to those patients who carried the virus prior to transplanta-
tion, although a few patients have acquired an infection, presumably 
as a result of blood transfusion. Provision of a new liver usually, 
but not always, lowers the titer of the virus, as measured by the sur-
face antigen,496,497 but return of the carrier state is almost univer-
sal,498-502 In spite of this generalization, some chronic carriers have 
apparently cleared the virus after transplantation499-503 with passive 
immunoprophylaxis. In our experience, those chronic carriers who 
have cleared the virus have been E antibody positive and E antigen 
negative, although this serologic profile is no guarantee that infec-
tion will not recur. Among those recipients who become reinfected, 
a small percentage will develop a carrier state and experience long-
ternl survival with minimal liver dysfunction. Recapitulation of the 
original chronic aggressive hepatitis jeopardized the recovery of 
many of the recipients.4!J(i-499,501 Delta agent coinfection is an 
additional confounding factor and recurs along with the B vi-
rus.497, 500. 501 Reinfection of the allograft after transplantation for 
acute fulminant hepatitis B is less certain, with several patients ex-
periencing long-term survival with viral immunity,497, 498 The survival 
with acute disease and fulminant hepatic failure has been accept-
able, although less favorable with chronic disease (Fig 60). 
In those who develop HBV disease after liver replacement, the on-
set of symptoms usually occurs 6 to 8 weeks after transplantation. 
The presentation varies from asymptomatic elevations of liver injury 
test results to nausea, vomiting, jaundice, and hepatic failure. The 
clinical syndrome, therefore, is not significantly different from viral 
hepatitis as seen in other immunosuppressed hosts. Serologic eval-
uation and needle biopsy of the graft confirm the diagnosis. 
Pathologic identification of acute hepatitis B as a cause of dysfunc-
tion rests on the recognition of preferential lobular alterations in the 
absence of significant inflammatory cell damage to bile ducts, arter-
ies, and venular endothelia.497 However, the pathologic appearance 
of HBV in the allograft is as varied as the complete spectrum of 
acute and chronic viral hepatitis as seen in the general population 
(Fig 61),145 Simply stated, viral hepatitis in the liver allograft looks like 
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FIG 60. 
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Patient survival (life table method) after liver transplantation with cyclosporine-prednisone 
for 65 adults with chronic B virus hepatitis compared with 13 adults with acute B virus hep-
alltis. 
viral hepatitis in other livers except for a relative paucity of inflam-
mation in some cases, even with severe clinical manifestations and 
pathologic changes. 
The natural history of hepatitis B infection of the allograft liver is 
becoming clearer. In our series of 59 patients who received allografts 
because of HBV disease, pathologic follow-up was available in 39 of 
46 recipients who survived for more than 60 days. Thirty-four of 
these 39 patients had histologic evidence of recurrent hepatitis B in-
fection, disease, or both. 
A very typical sequence of pathologic changes was observed in 
these specimens. The first evidence of recurrent hepatitis B infection 
was the detection of hepatitis B core antigen in the cytoplasm of he-
patocytes several weeks after transplantation. Little pathologic 
change was detected at this time. Several weeks thereafter, mild lob-
ular disarray, hepatocyte swelling, and mild spotty acidophilic ne-
crosis with regenerative change coincided clinically with the onset 
of elevated liver injury test results and signaled the development of 
disease activity. Most of the specimens at this time had the appear-
ance of a mild acute hepatitis as seen in the general population ex-
cept for a relative paucity of lobular portal inflammation. 
Follow-up of these patients over several weeks to greater than 5 
years revealed several clinicopathologic "syndromes." Six of the pa-
tients experienced a syndrome of unresolved lobular hepatitis, and 
five settled into a clinicopathologic profile resembling chronic carri-
ers with little disease activity. Eighteen others developed chronic ac-
tive hepatitis, and four of these became cirrhotic, 1.5 to 5 years after 
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FIG 61. 
Hepatitis B virus infection of the allograft causes pathologic lesions similar to those seen in 
the general population and in other immunosuppressed hosts. In A there is an acute hepa-
titis with lobular disarray, hepatocyte ballooning, and necrosis. e, in chronic active B viral 
hepatitis in the allograft, a portal infiltrate with active piecemeal necrosis (arrow indicates 
intact bile duct) (C, straight arrow) and preservation of the bile ducts (curved arrow) are 
the identifying features. D, the eventual outcome of many cases with chronic active hepa-
titis after transplantation is graft failure or cirrhosis, which may occur with surprising rapid-
ity (see text). 
transplant. A fifth patient rapidly became cirrhotic 147 days after 
liver replacement without any evidence of intervening chronic active 
hepatitis after transplantation. Follow-up of the few patients who 
have apparently cleared the virus with no serologic or histologic ev-
idence of recurrent B viral infection of the liver revealed nonspecific 
changes in three, non-B chronic active hepatitis in one and acute 
cellular rejection, which responded to bolstered immunosuppres-
sive therapy, in the remaining patient. 
It is not always easy for the pathologist to distinguish between re-
jection and hepatitis as a cause of malfunction. The most useful fea-
ture overall used to differentiate these two causes of malfunction is 
the focus of lymphocytic damage. The bulk of the injury associated 
with acute HBV is directed at hepatocytes and is recognized as lob-
ular alterations. Acute rejection, on the other hand, is directed at 
structures within the portal tracts. In chronic hepatitis, portal in-
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flammation is present, and lobular alterations may be minimal. In 
these cases, one has to determine if piecemeal necrosis or bile duct 
destruction is the more prominent feature. It must be stressed that 
an overall assessment of the entire biopsy specimen with careful ex-
amination of each portal tract must be performed. Individual cases 
may be quite difficult since both bile duct damage and significant 
piecemeal necrosis may be present. It has been our policy that if a 
significant amount of duct damage is detected, regardless of the 
presence of piecemeal necrosis, a diagnosis of rejection made. A 
therapeutic or diagnostic clinical trial of immunosuppressive ther-
apy is then initiated. This approach seems prudent, considering the 
fact that reductions of immunosuppression during hepatitis B infec-
tion may result in fulminant liver failure. 
NON-A, NON-B HEPATITIS 
Although precise identification of at least one of two viruses 
responsible for non-A, non-B hepatitis has just recently been 
achieved (hepatitis CJ,S04 it is undoubtedly a cause of allograft hepa-
titis?44, 145, 50S Episodes in patients with cryptogenic cirrhosis, in 
those with unrelated disorders, and in patients who were thought to 
have the disease prior to transplantation have been identified. It may 
therefore be recurrent or develop de novo. The onset of symptoms 
and laboratory abnormalities usually appear after 6 weeks. The clin-
ical presentation is as variable as that seen in the general popula-
tion: mild asymptomatic elevation of liver injury test results to mas-
sive hepatic necrosis. Bone marrow aplasia, which also can compli-
cate milder attacks of non-A, non-B hepatitis not requiring liver 
transplantation,S06,507 has been observed in children a few days or 
weeks after liver replacement.508,509 Four of the nine patients with 
marrow aplasia survived, usually with slow recovery of the he-
matopoietic system.508,509 At present, the diagnosis is based largely 
on biochemical evidence of liver injury combined with the histo-
pathologic profile, although supporting serologic data may soon be-
come available. 
The histopathologic appearance of presumed non-A-, non-B hep-
atitis may be as varied as that described for hepatitis B earlier. Nee-
dle biopsy specimens from patients thought to be infected during 
the acute stages show mild Kupffer's cell hypertrophy, spotty acido-
philic necrosis of hepatocytes, and a relative paucity of inflamma-
tion. However, lobular disarray, mixed inflammatOIY cell infiltration, 
hepatocyte ballooning, and necrosis, which may be bridging, have 
also been seen. The disease may also recur in a more fulminant 
fashion, as was experienced with two patients in Pittsburgh, where 
the clinical profile and histologic appearance of the failed graft was 
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remarkably similar to the native organ. Later, features of chronic per-
sistent or active viral hepatitis are not uncommon (Fig 62). 
Pathologically, in acute disease the diagnosis is based largely on 
the lobular insult and is usually not difficult to differentiate from re-
jection. In chronic disease where the histologic appearance is that of 
chronic persistence or active hepatitis, it may be hard to differenti-
ate from an indolent rejection reaction. It has been our policy that if 
there is evidence of significant duct damage, rejection is considered 
present.145 
HEPATITIS A VIRUS 
Although fulminant hepatitis A virus has been an indication for 
liver replacement, it has not as yet been identified as the cause of 
allograft dysfunction. Based on these observations, we expect that it 
may appear quite similar clinically and histologically to that seen in 
nongrafted livers. 
THE PATHOLOGIST'S VIEW OF BILIARY TRACT 
COMPLICATIONS 
Anastomotic breakdown, necrosis, strictures, ascending infection, 
and obstruction can affect the allograft biliary treeKU4~9MK 93 Although 
these complications are not uncommon in isolation, they often re-
FIG 62. 
The histologic appearance of presumed non-A, non-S viral hepatitis in the allograft is sim-
ilar to the type S virus. In this case a chronic active hepatitic lesion is seen. (From Deme-
tris AJ, Kaklzol S, Oguma S: Pathology of liver transplantation, in William JW led]: Hepatic 
Transplantation. Philadelphia, WB Saunders Co [in press]. Used by permission.) 
113 
flect arterial pathology since the biliary tree is dependent solely on 
the hepatic artery for its blood supply?46 Most often the diagnosis of 
biliary complications is made on the basis of clinical symptoms and 
the results of radiologic procedures such as ultrasonography and 
cholangiography (see previouslygKU4~9o In addition, during the early 
postoperative period, most patients have a percutaneous T tube in 
place that permits ready access to the biliary tree for radiologic pro-
cedures and assessment of bile flow. 
Needle biopsies are less useful than radiologic evaluations for the 
diagnosis of large biliary tract disorders because of the relative non-
specificity and insensitivity of early histologic findings?44.145 How-
ever, when access to the biliary tree is restricted, (late posttransplant 
period), biopsies may be more valuable as a screening tool. Biliary 
tract complications that have been recognized histologically include 
duct stricturing, obstruction, acute cholangitis, and biliary-vascular 
fistulas. 144. 145 The histologic features of these complications are 
identical to those seen in the nonallograft liver (Fig 63), which in-
clude a predominantly neutrophilic portal infiltrate, periductal 
edema, intraepithelial and intraductal neutrophils, mild ductular 
and cholangiolar proliferation, centrilobular hepatocanalicular 
cholestasis, and small clusters of neutrophils scattered throughout 
the lobules. Although acute cellular rejection is included in the 
pathologic differential, biliary tract disorders most commonly are as-
sociated with a neutrophilic and eosinophilic portal infiltrate, 
whereas rejection shows a predominance of mononuclear cells in 
the portal tracts. 
Recognition of biliary-vascular fistulas may be first noticed by the 
pathologist on needle biopsies and requires alertness to the abnor-
mal presence of RBes in bile duct lumens or, conversely, bile con-
cretions in blood vessels (see Fig 63). Radiologic localization of the 
abnormal communication, followed by corrective surgery or retrans-
plantation, is the usual course of events. 
SEPSIS 
Infection of the blood, especially with gram-negative organisms, 
can cause allograft dysfunction, which is usually manifested as jaun-
dice. Histologic alterations are also observed in the graft as a result 
of sepsis (endotoxemia) and are identical to those seen in nonal-
lograft livers.510 These changes include choiangiolar proliferation 
with bile plugging, acute cholangiolitis usually without cholangitis, 
and hepatocanalicular cholestasis. Kupffer's cells are often hypertro-
phied, and small clusters of neutrophils can be observed in the lob-
ules?44.145 
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FIG 63. 
The histologic manifestation of biliary tract complications in the allograft are similar to 
those in nonallografted livers. The most important of these features is the neutrophilic pre-
dominance of the portal infiltrate in the absence of reactive biliary epithelial cell changes, 
as shown in this case of acute cholangitis (A). When the biliary tree is obstructed, peri-
ductal edema accompanies the acute portal inflammation, and cholestasis is present in 
the lobules (B). Fistulas between the biliary tree and the vasculature are recognized by the 
presence of RBCs in bile ducts (C, arrow) or bile concretions in blood vessels (0, arrow). 
(From Demetris AJ, Kakizol S, Oguma S: Pathology of liver transplantation, in William JW 
led]: Hepatic Transplantation. Philadelphia, WB Saunders Co [in press]. Used by permis-
sion.) 
DIFFERENTIAL DIAGNOSIS OF DRUG AND TOXIC INJURY 
Drug and toxic injury to the allograft liver are difficult to identify 
with certainty. The patients receive many potential hepatotoxic 
drugs and are subjected to other therapeutic maneuvers that may 
damage the liver. Therefore, if one strictly adheres to criteria for or-
gan specific toxicity, it is extremely difficult to incriminate any agent. 
Regardless of these difficulties, erythromycin, prolonged peripheral 
alimentation, high-dose steroids, and azathoprine have been 
strongly suspected as causes of allograft malfunction.144,145 One 
might expect the allograft liver to behave similar to nongrafted livers 
in regard to drug toxicities, unless an MHC-restricted immunologic 
reaction is involved. 
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INFLUENCE OF 
HISTOCOMPATIBILITY 
Histocompatibility leukocyte antigen (RIA) or MRC compatibility 
has been shown to either improve patient survival or reduce the on-
set or incidence acute rejection in kidney511 and heart allografts.512 
Data collected by Markus and associates concerning the role of HIA 
matching in liver transplantation were less clear cut.513 No patient 
survival advantage was observed for RIA compatibility. By contrast, a 
statistically significant penalty in terms of survival was detected 
when either the A, B, or DR locus was matched. Although rejection 
as a cause of graft failure was more common when DR mismatching 
was present, other causes of patient death or graft failure were even 
more common when either class I or II loci were matched. Primruy 
nonfunctioning of the new liver was particulru'ly common in DR-
matched grafts. However, the diagnosis "primruy nonfunction" is 
somewhat of a wastebasket category, which often includes preserva-
tion injury, antibody-mediated rejection, vascular thrombosis, surgi-
cal misadventures, and cardiovascular instability in the donor or re-
cipient. Markus and associates suggested that MHC compatibility 
may provide the ideal setup for recurrent disease since some of the 
immunopathologic mechanisms important in the native diseases are 
thought to be MHC restricted.513 Alternatively, they suggested that 
the alloresponse itself may be MHC restricted. Donaldson and col-
leagues proposed a similar hypothesis.45!ol They found that DR-
matched but A and/or B locus-mismatched grafts were more prone 
to develop the vanishing bile duct syndrome (chronic rejection). 
They suggested that induction of DR antigens on bile duct cells en-
abled these cells to act as antigen-presenting cells, presenting the 
mismatched class I antigens in an MHC-restricted fashion to recipi-
ent effector cells. 
There are many possible explanations for the somewhat peculiar 
observations made with respect to RIA matching and liver allograft 
outcome. Like other allografts, livers seem to experience a lower in-
cidence of rejection when the DR locus is matched. Paradoxically, 
there does not appear to be a patient or graft survival advantage for 
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DR or class I matching. This may be due to graft loss or patient 
death from causes other than rejection (e.g., technical mishaps and 
infection). A higher incidence of recurrent native disease in HIA-
matched patients may be a possibility, since cellular "immune" 
mechanisms are thought to playa prominent role in native hepatic 
disease. This contrasts to most cardiac and renal diseases for which 
transplantation is performed, where cellular immunity is not 
strongly implicated. This argument is appealing because the im-
mune damage purportedly mediated by T lymphocytes in liver dis-
eases such as hepatitis B is thought to be MHC restricted. However, 
the pathogenic mechanisms responsible for many native liver dis-
eases have yet to be elucidated. Furthermore, recurrent disease 
must be proved after liver grafting, which is not an easy task. Rather 
than to continue speculation, reanalysis of the data after collection 
of a much larger patient population seems wise. 
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CANDIDACY, ORIGINAL DISEASE, 
AND OUTCOME 
In spite of the diversity of etiologies, manifestations, and variability 
of technical problems with different diseases, the sUIvival CUIves 
have not been greatly influenced by the original diagnosis with the 
exceptions of fulminant hepatic failure, chronic active hepatitis due 
to B virus, and liver malignancies (Fig 64).498,499,514-517 These obser-
vations, which have been extensively documented, are analogous to 
those in renal transplantation where the original kidney disease has 
been said to have little influence on the outcome. 
However, the foregoing summary is oversimplified, which could 
degrade the value of information summarized in the following pages 
that covers not onlv the influence of disease on outcome but also 
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FIG 64. 
Comparison of patient survival rates (life table method) after liver transplantation in adults 
receiving cyclosporine-prednisone for HBsAG-posltive postnecrotic cirrhosis (66 cases), 
primary hepatobiliary cancer (89 cases), fulminant hepatic failure (48 cases), and other 
nonmalignant indications for liver transplantation (827 cases). 
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many other factors, including the severity of the disease at the time 
of the liver replacement, issues of organ supply, and the role of so-
cioeconomic factors. Thus, the serious student of hepatology, liver 
surgery, and liver transplantation is urged to read this section and 
not skip to the next one. 
The medical issues of transplant candidacy are relatively clear. If a 
patient has end-stage nonmalignant liver disease that does not recur 
in the hepatic graft, there is little debate about the logic in principle 
of transplantation (Table 11). Transplantation is more debatable if re-
currence of a nonneoplastic disease is a predictable problem. The 
most controversial indication for liver transplantation is for the treat-
ment of hepatic malignancies. However, none of these broad appli-
cations can be arbitrarily excluded from future trials because there 
is such heterogeneity in each of these three categories. 
In adults, the diseases most commonly represented have been 
postnecrotic cirrhosis, primary biliary cirrhosis, alcoholic cirrhosis, 
sclerosing cholangitis, inborn errors of metabolism, and a heteroge-
TABLE 11. 
Indications for Liver Transplantation in 438 Pediatric and 1.031 Adult Patients 
Pediatric Adult Total % 
Acute hepatic failure 2:1 48 71 4.8 
Postnecrotic cirrhosis 44 361 405 27.6 
Alcoholic cirrhosis 113 113 7.7 
Biliary alresias 236 5' 241 16,4 
Congenital hepatic 6 4 10 0.7 
fibrosis 
Cystic fibrosis 3 4 7 0.5 
Inborn errors of 75 52 127 8.6 
metabolism 
Familial cholestasic 16 16 1.1 
syndrome 
Neonatal Igiant cell) 7 7 0.5 
hepatitis 
Primary biliary cirrhosis 210 210 14.3 
Secondal), bilial)' cirrhosis 9 13 22 1.5 
Primal), sclerosing 4 99 103 7.03 
cholangitis 
Budd-ChiaIi syndrome 2 21 23 1.6 
Benign tumors 4 9 13 0,9 
Primary liver cancer 8 59 67 4.6 
Bile duct cancer 18 18 1.2 
Metastatic cancer 12 12 0.8 
Liver trauma 1 2 3 0.2 
Secondal)' sclerosing 1 0.1 
cholangitis 
Total 438 1,031 1,469 100.0 
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nous group of hepatic malignancies (see Table 11). The 5-year life 
survival curves of the principal benign adult diseases are shown in 
Figure 65. There has been little variability of survival with these be-
nign diagnoses in contrast to the poorer results in the neoplastic 
group (see Fig 64). 
More than one half of the pediatric recipients have had biliary 
atresia, with inborn metabolic errors a distant second.514, 516-526 Sur-
vival in the biliary atresia patients is inferior to the other categories 
(Fig 66). The principal mortality has been perioperative and has been 
related to technical difficulties caused by earlier Kasai operations. 
The experience reflected in these life survival curves will influence 
future case selection. However, other factors could be singly or cu-
mulatively even more important for prognosis than the original diga-
nosis. Judgment about what constitutes candidacy has been in a 
state of flux since the first clinical attempts in 1963, and the time is 
not yet ripe to freeze guidelines. 
MALIGNANT LNER DISEASE 
In the original efforts at clinical liver transplantation,18 all of the 
patients whose reason for transplantation was primary hepatic ma-
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their first transplant), Included are 296 cases of postnecrotic cirrhosis (excluding HBsAG-
positive patients), 210 cases of primary biliary cirrhosis, 113 cases of alcoholic cirrhosis, 
99 cases of primary sclerosing cholangitis, and 52 cases of inborn errors of metabolism, 
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olism, 44 cases of postnecrotic cirrhosis, and 8 cases of primary hepatobiliary cancer. 
lignancy and who survived the perioperative period died vvithin 13 
months of recurrent tumor. Smaller incidental malignancies be-
haved differently. The longest survivor in the world today received 
her new liver at the University of Colorado on January 22, 1970 for 
biliary atresia. The excised liver contained a 3-cm hepatoma. That 
little girL 3 years old at the time of operation, will complete her 20th 
postoperative year in a few months. She is married to a United States 
Marine and lives in Okinawa. The same observations with incidental 
malignancies have been made many times since?8Ii. ,,27 
In spite of numerous disappointments, liver transplantation as a 
means to extend resectability limits for hepatic neoplasms is still be-
ing probed by many transplantation teams, often in combination 
with adjuvant chemotherapy or other experimental treatment proto-
COIS.528-530 The percentage of tumor cases in large programs ranges 
fron1 4% to 34% .5]4, 518. 519, R~1-RP4 It has been about 5% at the Colo-
rado-Pi.ttsburgh program (see Table 11). 
Although strenuous efforts are made beforehand to rule out 
metastases, a high rate of recurrence of all kinds of hepatic malig-
nancies continues to be seen after total hepatectomy and trans-
plantation.* Metastases have had a tendency to home to the new 
liver?8,531 Death from tumor recurrence has been reported as early 
'References 18, 499, 514, 527, 531, 534-536. 
]22 
as 3 months, but the principal mortality has been between 6 and 36 
months (Fig 67). Small incidental malignancies that develop in cir-
rhotic livers usually do not recur, but extensive cancers recur in the 
majority of cases:'i27, 5:n, 534, 535 The results also are influenced by the 
tumor cell type (Fig 68), presence of hilar lymph node metastases, 
and presence or absence of underlying liver disease.67, 499. 527, 531, 536 
Fibrolamellar hepatoma, a slowly growing relatively uncom-
mon hepatocellular carcinoma with distinctive histopathologic fea-
tures,537, 538 is a "favorable" malignancy, and long survival has been 
accomplished even of patients with huge tumors that have invaded 
the diaphragm.67, 527,5:11,534,539 Most authors have reported poor re-
sults with duct cell carcinomas, including the small Klatskin tumors 
that are located high in the hepatic hilum,527, 530-532, 534 but a recent 
German experience has been more optimistic.536 Recurrence has 
been exceptionally common in patients with conventional hepato-
cellular carcinomas.527 Epithelioid hemangioendotheliomas54o oc-
cupy an intermediary position in that survival for at least 2 years has 
been achieved in more than one half of reported patients.531, 541 
\'\fhether to continue treating primary hepatic malignancies is con-
troversial. It is difficult to resist continuing these efforts for the treat-
ment of hepatic malignancies in carefully screened recipients, not 
only because there is a chance of success but because there is so much 
potential information to be acquired about the biologic behavior of 
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FIG 67. 
Patient su rvival rates for (life table method) after liver transplantation for primary hepato-
cellular cancer compared with liver transplantation for nonmalignant diseases but with an 
incidental hepatocellular carcinoma discovered on subsequent pathologic examination of 
the removed native liver. 
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FIG 68. 
Patient survival (life table method) after liver transplantation for benign and malignant tu-
mors that could not be treated by subtotal resection. Included are 13 patients with benign 
tumors, 54 with hepatocellular carcinoma, 18 with bile cancers, 8 with epithelioid heman-
gioendotheliomas, and 12 with secondary tumors originating outside the liver. 
these tumors and the influence on them of immunomodulation and 
chemotherapy. Even a few patients with metastatic liver disease have 
benefited from liver transplantation,514, 529, 530, ,,35, 542, 543 particularly 
when the primaries were neuroendocrine in origin.514, 535, 536 In one 
remarkable case, a patient with multifocal liver metastases from a 
carcinoma of the breast was successfully treated with chemother-
apy, autotransplantation of the bone marrow, and liver transplanta-
tion.529 Ultimately, she developed recurrences; further efforts at ap-
plying this concept have failed,530 
BENIGN DISEASE: THE POTENTIAL CANDIDACY POOL 
The criteria for case selection were blurred until 1980 because of a 
mortality within the first postoperative year that exceeded 60% (Fig 
69). It was impossible to tell for certain how much case selection 
was influencing results. When this was changed with the advent of 
cyclosporine (see Fig 69), some issues of candidacy became clearer. 
In addition, with the better expectations and more general avail-
ability of liver transplantation, the conceptual appeal of liver trans-
plantation was so great that this procedure became the court of last 
appeal for an astonishing number of patients with lethal hepatic dis-
ease. Estimates of yearly need for liver transplantation have varied 
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FIG 69. 
Patient and primary graft survival rates (life table method) after liver transplantation. One 
hundred seventy recipients were treated with azathioprine (AZA) and steroids between 
March 1963 and February 1980 compared with 1,469 recipients treated with cyclosporine 
(CYA) and steroids between March 1980 and December 1988. Follow-up is complete 
through 31 July 1989. 
from as low as 15 per million population67 to as high as 200 per mil-
lion in an unpublished Canadian projection (Dr. Cal Stiller, personal 
communication, University of Western Ontario, London, Ontario). 
Based on these figures, and without a cap imposed by organ supply, 
between 4,000 and 50,000 liver transplantations per year could be 
needed in the United States. Since there are no practical means of 
artificial organ support analagous to renal dialysis, the waiting list of 
recipients does not grow from year to year. 
The variability of inclusion and exclusion factors of candidacy ac-
count for the wide-ranging estimates of need. Some of the earlier 
low estimates were based on the assumption that patients with tu-
mors would be excluded, that the upper age limit would be SO years, 
that patients with Laennec's cirrhosis or other "sin factors" would be 
eliminated from candidacy, and that the list of applications would 
not be as extensive as has proved to be the case. Furthermore, a 
number of factors or diagnoses that precluded or strongly discour-
aged transplantation 5 or 10 years ago are no longer absolute con-
traindications, and some are no longer even questionable. 
Laennec's Cirrhosis 
A prime example is alcoholic cirrhosis. If there is a history of alco-
holism, it is necessary on behalf of the patient to obtain consultation 
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with those who understand this disease. The objective is to ensure 
abstinence after transplantation by arranging in advance for holistic 
care. In properly selected cases, Laennec's cirrhosis may be a good 
indication (see Fig 65).544 Recidivism with alcohol use has been less 
than 10%. 
Older Age 
An absolute upper age limit has been eliminated by demonstrating 
that recipients older than 50 years have a similar 5-year survival as 
younger adults.:i45 
Young Age or Small Size 
The transplantation of very small infants, even in the newborn pe-
riod of life, has become common, but the results are not as good as 
with larger children.546, 547 
Portal Vein Thrombosis 
Although this was fom1erly a contraindication to transplanta-
tion,541l .'>49 the newly developed vein graft techniques (see Fig 27) 
routinely allow liver replacement in recipients who have throm-
bosed portal, splanchnic, or superior mesenteric veins . .'>49,550 The 
vein grafts are jumped from the superior mesenteric vein below the 
transverse mesocolon, brought anterior to the pancreas, and used 
for a portal anastomosis in the hepatic hilum. 
Multiple Previous Operations 
Previous upper abdominal operations can complicate transplanta-
tion enormously, particularly in patients with small cirrhotic livers 
that have extensive scarring of their inflow and outflow vessels with 
obliteration of potential planes of dissection. The routine measure-
ment of liver size with imaging techniques helps to identifY such 
problem cases in advance.5 .'>l The portal vein is always studied for 
patency using ultrasound and dynamic computed tomography (CT) 
scanning techniques. In uncertain cases, magnetic resonance imag-
ing is used. Splenectomy or any kind of shunting can alter the portal 
vein, and the majority of complications from transplant portal vein 
reconstruction have been in patients with such earlier operations?30 
The mesocaval and the distal splenorenal (Warren) shunts have been 
the least hamlful of these procedures since they do not involve dis-
section of the portal hilum. When transplantation is performed, it is 
necessaIY to close the shunt to have optimal vascularization of the 
graft. 
The usual indication for a shunt operation is variceal hemorrhage, 
and the objective is to reduce portal hypertension. Should shunting 
operations ever be recommended as treatment for variceal hemor-
rhage, knowing that these procedures can jeopardize the ultimate 
126 
step of liver transplantation? Probably uncommonly, since endo-
scopic sclerosis of varices is an effective alternative.552 In some pa-
tients with child's class A (good risk) cirrhosis, a distal splenorenal 
anastomosis might be the preferred way to relieve portal hyperten-
sion. We are using this approach in a small number of highly se-
lected patients. However, it is important to emphasize that the liver 
transplantation itself decompresses portal hypertension through the 
capillary bed of the normal new liver. In patients who had variceal 
bleeding and who were too sick to be considered for any operation 
other than transplantation, the 5-year survival after liver replacement 
was far superior to that reported in series of generally better-risk pa-
tients treated with shunting operation.553 The obvious limitations of 
the shunt approach to variceal bleeding has greatly reduced the fre-
quency of portal diversion procedures in Western countries. 
Other operations in the upper abdomen that were designed to 
palliate complications of liver disease can create even more serious 
problems. Examples are procedures that disconnect venous collater-
als going to lower esophageal varices and radical duct reconstruc-
tions such as those used to treat sclerosing cholangitis or biliary 
atresia (Kasai operation). 
As an alternative to these open operations, there has been greater 
use of interventional radiologic or endoscopic procedures, such as 
sclerosis of esophageal varices, and transhepatic duct stenting or 
dilatation. However, problem patients with previous shunts, duct 
reconstructions, or other operations in the hepatic hilum should 
not be denied transplantation for this reason. Although the trans-
plant operations are made more formidable, the results in experi-
enced hands can be almost as good as with a virgin operative 
field?4,554-558 
Chronic B Virus Carrier State 
It was already mentioned that there is a very high rate of recurrent 
chronic active hepatitis in these patients, for which there is no effec-
tive prevention. Because of this, some programs exclude B virus car-
riers from candidacy, However, the fact that many such patients 
have achieved benefit from transplantation makes it difficult to make 
the carrier state an absolute contraindication. 
Most efforts to treat HBsAb carriers with hyperimmune globulin 
(HBIgGJ or interferon alpha have failed.4 'J7, 498, 501, 503 The volume of 
commercial HBIgG that has been required to treat these patients has 
been so large as to be impractica1.503 However, a human monoclonal 
antibody directed against hepatitis B viruses has been produced 
(Sandoz Corporation, East Hanover, New Jersey) by fusing peripheral 
blood lymphocytes from an immune adult human male to a mouse 
X human myeloma cell line.559 The resulting human monoclonal 
HBIgG is 50,000 times more potent than commercially available 
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HBIgG prepared from the blood of immune donors. Seven patients 
were treated with this monoclonal HBIgG beginning preoperatively 
or at the anhepatic phase of liver transplantation.54 The first recipi-
ent had reduction of smface antigen titer from very high to barely 
detectable levels. In the second patient, the suJt'ace antigen level was 
undetectable for 5 months, after which it reappeared in low titer at 
the same time as core antigen was identified in the hepatocytes of a 
biopsy specimen that otherwise was normal. The half-life of this hu-
man monoclonal IgG was long enough to allow maintenance of an 
antibody excess with injections 2 to 4 weeks apart.54 Five patients 
have been treated with larger doses, and all are free of antigenemia 
after 2 to 7 months. It remains to be seen if the recurrent disease 
pattern is appreciably altered by this kind of therapy. 
Recipients who possess antibodies directed against the HBV sur-
face antigen have been free of hepatitis B virus following transplan-
tation. However, it has been recently recorded that patients with the 
human immunodeficiency virus (HIV) can regress from an appar-
ently immune state, as defined by anti-B virus antibodies, to an in-
fectious carrier state, apparently by reactivation of residual virus as 
their immune system fails.560 Theoretically, the same thing could oc-
cur in a liver transplant recipient maintained on standard posttrans-
plant immunosuppression therapy. 
Non-A, Non-B Hepatitis 
Recurrence of non-A, non-B hepatitisl44,505 has not been common. 
The low incidence of recurrence may merely reflect the difficulty of 
establishing the diagnosis. 
Other Recurrent Diseases 
The only other unequivocal example of disease recurrence has 
been with the Budd-Chiari syndrome.498, 499,561,562 This can be pre-
vented with anticoagulation.561 , 56:1 An initial report of recurrence of 
primary biliary cirrhosis564 in three patients has recently been 
followed by an update on these patients and evaluation of 12 more 
primary biliary cirrhosis patients who have survived for more than 
1 year. A surprising percentage565 of these long-term survivors 
showed clinical and histologic evidence of recurrent disease. Other 
groups have not been able to confirm these observations in larger 
series,447,566-568 although the antimitochondrial antibodies usually 
do not disappear after transplantation or else they reappear after 
disappearing transiently.566,5Ii8 The reason for this discrepancy is 
not readily apparent, but it appears that cyclosporine may alter dis-
ease progression and histology of primary biliary cirrhosis affecting 
either a native liver or allograft.565 Therefore, recurrences will proba-
bly not be severe or frequent enough to vitiate the value of trans-
plantation. 
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A syndrome resembling sclerosing cholangitis in a liver homo-
graft has been reported,569 but the same diagnosis has been 
made after transplantation in patients who had non-biliary tract 
disease.l44 There has been one report of recurrent autoimmune 
hepatitis.570 
Human Immunodeficiency Virus Carrier State 
Whether patients with antibodies to HIV should be excluded from 
candidacy is an unresolved issue. When screening tests for this dis-
ease became generally available in the spring of 1985, examples of 
HIV infections in kidney recipients were almost immediately re-
ported.571,572 
During late 1985, a massive study of the stored sera of 1,043 kid-
ney, heart, or liver recipients treated between 1981 and 1986 was be-
gun at the University of Pittsburgh.573 Eighteen (1.7%) were found to 
be asymptomatic carriers. The liver recipients were most commonly 
affected. In about one third of the liver recipients, the HIV antibodies 
were demonstrated in their sera, which had been collected and 
stored before the transplantation. Seroconversion after liver trans-
plantation occurred in the remaining patients, for a total incidence 
of 2.6%. The liver allograft itself was a source of infection in a minor-
ity of cases,573, 574 and most infections were attributed to blood com-
ponent therapy. Seroconversion still occurs at Pittsburgh,573 as well 
as other institutions, despite the institution of screening enzyme im-
munoassays in March 1985.575,576 
Almost certainly the presence of HIV antibodies would have pre-
cluded candidacy if the diagnosis in the foregoing cases had been 
made in advance. As it turned out, these unfortunate victims of HIV 
as well as 7 additional patients became available for long-term study 
under immunosuppression.577 Eleven of these 25 recipients were in-
fected before transplantation, although this was not known until 
later in 8. The other 14 were infected perioperatively. Ten of the 25 
recipients were infants or children. The organs transplanted were 
the liver (n = 15) and the heart or kidney (n = 5 each). After a mean 
follow-up of 2.75 years (range 0.7-6.6 years), 13 recipients are alive. 
Survival is 7 out of 15,2 out of 5, and 4 out of 5 of the liver, heart, and 
kidney recipients, respectively. The best results were in the pediatric 
group (70% survival), in which only 1 of 10 patients died of AIDS. In 
contrast, AIDS caused the death of 5 of 15 adult recipients and was 
the leading cause of death. Transplantation plus immunosuppres-
sion appeared to shorten the AIDS-free time in HIV-positive patients 
compared with nontransplant hemophiliac and transfusion control 
groups. Accidental accrual of HIV-positive transplant recipients has 
slowed markedly since the systematic screening of donors, recipi-
ents, and blood products was begun in 1985. However, patients 
known to be HIV positive are still being treated. 
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It is clear that many patients can have prolonged benefit from liver 
transplantation in spite of having positive HIV test results. How to 
use this information for decision making varies from center to cen-
ter. The most commonly accepted policy in the United States is to 
screen all recipients but not to exclude transplantation solely be-
cause of a positive HIV test result. If transplantation is undertaken, 
the health care personnel must be protected from infection. It is a 
miracle that none of the surgeons who operated on our patients in 
the early 1980s without knowing the risk has (to our knowledge! 
been infected. Screening of potential donors for HIV is obligatOlY at 
all centers, and a 50-minute test for this purpose has been de-
scribed.578 The use of tests that identny the HIV antigens in addition 
to the antibodies579 may make donor screening more foolproof than 
it presently is. 
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TIMING OF TRANSPLANTATION 
In the early days of liver transplantation, this therapeutic step 
seemed so drastic that it was used as a last resort. What was then 
defensible conservatism has become regressive today if the patient is 
allowed to deteriorate to the point of requiring life support systems 
before thinking of the transplant option. The rapidity of this deterio-
ration is highly variable. 
FULMINANT HEPATIC FAILURE 
The diagnosis of fulminant hepatic failure (FHF) can be made 
when there is sudden massive necrosis of a liver that previously has 
functioned normally.580-582 The term FHF has not been used for 
acute exacerbation of previously unrecognized chronic disease or 
for acute Wilson's disease. It was rarely treated with liver transplan-
tation before 1982."7 The results with transplantation has not been 
good enough to justil)' this drastic step for a disease syndrome from 
which recovery might occur in 5% to 20% of cases.580-582 Since then, 
FHF has been accepted as an emergency indication for transplanta-
tion in almost every liver transplant program worldwide. In several 
large series,583-591 the predominant diagnoses have been non-A, 
non-B hepatitis, B virus hepatitis, and toxic hepatitis from a variety 
of agents. Mushroom poisoning has been a much publicized toxic 
etiology.592 In our hands, the original diagnosis has strongly influ-
enced the outcome (Fig 70). The best results have been with B virus 
hepatitis. 
A decision to proceed with liver replacement often must be made 
in a few hours. The systematic collation of multiple parameters can 
help distinguish patients who have a good chance of recovery from 
those who will die without transplantation.593, 594 The etiology of the 
FHF may be an important prognostic determinant.594 Premonitors of 
imminent death include relentless progression over a 7- to 14-day 
period, grade 3 or 4 encephalopathy, severe coagulopathy, rapid 
shrinkage of the liver as documented with imaging techniques, met-
abolic acidosis, cardiovascular instability, and sepsis.585.586 By the 
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Patient survival (life table method) after liver transplantation in adults and children for ful-
minant hepatic failure. Included are 9 cases of drug-related liver failure, 13 cases of acute 
B virus hepatitis, 31 cases of acute non-A, non-B hepatitis, 13 cases of acute hepatitis A, 
and 4 cases of fulminant hepatic failure of unknown etiology. 
time there is grade 4 encephalopathy and ventilator dependence, it 
usually is too late. 
If transplantation is performed before these grave findings, some 
livers with reversible lesions may be replaced unnecessarily. A liver 
biopsy after correction of the coagulopathy may provide decisive in-
formation. If clotting cannot be corrected well enough to permit a 
closed needle biopsy, the patient can be explored with a new liver in 
hand with the option of aborting the operation if the open biopsy 
looks favorable histopathologically. In spite of the pitfalls associated 
with liver replacement for FHF, current posttransplant survival rates 
of 55% to 75%583-591 compare favorably with the most optimistic 
projections of 20% for medical management alone. The results make 
it certain that these efforts will continue. The perioperative mortality 
frequently has been due to brain stem herniation during or just after 
transplantation, sometimes in spite of continuous monitoring of in-
tracranial pressure. Early referral to liver transplant centers, ex-
tremely aggressive evaluation plus medical treatment, and an early 
decision for surgical exploration with immediate transplantation as 
an option will be necessary to improve results. 
It will be unfortunate if the availability of transplantation causes 
the therapeutic pendulum to swing too far toward liver replacement. 
13.2 
In the hepatology unit at King's College, London, the admission of 
patients with FHF to an intensive care unit, the continuous monitor-
ing of intracranial pressure, and attention to multiple details has re-
sulted in greatly improved survival (more than 50%) of patients 
whose survival expectation in the past would have been less than 
20% .594 They emphasize the value of IV mannitol treatment as a 
means of brain shrinkage and hypoventilation on respirator control 
to encourage cerebrovascular vasodilitation by keeping the Pco2 ele-
vated.594 
Similarly, Levy Sinclair and associates of Toronto have reported 
the astonishing recovery of patients (10 or 17) with FHF.595 Some of 
their patients had liver biopsies in which it was difficult to find a 
single living hepatocyte. They ascribed their success to prostaglan-
din E, namely, Prostin, a synthetic prostaglandin that can be given 
intravenously or orally. In their opinion, an important, and possibly 
the principal, value of Prostin was to preserve the integrity of the he-
patic microvasculature and thus to ensure a viable scaffold on which 
regeneration could proceed. 
END-STAGE CHRONIC DISEASE 
Ideally, a candidate for liver replacement should have an unequiv-
ocal need for transplantation but still be well enough to participate 
in the complex process of recovery. A decision to go forward re-
quires input from the primary physician, who may see gradually 
evolving and often appalling social and vocational invalidism that 
may not be evident at first examination. The disability may be re-
flected in the loss of intellectual capacity with encephalopathic de-
mentia, frequent hospitalizations for other complications of liver fail-
ure, inability to function in a domestic environment, and arrest of 
growth and development in infants and children. These issues of 
quality of life loom large in most patients long before the truly tenni-
nal events of chronic hepatic failure. Formulas for candidacy based 
on liver function tests have not been helpful because the abnormal-
ities in these tests are so variable from disease to disease or even 
within the same disease. Patients with cholestatic disorders (e.g., bil-
iary atresia and primary biliary cirrhosis) usually become deeply 
jaundiced with good preservation of hepatic synthetic functions for 
a long time,520. 525. 557 whereas patients with hepatocellular disease 
may not be jaundiced in spite of the most profound depressions in 
albumin and prothrombin synthesis.548 
The liability of procrastinating too long before making a decision 
for transplantation has yet to be defined. In one study in which 12% 
of candidates died "while waiting," most of the lost patients had ar-
rived at the transplant hospital on ventilators and had GI bleeding, 
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coagulopathies, the hepatorenal syndrome, aspiration pneumonitis, 
subacute bacterial peritonitis, or other end-stage complications.596 
In another center, the mortality in patients considered too well to be 
placed on the active waiting list was greater than for those admitted 
to candidacy.597 When the mistake of underestimating disease sever-
ity with the supervention of a catastrophic complication is made, re-
suscitation is sometimes successful. However, the outlook after sub-
sequent transplantation is demonstrably degraded,598,599 notwith-
standing observations in a small group of pediatric liver recipients 
that disease severity did not seem to influence posttransplantation 
prognosis .600 
The most precise studies of disease staging vs. posttransplantation 
outcome have been in adult patients with primary biliary cirrho-
sis.60l, 602 In the most recent of these investigations,601 disease sever-
ity was defined with a formula in which age, serum bilirubin level, 
serum albumin level, prothrombin time, and edema severity accu-
rately predicted life expectancy without transplantation.603 The 
overall survival in transplant recipients was greatly improved relative 
to these predictions (Fig 71). However, the patients who were still in 
reasonable condition had a low perioperative mortality and a 2-year 
survival of 80% i those with the most serious deterioration had a high 
perioperative mortality and a 2-year sUIvival of only 55% (Fig 72) .601 
The consensus in most centers is that transplantation should be 
considered at an earlier time before the stage of catastrophic com-
plications is reached.6lJ4 
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before referral and treatment of patients with this disease. (From Markus BH, Dickson ER, 
Grambsch PM, et al: N Engl J Med 1989; 320:1709-1713. Used by permission.) 
Recently, an increasing number of patients with normal liver func-
tion and nonmalignant hepatic masses have had orthotopic trans-
plantation for polycystic disease/l7,219 cystic hygroma,605 and ade-
nomatosis. The size of those lesions and the consequent disability 
and life-threatening complications of the mass lesions were the indi-
cations for operation. The largest of the excised livers weighed 
16.5 kg.605 
THE QUESTION OF RETRANSPLANTATION 
Before the advent of cyclosporine, retransplantation was a rare 
event. Consequently, the graft and patient survival were almost syn-
onymous (see Fig 69). Almost immediately after the introduction of 
cyclosporine, attempts at retransplantation began to be made and 
with enough success to warrant further such efforts.67 Now the pa-
tient survival curves began to be 10% to 15% above the graft survival 
curves (see Fig 69). In the United States at the present time, approx-
imately one fifth of all liver grafts are used for retransplantation. The 
need for retransplantation is often extremely urgent, and many pa-
tients have a clinical syndrome comparable with or worse than ful-
minant hepatic failure. 
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Survival of patients who required only one graft (1,125 cases) is significantly better (p < 
0.001) than for patients requiring two transplants (268 cases) or three or more transplants 
(76 patients). 
The success rate with retransplantation is only about one half of 
that if a primary graft succeeds (Fig 73). The chances of 5-year sur-
vival with a "take" of the first graft is about 75% (see Fig 73), almost 
twice as good as the expectation if two or more grafts are needed. 
This low success rate with retransplantation has caused ethicists to 
question the probity of continuing these efforts. Yet, the salvage of so 
many patients whose first grafts have failed seems more than ade-
quate justification for what has been done. 
If the option of retransplantation was foreclosed, it would have a 
chilling effect on donor acceptance since the philosophy of one 
chance only would discourage the transplantation of grafts with 
more than minimal preservation times and would greatly tighten the 
requirements for donor consideration. No liver transplant surgeon of 
whom we are aware would countenance the concept of patient 
abandonment implicit in a policy that precludes or even discour-
ages retransplantation in a patient who is potentially salvageable. 
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INBORN ERRORS OF METABOLISM: 
A PANDORA'S BOX 
Patients with liver-based inborn errors of metabolism can be 
treated by providing a phenotypically normal liver.237, 464, 606-639 It 
was recognized long ago and confirmed repeatedly since that the 
a-globulins, haptoglobin/37, 464 and group-specific component,464 as 
well as other products of hepatic synthesis,64o-645 permanently re-
tain the original metabolic specificity of the donor after transplanta-
tion. These observations made it virtually certain that liver trans-
plantation would become a decisive way to treat the inborn errors of 
metabolism that resulted partly or completely from deficiencies of 
specific liver enzymes or from abnormal products of hepatic synthe-
sis. This expectation has been fulfilled in many patients for whom 
follow-ups of as long as 18 years after transplantation are available 
(Table 12). With other disorders in which the pathogenesis was not 
well understood, the transplantation itself became a powerful re-
search tool by showing the extent of correction and by elucidating 
the mechanisms by which correction was accomplished (see Ta-
ble 12). In one patient, the opposite of a therapeutic correction was 
achieved in that a coagulation defect present in the donor was con-
ferred on the recipient.646 
In the majority of these recipients, the inborn error had itself been 
responsible for damage to the liver, and a conventional indication of 
liver failure or the development of malignant tumors prompted the 
liver replacement. In these cases, the correction of the metabolic er-
ror was incidental. However, an increasing number of transplanta-
tions have been carried out solely for the purpose of correcting the 
inborn error, and in many of these latter patients (see Table 12), the 
excised liver has been anatomically normal. 
Many inborn errors not correctable by liver transplantation can be 
effectively treated with allogeneic bone marrow engraftment.647 De-
termining which kind of transplantation will be effective is crucial 
whenever somatic metabolic engineering is considered. The guide-
lines for decision making have become increasingly clear.54,647 
137 
.
.
.
.
 
~
 
[IJ
 
TA
BL
E 
12
. 
In
bo
rn
 E
rr
or
s 
T
re
at
ed
 W
ith
 L
iv
er
 T
ra
ns
pl
an
ta
ti
on
 
C
or
re
ct
io
n 
o
f M
et
ab
ol
ic
 
L
on
ge
st
 
A
ss
oc
ia
te
d 
Li
ve
r 
D
is
ea
se
 
E
xp
la
na
tio
n 
o
f D
is
ea
se
 
D
ef
ec
t 
Su
rv
iv
al
 
D
is
ea
se
 
R
ef
er
en
ce
 
Ci
 l-
A
nt
ill
yp
si
n 
St
ru
ct
ur
al
 a
bn
or
m
al
ity
 o
f t
he
 
Y
es
 
13
 y
r*
 
C
ir
rh
os
is
 
60
6-
60
9 
de
fi
ci
en
cy
 
pr
ot
ea
se
 in
hi
bi
to
r s
yn
th
es
iz
ed
 in
 
liv
er
 
W
ils
on
's 
di
se
as
e 
A
bn
or
m
al
 b
ili
aJ
Y
 c
o
pp
er
 e
x
c
re
tio
n,
 
Y
es
 
16
.5
 y
r*
 
C
ir
rh
os
is
 
60
6,
61
0-
61
1;
 
de
cr
ea
se
d 
c
o
pp
er
 b
in
di
ng
 to
 
c
e
ru
lo
pl
as
m
in
, a
n
d 
c
o
pp
er
 
a
c
c
u
m
u
la
ti
on
 in
 t
is
su
es
; 
a
u
to
so
m
al
 r
e
c
e
ss
iv
e 
ge
ne
 m
a
pp
ed
 
to
 c
hr
om
os
om
e 
13
 
T
yr
os
in
em
ia
 
Fu
m
ar
oy
la
ce
to
ac
et
at
e 
hy
dr
ol
as
e 
N
ea
rl
y 
c
o
m
pl
et
e 
7.
5 
yr
* 
C
ir
rh
os
is
, 
61
7-
61
9 
de
fi
ci
en
cy
 
he
pa
to
m
a 
T
yp
e 
I g
ly
co
ge
n 
G
lu
co
se
-6
-p
ho
sp
ha
ta
se
 d
ef
ic
ie
nc
y 
Y
es
 
7 
yr
* 
G
ly
co
ge
n 
st
or
ag
e,
 
62
0 
st
or
ag
e 
di
se
as
e 
fib
ro
si
s, 
tu
m
or
s 
T
yp
e 
IV
 g
ly
co
ge
n 
A
m
y]
o-
1: 
4,
1:
 6
-t
ra
ns
gl
uc
os
id
as
e 
In
co
m
pl
et
et
 
4.
5 
yr
* 
C
ir
rh
os
is
 
60
6,
61
2 
st
oI
'3
ge
 d
is
ea
se
 
(b
ra
nc
hi
ng
 en
z
ym
e)
 d
ef
ec
t 
C
ys
tic
 fi
br
os
is
 
U
nk
no
w
n;
 p
an
ce
ll
ul
ar
 d
is
ea
se
, l
iv
er
 
N
ot
 k
no
w
n 
4.
5 
yr
' 
C
ir
rh
os
is
 
62
1,
62
2 
o
ft
en
 a
ff
ec
te
d 
N
ie
m
an
n-
Pi
ck
 
Sp
hi
ng
om
ye
lin
as
e 
de
fic
ie
nc
y,
 
N
ot
 k
no
w
n 
2
y
r 
(d
ied
) 
,'
\Jo
ne
 
62
3 
di
se
as
e 
sp
hi
ng
om
ye
lin
 s
to
ra
ge
 
Se
a-
bl
ue
 h
is
tio
cy
te
 
U
nk
no
w
n,
 n
e
u
ro
v
is
ce
ra
l 
lip
oc
hr
om
e 
N
o 
7 
yr
* 
C
ir
rh
os
is
 
62
4 
sy
nd
ro
m
e 
st
or
ag
e 
E
ry
th
ro
po
ie
tic
 
H
ep
at
ic
 f
er
ro
ch
el
at
as
e 
de
fic
ie
nc
y,
 
In
co
m
pl
et
e 
1.
5 
yr
 
C
ir
rh
os
is
 
62
5,
62
6 
pr
ot
op
or
ph
yr
ia
 
?o
ve
lp
ro
du
ct
iv
e 
o
f 
pr
ot
op
or
ph
yr
in
 b
y 
e
ry
th
ro
po
ie
tic
 
tis
su
es
 
.
.
.
 ~ 
C
rig
le
r-
N
ajj
ar 
G
lu
cu
ro
ny
l t
ra
ns
fe
ra
se
 d
ef
ic
ie
nc
y 
Y
es
 
sy
nd
ro
m
e 
T
yp
e 
1 
Pe
ro
xi
so
m
al
 a
la
ni
ne
: g
ly
ox
yl
at
e 
Y
es
 
hy
pe
ro
xa
lu
na
 
a
m
in
ot
ra
ns
fe
ra
se
 d
ef
ic
ie
nc
y 
U
re
a 
c
yc
le
 e
n
z
ym
e 
O
rn
ith
in
e 
c
a
rb
am
oy
ltr
an
sf
er
as
e 
Y
es
 
de
fi
ci
en
cy
 
de
fi
ci
en
cy
 
C 
pr
ot
ei
n 
D
ef
ec
tiv
e 
C 
pr
ot
ei
n 
sy
nt
he
si
s 
Y
es
 
de
fi
ci
en
cy
 
Fa
m
ili
al
 
L
ow
-d
en
si
ty
 li
po
pr
ot
ei
n 
re
c
e
pt
or
 
In
co
m
pl
et
e 
hy
pe
rc
ho
le
st
er
ol
em
ia
 
de
fic
ie
nc
y,
 lo
w
-d
en
si
ty
 
li
po
pr
ot
ei
n 
o
v
e
rp
ro
du
ct
io
n 
H
em
op
hi
lia
 A
 
Fa
ct
or
 V
III
 d
ef
ic
ie
nc
y 
Y
es
 
H
em
op
hi
lia
 B
 
Fa
ct
or
 IX
 d
ef
ic
ie
nc
y 
Y
es
 
'P
at
ie
nt
s 
in
 U
ni
ve
rs
ity
 o
f C
ol
or
ad
o-
U
ni
ve
rs
ity
 o
f P
itt
sb
ur
gh
 s
e
ri
es
. F
ol
lo
w
-u
p 
to
 J
an
ua
ry
 1
93
9.
 
tA
m
yl
op
ec
tin
 d
ep
os
its
 f
ou
nd
 in
 h
ea
rt
 b
io
ps
y 
4 
yr
 a
ft
er
 tr
an
sp
la
nt
at
io
n .
 
4
y
r 
N
on
e 
62
7,
62
8 
8 
m
o
. 
N
on
e 
62
9 
8 
m
o
.'
 
N
on
e 
63
0 
2.
25
 y
r'
 
1\
:o
ne
 
63
1 
6 
y
r'
 
N
on
e 
63
2-
63
5 
4 
y
r'
 
C
ir
rh
os
is
, a
 
63
6-
63
8 
c
o
m
pl
ic
at
io
n 
o
f 
bl
oo
d 
c
o
m
po
ne
nt
 
th
er
ap
y 
6 
m
o
. 
C
ir
rh
os
is
, a
 
63
9 
c
o
m
pl
ic
at
io
n 
o
f 
bl
oo
d 
c
o
m
po
ne
nt
 
th
er
ap
y 

TRANSPLANTATION OF MULTIPLE 
ORGANS 
The increasing boldness with which hepatic transplantation has 
been applied is evident from the many reports of transplantation of 
the liver plus kidney17, 219, 648-651 and less frequently used combina-
tions of the liver plus pancreas/81 liver plus heart,632-635,652 and 
liver plus heart and lung.653 In these cases, the liver transplantation 
and transplantation of the other organ have been done in disconti-
nuity so that two standard procedures were performed in the same 
individual. 
A different concept has been the inclusion of the liver in visceral 
organ clusters. The most complex operation of this kind has been of 
the liver and pancreas plus the entire GI tract in two children with 
the Sh0I1-gut syndrome and secondary liver failure that developed 
during parenteral hyperalimentation.654,655 One of these grafts (Fig 
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FIG 74. 
Left, delineation in embryonal life of that region of the GI tract (dark shaded) that was re-
sected in the organ cluster operation (E = esophagus; LB = lung bud; L = liver; P = pan-
creas). Right, the adult organs deriving from the shaded primitive analogue. (From Starzl 
TE, Todo S, Tzakis A: Ann Surg 1989; 210:374-386. Used by permission.) 
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74) provided function of all of the organs for more than 6 months 
before the recipient died of complications of lymphoproliferative tu-
mors in the liver.654 With an organ mass of this size, the possibility of 
carrier lymphoid tissue causing GVH disease was feared. In the long-
est surviving patient, donor pretreatment with OKT3 may have re-
duced this threat,654 as has been demonstrated to occur with anti-
lymphocyte serum in rats.65G 
A less drastic version of multivisceral transplantation is the use of 
an organ cluster in which the pancreas, duodenum, and part of the 
proximal jejunum have been included with the liver.54,657 These 
clusters have been used to replace upper abdominal organs that 
were removed (see Fig 74) in treating sarcomas and carcinoid tu-
FIG 75. 
The CT scan (top) of patient whose upper abdomen was filled with spindle cell sarcoma at 
the time of operation. The tumor-laden liver is the structure to the left of the operating room 
photograph (bottom). Most of the right half of the diaphragm was removed with the spec-
imen, The transverse colon is marked with white arrows, The margins were free of tumor, 
and none of the 38 lymph nodes studied had metastases. (From Starzl TE, Todo S, Tzakis 
A: Ann Surg 1989; 210:374-386. Used by permission,) 
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FIG 76. 
Removal of organ cluster graft 
from donor. The specimen IS 
initially cooled with an aortic 
infusion of UW solution after 
crossclamping the proximal 
abdominal aorta. Once the 
specimen has been removed with 
a Carrel patch containing the 
origin of the celiac axis (CA) and 
superior mesenteric artery (SMA), 
the liver is secondanly perfused 
on the back table with UW 
solution (insert) through the 
superior mesenteric vein (SMV). 
(From Starzl TE, Todo S, Tzakis A: 
Ann Surg 1989; 210374-386. 
Used by permission.) 
mars of the pancreas ar duodenum with liver metastases (Fig 75), 
bile duct carcinomas with liver metastases, and a hepatoma that had 
invaded the duodenum and colon.657 The organs removed from the 
recipient in continuity have included the liver, stomach, pancreas, 
FIG 77. 
Completed reconstruction in the recipient. 
(From Starzl TE, Todo S, Tzakis A: Ann 
Surg 1989; 210:374-386. Used by 
permission.) 
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FIG 78. 
This is an alternative to the reconstruction after an upper abdominal exenteration in which 
only the liver is replaced. This operation leaves the patient diabetic, but of 15 patients 
treated in this way, 13 are alive with follow-ups of several weeks to as long as 6 months. 
(From Tzakis A, Todo S, Starzl TE: Transplant Proc February 1990 [in press]. Used by per-
mission.) 
spleen, duodenum, proximal jejunum, and ascending plus trans-
verse colon (see Fig 74). The organs transplanted are shown in Fig-
ure 76. The completed recipient operation is shown in Figure 77. 
Of 15 such patients, 9 are alive after 6 to 14 months, 8 without ev-
idence of recurrent tumor. The ninth survivor may have stable pul-
monary metastases. The majority of the survivors have been rehabil-
itated. This experience has illustrated how major components of the 
GI tract can be transplanted and has demonstrated how the use of 
organ clusters can allow extirpative procedures of a magnitude not 
previously imaginable. 
The major limitations of the cluster operation have been the diffi-
culty of finding appropriate organ donors, the difficulty of the oper-
ation, and the complexity of postoperative care. Considering the fact 
that of the organs being replaced, only the liver is indispensable, an 
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alternative was developed in which the same resection was per-
formed but only the liver was transplanted (Fig 78). Fifteen such pa-
tients have been so treated, but the follow-ups are too short to merit 
comment. This variation of the OIiginal cluster procedure has been 
developed as a more pragmatic operation but at the expense of ren-
dering the patient apancreatic. Malabsorption has been a serious 
clinical problem thus far, and thus it may influence cyclosporine 
doses. The day-to-day treatment of diabetes mellitus has not been 
difficult. If management of the iatrogenic diabetes mellitus proves 
difficult pancreas transplantation at a more favorable moment re-
mains an option. 
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QUALITY OF LIFE 
Even in the early days of liver transplantation, the physical and 
emotional decay caused by chronic liver disease could be stopped 
and reversed in many of the recipients who survived chronically. 
The most powerful determinants of their quality of life were the liver 
function profile at the I-year convalescent mark and the quantity of 
steroids needed to maintain this function.658 The adverse steroid 
factor in the quality of posttransplant life has been reduced since 
the introduction of cyclosporine. Several studies have shown the re-
markable restoration of physical and emotional well-being that can 
be expected in infants and children,658-GGO including resumption of 
growth or even catch-up growth.G61 
Similarly, a recent group of adult liver transplant recipients stud-
ied objectively before and again 2 years after operation demon-
strated broad improvement in social interaction, home management, 
aleitness, the utilization of recreation and leisure time, and overall 
psychosocial functioning(iG2 A number of other findings were ob-
tained from these investigations. First, the severity of stress experi-
enced by the patient and the spouse after transplantation correlated 
significantly with the ease of recovery. More than 90% of the recipi-
ents who had a single transplantation state that they have no prob-
lems or only minor health problems 2 years after transplantation. 
More than 85% have returned to work and state that they are able to 
perform their jobs well. In contrast, the smaller number who re-
quired more than one transplant had a much poorer outcome, with 
only 43% being able to work because of one or more disabilities. 
The follow-up of patients treated in the cydosporine era dates 
back to only 1980. However, a bellwether group of survivors remains 
from an original series of 170 patients treated from 1963 to 1979.67.66:1 
Twenty-eight of these recipients are still living after 10 to 19 years. 
These represented exactly one half of the survivors at 1 year. Only 
two patients who were alive at 5 years died subsequently. One of the 
late deaths was caused by chronic rejection 12.5 years after retrans-
plantation. The other death was from a lymphoma after 13.5 years. 
Rehabilitation has been complete in the long sUIvivors.663 
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THE OPTION OF AUXILIARY 
TRANSPLANTATION 
With the auxiliary operation, as originally described in unmodified 
dogs/ the extra liver was placed in the right paravertebral gutter, 
rearterialized from convenient adjacent vessels, and provided with a 
portal venous inflow with systemic blood from the recipient iliac 
FIG 79. 
~~r-+-Celiac axis 
graft 
This is the kind of auxiliary liver transplantation that has permitted several long-term suc-
cesses. Note that the graft receives a portal flow from the splanchnic venous system 
(S.M V.) and is drained into the inferior vena cava (t. V.C.). The principles of II-lis operation 
were originally worked out by Marchioro and colleagues. 18 (From Starzl TE [with the assis-
tance of Putnam CW]: Experience In Hepatic Transplantation. Philadelphia, WB Saunders 
Co, 1969. Used by permission.) 
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vein or lower vena cava. The graft outflow was drained into the re-
cipient inferior vena cava. It was observed that auxiliary grafts were 
much more severely damaged than were orthotopically placed liv-
ers, primarily because of rapid hepatocyte atrophy.664 These adverse 
effects could be prevented by diverting splanchnic venous flow 
through the auxiliary liver and away from the recipient'S own liv-
er,665 suggesting that the splanchnic venous blood contained spe-
cific liver-supporting factors. The most important of these so-called 
portal hepatrophic substances was proved to be insulin.325,666 
The condition of providing a splanchnic venous inflow to the graft 
has been met in almost all of the subsequent clinical trials, which by 
1978 numbered more than 50 (Fig 79).667 Auxiliary liver transplanta-
tion with unquestionable prolongation of life was first achieved at 
the New York Memorial Hospital on December 13, 1972.668 The re-
cipient, who had biliary atresia, still is alive with a follow-up of more 
than 16 years.6B9 In 1980, Houssin and associates in Paris reported a 
29-month survival of an adult who was given an extra liver.67o This 
patient was HBsAg-positive and died 8 years following transplanta-
tion from a hepatocellular carcinoma in his host liver (H. Bismuth, 
personal communication, January 1989). 
With the increased success of orthotopic liver transplantation, in-
terest in auxiliary transplantation waned. Very few further effmts 
were reported in the last decade.671 The resulting pessimism has 
been lightened by a recent report of the transplantation of whole liv-
ers or liver fragments to the right paravertebral gutter of six adult re-
cipients using essentially the same operation as that tried in earlier 
times.6n At the time of reporting with follow-ups of 5 to 23 months, 
all six recipients were alive. Cautious further trials undoubtedly will 
be forthcoming. 
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PRACTICAL LIMITATIONS 
ORGAN SUPPLY 
Organ supply increasingly will influence candidacy criteria. How-
ever, discussions about rationing transplant seIVices for this reason 
are premature since the balance between the need and supply of liv-
ers has not been determined. In the United States, the yearly rate of 
liver transplantations has reached approximately 1,600,673 averaging 
147 per month between July and December 1988 (Dr. William 
Vaughn, United Network of Organ Sharing, personal communication, 
1989). The annual European total is approaching this figure.674 
Policies about organ donation will have to be reexamined if sub-
stantial further growth is to occur. Probably, many potential liver do-
nors are being rejected for inappropriate reasons. The arbitrary up-
per age limit for liver donors observed by most programs675 cannot 
be justified since the liver is the only organ that does not undergo 
senescence.676 Atherosclerosis of its arterial supply usually is not 
found beyond the origin of the celiac axis.676 A limited experience 
with livers from donors older than 50 years has been encouraging.677 
Other potential donors of all ages often are excluded because of 
poor blood gases, a need for inotropic or vasopressor drugs, minor 
abnormalities of liver function test results, or the existence of other 
diseases such as diabetes mellitus.675 The results with such donors 
both in the United States161, 162 and Europe163 have been as good as 
with so-called perfect donors. The use of better preselvation tech-
niques51- 53 that allow safe storage of liver grafts for 1 day instead of 
the previous 6 or 8 hours should reduce organ wastage, since with 
this extra time, countrywide and worldwide networks of organ shar-
ing can be set up. 
ECONOMIC FACTORS 
The ability to pay for liver transplantation has had a profound in-
fluence on candidacy. Ironically, the feasibility first and then the 
practicality of liver transplantation were established without consid-
ering how to finance this revolutionary foml of therapy. In 1983, a 
planning commission for the state of Massachusetts estimated the 
average cost of liver transplantation in the first year would be 
$238,000,678 although the actual costs were only one third this high 
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in a large program already in existence.-llA It is clear that astronomi-
cal bills can be generated if patients are too disabled by the time of 
transplantation, if the first liver graft does not function well, and if 
serious complications develop, including the need for retransplanta-
tion.1l4 
Because of their fear of runaway expenses, many health insurance 
carriers and government agencies have avoided financial responsi-
bility to their constituents by classifYing liver transplantation as "ex-
perimental,,679 in spite of the Consensus Development Conference 
conclusion to the contrary. The response to cost-conscious funding 
agencies is that liver transplantation can eliminate repeated and ex-
pensive hospitalization of patients who are slowly dying with 
chronic hepatic disease.68o-682 Such considerations were part of a 
bitter controversy in Australia68:l, 684 about the establishment of what 
eventually proved to be two outstanding programs.68S, 686 
So far, liver transplantation in the United States has been paid for 
by a heterogenous system of private health care insurance programs, 
government agencies, and public or private fund-raising activities. 
One highly visible consequence has been the recurrent spectacle of 
a family or patient pleading on television or through other media for 
economic support or for an organ. All the while, statistics that show 
gross underparticipation in this new kind of health care by blacks 
and presumably other disadvantaged groups have been accruing.687 
Development of a system that allows all citizens equal and reason-
able access to this kind of treatment without the extraordinaIY ex-
penses of past programs such as the federally financed End Stage 
Renal Disease program may require new and creative administrative 
approaches. 
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after, 144 
ABO-compatible donors: 
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Adenovirus 
granuloma in liver due to, 107 
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Alcoholic cirrhosis: survival after liver 
transplant, 121 
Alphal-antitrypsin deficiency, 138 
Anaphylatoxins, 65 
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site formation, 30 
splenic artery to anomalous right 
hepatic artery, 11-12 
vessels, small, avoiding strictures, 
34 
Anomalies 
donor, 10-12 
hepatic artery, right, 11-12 
Antibody-mediated rejection: 
histopathology, 62 
<Xl-Antitrypsin deficiency, 138 
Aorta 
cold fluid into, 9 
crossclamping of, 143 
Aortic infusion 
for core cooling of liver, 10 
of UW solution, 143 
Arteries 
grafts, posterior routes, 15 
hepatic (see Hepatic arteIY) 
interlobular, deformed pattern, 52 
mesenteric (see Mesenteric artery) 
splenic, anastomosis to anomalous 
right hepatic artery, 11-12 
Atresia: biliary, survival after liver 
transplant, 122 
Auxiliary liver transplant: option of, 
149-150 
Azathioprine, 125 
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Bacterial 
infections, 101-102 
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Benign disease, 124-130 
Bile 
cancer, survival after liver 
transplant, 124 
duct 
after hepatic artery early clotting, 
47 
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plugs, cholangiolar, 55 
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atresia, survival after liver 
transplant, 122 
cirrhosis, survival after liver 
transplant, 121, 134 
reconstruction, 34- 36 
gallbladder conduit, 
Waddell-Calne technique for, 
37 
tract 
complications, histologic 
manifestations, 115 
complications, pathologist's view 
of,113-115 
reconstruction, 1 
Bilirubin: in cholangiolar bile plugs, 55 
Biloma 
drainage with catheter, 46 
formation within dearterialized 
liver, 46 
Biopsy 
back-table, 44 
liver, before and after FK 506, 81 
reperfusion, hepatocellular necrosis 
in,54 
Blood: formation of hepatocytes, 53 
Budd-Chiari syndrome, 128 
Bypass, veno-venous, 20-23 
pump-driven, 20 
Cachectin, 66 
Cancer 
c 
bile, survival after liver transplant, 124 
187 
Cancer (cont.) 
hepatobiliary, survival after liver 
transplant, 119, 122 
hepatocellular, survival after liver 
transplant, 123 
liver, 121-124 
Candida,48 
Candidacy, 119-130 
potential candidacy pool, 124-130 
Carcinoma: hepatocellular, survival 
after liver transplant, 123, 124 
Carrel patch, 143 
Catheter: for biloma drainage, 46 
Celiac axis: folded with origin of 
superior mesenteric artery, 13 
Cell(s) 
endothelial, denudation, 53 
Kupffer's cell hypertrophy, 103 
C5a, 65 
Children 
liver transplant 
indications for, 120 
survival rates, 73, 122 
situs inversus, reconstruction after 
transplant to, 39 
Cholangiolar 
bile plugs, 55 
proliferation, 55 
Cholangiolitis: acute, 55 
Cholangitis 
after liver transplant, 47 
sclerosing, survival after liver 
transplant, 121 
Choledochocholedochostomy: with T 
tube stent, 1 
Choledochojejunostomy, 1 
Cholestasis: hepatocanalicular, 55 
Cirrhosis 
alcoholic, survival after liver 
transplant, 121 
biliary, survival after liver 
transplant, 121, 134 
Laennec's, 125-126 
postnecrotic 
survival after liver transplant, 121, 
122 
survival rates after liver 
transplant, 119 
Clones 
cyclosporine-resistant, development 
of,78 
expansion, lymphocytes and 
cyclosporine, 78 
188 
"rogue," FK 506 and cyclosporine, 
79 
CMV (see Hepatitis, cytomegaloviralJ 
Cold 
fluid into aorta, 9 
ischemia, 49 
preservation injury, 53 
Colony-stimulating factor, 66 
Complement 
3a,65 
5a, 65 
Computed tomography: of abdominal 
sarcoma, 142 
Conduit biliary reconstruction: with 
gallbladder, with 
Waddell-Calne technique, 37 
Connective tissue: necrosis, 48 
Cooling 
core 
hypothermia and, 4- 6 
of liver with aortic infusion, 10 
for multiple organ procurement, 
6-7 
initial, 4-12 
perfusion after, ex vivo, 13 
in situ 
first technique, by extracorporeal 
hypothermic perfusion, 5 
principle of, 8 
liver, 9 
Core (see Cooling, core) 
C protein deficiency, 139 
Crigler-Najjar syndrome, 139 
Cross clamping, 27 
of aorta, 143 
CT: of abdominal sarcoma, 142 
C3a, 65 
Cut-down liver, 40 
Cyclosporine, 73-76, 125 
Eck fistula model for study of, 
75 
with FK 506 
kidney function and, 83-84 
"rogue" clones and, 79 
limitations of, 73-74 
liver regeneration and, 74-76 
lymphocyte cultures and clonal 
expansion, 78 
with prednisone, 110, 119 
-resistant clones, development of, 
78 
with steroids, 121, 122 
Cystic fibrosis, 138 
Cytokines: activated by endotoxin, 
65-66 
Cytomegaloviral (see Hepatitis, 
cytomegaloviral) 
D 
Dearterialized liver: biloma formation 
within, 46 
Development, 3-41 
Diagnosis, differential 
of drug injury, 115 
of graft dysfunction, 85- 99 
of toxic injury, 115 
Donor(s) 
ABO-compatible, perioperative 
immune events with, 57-60 
ABO-incompatible, perioperative 
immune events with, 60-63 
anomalies, 10-12 
cadaveric, total midline incision for, 
7 
hepatectomy, 4-12 
non-heart-beating, liver 
procurement in, 7-10 
Drug injury: differential diagnosis, 
115 
E 
Eck fistula model: for cyclosporine 
study, 75 
Economic factors: limiting liver 
transplant, 151-152 
Embryonal delineation: of GI tract 
region, 141 
Endorphin, 66 
Endothelial cell: denudation, 53 
Endotoxemia, 63-70 
Endotoxin 
levels 
(in dog), 67-68 
at end of anhepatic phase with 
graft survival, 69 
soluble mediators activated by, 
65-66 
Epstein-Barr virus hepatitis, 
105-108 
Erythropoietic protoporphyria, 138 
Extracorporeal hypothermic 
perfusion, 5 
F 
Fat: lysed hepatocytes releasing, 44 
Fatty vacuolization: of hepatocytes, 
53 
Fibrin deposition, 44 
Fibrosis: cystic, 138 
Fistula: Eck, model for cyclosporine 
study, 75 
FK 506, 76-84 
with cyclosporine 
kidney function tests and, 83-84 
"rogue" clones and, 79 
liver biopsy before and after, 81 
liver function tests and, 81-82 
study in eight recipients, 80 
Fungal infections, 101-102 
G 
Gallbladder: conduit biliary 
reconstruction, Waddell-CaIne 
technique for, 37 
Glomerulus: deformed pattern, 52 
Glycogen storage disease 
type I, 138 
type IV, 138 
Graft(s) 
arterial, posterior routes, 15 
dysfunction, differential diagnosis, 
85-99 
early graft function, 43-56 
homograft (see Homograft) 
portal vein, antepancreatic, 33 
reperfusion of, 52 
revascularization, 30-34 
syndromes vs. time after transplant, 
102 
vascular, 14 
antepancreatic route, 15 
-vs.-host disease, 98-99 
Granuloma: in liver, due to 
adenovirus, 107 
H 
Hemangioendothelioma: epithelioid, 
survival after liver transplant, 
124 
Hemophilia 
A,139 
B, 139 
189 
Hemostasis 
need for, 36-38 
for recipient, 26 
Hepatectomy 
donor, 4-12 
recipient, 23-26 
Hepatic artery 
clotting, early, 47 
originating from supelior 
mesentelic artery, 11 
alternative methods for, 12 
light, anomalous, splenic artery 
anastomosis to, 11-12 
thrombosis, 48 
Hepatic duct: common, homograft, 
typical extrinsic mass effect on, 
35 
Hepatitis 
A virus, 113 
acute, 132 
adenoviral, 108 
B virus, 109-112 
acute, 132 
chronic, carlier state, 127-128 
chronic, sUIvival after liver 
transplant in, 110 
infection of allograft, 111 
cytomegaloviral, 102-104 
histologic features, 103 
necrosis in, 103 
Epstein-Barr virus, 105-108 
herpes simplex, 104-105 
non-A, non-B, 112-113, 128 
acute, 132 
histologic appearance, 113 
opportunistic viruses, 102 
varicella-zoster, 104-105 
viral, allograft, clinicopathologic 
features, 102-108 
viruses, 109-115 
Hepatobilimy cancer: survival after 
liver transplant, 119, 122 
Hepatocanalicular cholestasis, 55 
Hepatocellular 
cancer, survival after liver 
transplant, 123 
carcinoma, survival after liver 
transplant, 123, 124 
necrosis in reperfusion biopsy, 54 
Hepatocytes 
blood formation, 53 
190 
centrilobular, swelling of, 55 
fatty vacuolization, 53 
leukocytes adherent to, 53 
lysed, releasing fat, 44 
steatosis, macrovesicular, 44 
Herpes simplex hepatitis, 104-105 
Hilar necrosis, 48 
Histiocyte: sea-blue histiocyte 
syndrome, 138 
Histocompatibility: influence of, 
117-118 
HIV carrier state, 129-130 
Homograft 
hepatic duct, typical extrinsic mass 
effect on, 35 
vascular, 12 
washing out, technique, 32 
Human immunodeficiency virus 
carrier state, 129-130 
Humoral rejection (see Rejection, 
hyperacute) 
Hypercholesterolemia: familial, 139 
Hyperoxaluria: type 1, 139 
Hypothermia: and core cooling, 4-6 
Hypothermic perfusion: 
extracorporeal, 5 
I 
IL (see Interleukinl 
Immune events, perioperative, 
57-70 
with ABO-compatible donors, 
57-60 
with ABO-incompatible donors, 
60-63 
endotoxemia, 63-70 
Immunosuppression: due to rat liver 
transplant, and tolerance 
induction, 86-87 
Inborn errors of metabolism, 
137-139 
as Pandora's box, 137-139 
survival after liver transplant, 121, 
122 
Indications: for liver transplant, 120 
Infant: very small, transplantation of 
liver in, 126 
Infections, 101-108 
bacterial, 101-102 
fungal, 101-102 
Interleukin 
1, 66 
2, 66 
lymphocytes and, 77 
Interlobular artery: defOlmed pattern, 
52 
Intestinal decontamination: selective, 
101 
Ischemia, 49-56 
cold,49 
warm ischemia time, 49 
K 
Kidney 
function, cyciosporine and FK 506, 
83-84 
transplant (see Transplantation of 
kidneyl 
Kupffer's cell hypertrophy, 103 
L 
Laennec's cirrhosis, 125-126 
Leukocyte(sJ 
adherent to hepatocytes, 53 
sludging, 44 
Leukotrienes, 65 
Life: quality of, 147 
Liver 
benign disease, 124-130 
biopsy before and after FK 506, 81 
cancer (see under Cancer) 
cooling, 9 
core, with aortic infusion, 10 
cut-down, 40 
de arterialized, biloma formation 
within, 46 
disease 
end-stage chronic, timing of liver 
transplant in, 133-135 
severity and projected smvival, 
135 
Epstein-Barr virus in, 106 
failure 
drug-related, 132 
fulminant, survival after liver 
transplant, 119, 132 
fulminant, timing of liver 
transplant in, 131-133 
function tests and FK 506, 81-82 
granuloma due to adenovirus, 107 
procurement in non-heart-beating 
donors, 7-10 
regeneration and cyciosporine, 
74-76 
removal 
from above downward, 28 
fI'Om below upward, completion of, 
25 
from below upward, technique, 24 
replacement (see Transplantation of 
liverl 
transplantation (see 
Transplantation of liver) 
Lymphocytes 
cultures 
cional expansion of cyciosporine, 
78 
technique, 77 
interleukin 2 and, 77 
Lymphocytosis: sinusoidal, and 
Epstein-Barr virus, 106 
Lysed hepatocytes: releasing fat, 44 
M 
MacI'Ovesicular steatosis, 44 
Malignancy (see Cancerl 
Mesenteric artery, superior 
origin folded with celiac axis, 13 
right hepatic arteIY originating 
from, 11 
alternative methods, 12 
Metabolism (see Inborn erI'Ors of 
metabolism) 
Microvascular injury, 49 
Model: Eck fistula, for cyciosporine 
study, 75 
Mucocele: formation prevention, 36 
Multiple organ(sl 
procurement 
core cooling for, 6-7 
in situ cooling for, principle of, 
8 
transplantation of, 141- 145 
Multiple previous surgery, 126-127 
N 
Necrosis 
bile duct, 48 
connective tissue, 48 
in hepatitis, cytomegaloviraL 103 
191 
Necrosis (cont.) 
hepatocellular, in reperfusion 
biopsy, 54 
hilar structures, 48 
tumor necrosis factor, 66 
Niemann-Pick disease, 138 
Older age, 126 
Organ 
o 
cluster operation, 141-145 
multiple (see Multiple organ) 
supply limiting liver transplant, 151 
Original disease, 119-130 
Orthotopic liver transplant, 1 
Outcome, 119-130 
PAF,65 
Perfusion 
p 
ex vivo, after initial cooling, 13 
hypothemlic, extracorporeal, 5 
Perioperative immune events (see 
Immune events, perioperative) 
Piggyback technique, 27-30 
recipient vena cava preparation 
steps for, 29 
Platelet-activating factor, 65 
Pmtacaval shunt model: for 
cyclosporine study, 75 
Portal vein 
graft from, antepancreatic, 33 
thrombosis, 126 
Prednisone: with cyclosporine, 110, 
119 
Preexisting disease: early graft 
function in, 43-45 
Preservation, 12-18 
cold injury, 53 
ex vivo perfusion after initial 
cooling, 13 
slush 
techniques, 14 
UW solution for, 14-18 
vena cava, 27-30 
inferior, 29 
Prevention: of rejection, 71-84 
Procurement 
liver, in non-heart-beating donors, 
7-10 
192 
multiple organ 
core cooling for, 6-7 
in situ cooling for, principle of, 8 
Prostaglandins, 65 
Protein: C protein deficiency, 139 
Protoporphyria: erythropoietic, 138 
Prototype: of human kidney 
transplant, 72-76 
Pump-driven veno-venous bypass, 20 
Q 
Quality ofiife, 147 
R 
Recipient 
closure, 26 
crossclamping, 27 
hemostasis for, 26 
hepatectomy, 23-26 
incision for, 19 
operation, 18-41 
modifications of standard 
procedure, 38-41 
Reconstruction 
after abdominal exenteration, 
upper, 144 
biliary, 34-36 
gallbladder conduit, 
Waddell-Caine technique for, 
37 
in multiple organ transplant, 143 
after transplant to child with situs 
inversus, 39 
Waddell-Caine (see Waddell-Caine 
technique) 
Rejection 
acute cellular, 91-96 
histopathologic grading system, 95 
histopathology of, 93 
antibody-mediated, histopathology, 
62 
chronic, 96-98 
histopathologic features, 97 
clinicopathologic features, 91- 99 
humoral (see hyperacute below) 
hyperacute, 57 
diagnosis, criteria for, 63 
of liver transplant in rat, early 
histologic events, 91 
prevention, 71- 84 
tolerance induction and, 85-91 
Reperfusion 
biopsy, hepatocellular necrosis in, 
54 
of graft, 52 
Retransplantation 
after biloma formation, 46 
question of, 135-136 
Revascularization: of graft, 30-34 
"Rogue" clones: FK 506 and 
cyclosporine, 79 
Rubber: silicon rubber compound, 52 
s 
Sarcoma: abdominal, CT of, 142 
Sclerosing cholangitis: survival after 
liver transplant, 121 
Sea-blue histiocyte syndrome, 138 
Shunt: portacaval, model for 
cyclosporine study, 75 
Silicon rubber compound, 52 
Sinusoidal endothelial cells, 53 
Situs inversus: in child, 
reconstruction after transplant 
to, 39 
Sludging: leukocyte, 44 
Slush 
preseIVation, UW solution for, 
14-18 
techniques, 14 
Solutions 
test, characteristics and 
constituents, 16 
UW (see UW solution) 
Space of Disse: loss of, 53 
Splenic artery: anastomosis to 
anomalous right hepatic artery, 
11-12 
Steatosis: macrovesicular, 44 
Stent: T tube in 
choledochocholedochostomy, 1 
Steroids, 125 
with cyclosporine, 121, 122 
Swelling: of centrilobular hepatocytes, 
55 
T 
Technical failure, 45-49 
Test solutions: characteristics and 
constituents, 16 
Thrombosis 
hepatic artery, 48 
portal vein, 126 
vascular, "medical" factors 
contributing to, 49 
Timing: of transplantation, 131-136 
Tissue factor, 65 
Tolerance induction 
effector pathways, 90-91 
immunosuppression due to rat 
liver transplant and, 86-89 
inductive pathways, 89-90 
rejection and, 85-91 
Tomography, computed: of 
abdominal sarcoma, 142 
Toxic injury: differential diagnosis, 
115 
Transplantation of kidney 
human prototype, 72-76 
survival, 72 
Transplantation of liver 
auxiliary, option of, 149-150 
candidacy, 119-130 
potential candidacy pool, 
124-130 
cholangitis after, 47 
cooling (see Cooling) 
development, 3-41 
donor (see Donor) 
dysfunction, differential diagnosis, 
85-99 
economic factors limiting, 
151-152 
function, early graft, 43-56 
graft syndromes vs. time after 
transplant, 102 
indications for, 120 
infection in (see Infections) 
organ supply limiting, 151 
original disease, 119-130 
orthotopic, 1 
outcome, 119-130 
in preexisting disease, 43-45 
preseIVation (see PreseIVation) 
procurement (see Procurement) 
in rat, unique properties, possible 
mechanisms underlying, 
87-88 
recipient (see Recipient) 
reconstruction to child with situs 
inversus, 39 
rejection (see Rejection) 
193 
Transplantation of liver (cont.) 
retransplantation (see 
RetransplantationJ 
survival after one graft vs. survival 
after two or more grafts, 136 
survival rates, 73 
technical failure, 45-49 
timing of, 131-136 
tolerance induction (see Tolerance 
induction) 
Transplantation of multiple organs, 
141-145 
T tube: stent in 
choledochocholedochostomy, 1 
Tumods) 
benign, survival after liver 
transplant, 124 
necI'Osis factor, 66 
Tyrosinemia, 138 
u 
Ultrastructure: of endothelial cells, 
sinusoidal, 53 
Urea cycle enzyme deficiency, 139 
UW solution 
aortic infusion of, 143 
for slush preselvation, 14-18 
V 
Vacuolization: fatty, of hepatocytes, 
53 
Varicella-zoster hepatitis, 104-105 
Vein (see Portal vein) 
Vena cava 
inferior, liver transplant piggyback 
onto, 29 
194 
preservation, 27-30 
recipient, preparation steps in 
piggyback technique, 29 
retrohepatic, cleaning the 
dissection, 31 
Veno-venous bypasses, 20-23 
pump-driven, 20 
Vessels 
grafts, 14, 15 
homografts, 12 
micI'Ovascular injury, 49 
small, anastomoses, avoiding 
strictures, 34 
thrombosis, "medical" factors 
contributing in, 49 
Viruses 
adenovirus (see Adenovirus) 
hepatitis (see under Hepatitis) 
HlV carrier state, 129-130 
W 
Waddell-Caine technique 
complications, 38 
for gallbladder conduit biliary 
reconstruction, 37 
Washing out: the homograft, 
technique, 32 
Wilson's disease, 138 
y 
Young age, 126 
z 
Zoster-varicella hepatitis, 104-105 
